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Abstract 
Atmospheric pollution is a global problem with a significant health risk. For example, 
inhalation of diesel exhaust particles (DEP), a major component of atmospheric 
pollution, increases the incidence of exacerbations in patients with chronic 
obstructive pulmonary disease (COPD). DEP comprise a carbon core with adsorbed 
chemical compounds, metals and endotoxin. Inhaled DEP deposit in the lung and 
are targets for macrophages. Macrophages normally clear inhaled DEP and maintain 
lung sterility. However, macrophages also drive COPD pathophysiology by releasing 
inflammatory mediators. DEP heighten chronic inflammatory processes and induce 
cytotoxicity in macrophages. However the effects of DEP on macrophages from 
COPD patients remain unclear. The hypothesis underlying the present thesis was 
that 'DEP modulate macrophage pro-inflammatory mediator release and 
phagocytosis, and this is more prominent in COPD. To address this hypothesis, 
monocyte-derived macrophages (MDM) from non-smokers, smokers and patients 
with COPD were exposed to three types of DEP, termed DEP-N (generated from a 
light engine), standard reference material (SRM)-1650B, SRM-2975 and control inert 
beads, and MDM viability, mediator release and phagocytosis were examined. 
Characterisation of the DEP showed each sample to be heterogeneous in size, and 
subject to aggregation. Fe and Cu metals were associated with the DEP-N sample 
but not with SRM-1650B or SRM-2975. DEP at concentrations ≤ 100µg/ml did not 
induce cytotoxicity in MDM from non-smokers, smokers and patients with COPD, as 
determined by MTT. DEP-N, but not SRM-2975, SRM-1650B or inert beads, 
stimulated CXCL8 release by MDM compared with non-stimulated controls. This was 
not due to endotoxin in the DEP-N samples. MDM from non-smokers and COPD 
patients were twice as responsive to DEP-N as cells from smokers. DEP-N-treated 
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MDM activated p38 and ERK 1/2 MAPK pathways. A p38 inhibitor (PF-755616) or 
MEK inhibitor (PD98059) suppressed DEP-N-induced MDM activation of p38 or ERK 
1/2 respectively, with associated inhibition of CXCL8 release, with no effect on 
viability. DEP-N inhibited MDM phagocytosis of beads from all subject groups in a 
concentration-dependent manner, which was to some extent, associated with 
decreased cell viability. 
In conclusion, DEP-N, but not SRM, stimulated MDM CXCL8 release and 
suppressed phagocytosis, possibly as a result of differences in surface-adsorbed 
metals. The combined, opposite functional effects of DEP may, at least in part, 
contribute to the association between DEP exposure and incidence of exacerbations 
in patients with COPD. DEP-induced CXCL8 release was mediated via p38 and ERK 
1/2 MAPK pathways, which suggests that inhibition of p38 or ERK 1/2 signalling may 
have therapeutic potential in COPD.  
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IL Interleukin 
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MOPS 3-(N-morpholino)propanesulfonic acid 
 
MTT 3-(4,5-Dithiazol-2-yl)-2,5-Diphenyltetrazolium 
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TNF Tumour necrosis factor 
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1.1 Introduction 
Air pollution is increasing worldwide and has adverse effects on respiratory health 
(Dockery & Pope 1994; Kampa & Castanas 2008). Chronic obstructive pulmonary 
disease (COPD) is a respiratory condition affecting 200 million individuals globally, 
and is currently the fourth leading cause of death worldwide (Barnes 2004; 
Vermaelen & Brusselle 2013). COPD patients are susceptible to deleterious effects 
to their health caused by elevations in atmospheric pollution. In urban environments, 
a major contributor of atmospheric pollution is diesel exhaust particles (DEP), and 
inhalation of these particles are associated with increased respiratory symptoms in 
patients with COPD (Sunyer et al. 1993; Anderson et al. 1997; Sunyer et al. 2000). 
The small diameter (<0.1µm - <10µm) of DEP favour their deposition within the lung. 
Large particles deposit in the upper respiratory tract (>6µm) or nasal passages 
(Dockery & Pope 1994) and smaller particles (<2.5µm) deposit in terminal airways 
and become targets for alveolar macrophages, which, in turn, have been implicated 
in the pathophysiology of COPD (Donaldson & Stone 2003; Barnes 2004). DEP 
deposited in the alveolar compartment of the lung may stimulate inflammatory 
responses by pulmonary cells. The coupled effect of DEP-induced inflammation and 
macrophage activation in patients with COPD may contribute to the adverse health 
effects associated with elevations in atmospheric pollution. The present thesis 
describes research work aimed at understanding some of the effects of DEP on 
macrophage function. 
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1.2 Air Pollution  
Atmospheric pollution is the contamination of indoor or outdoor air by biological, 
chemical and/or physical pollutants, in amounts sufficient to cause adverse effects in 
humans and/or animals, or to the natural environment (Olmo et al. 2011; Bell & 
Davis 2001). Pollutants generally have a complex composition and are emitted or 
formed by primary or secondary routes (Sonibare 2011). Primary pollutants, for 
example carbon monoxide (CO), sulfur dioxide (SO2) or nitrogen oxides (e.g NO2), 
are released directly into the atmosphere (Wanner 1993). Secondary pollutants are 
formed by interaction between primary pollutants in the atmosphere, for example the 
production of ozone or acid rain (Sonibare 2011). Atmospheric pollutants encompass 
heterogeneous liquid or solid particles, the latter including pollen, dust and soot. 
These particles are commonly referred to as particulate matter (PM) and are 
classified according to their aerodynamic diameter. For example, particles with 
diameters of approximately 0.1µm, 2.5µm or 10µm are referred to as PM0.1, PM2.5 or 
PM10 respectively (Backes et al. 2013). 
1.2.1 Diesel Exhaust Particles  
PM10 have been studied extensively and elevations in levels of atmospheric PM10 
are associated with adverse effects on respiratory health, such as reduced lung 
function, disease exacerbations, increased hospitalisations and mortality, as 
determined by epidemiological studies (Bell & Davis 2001; Dockery & Pope 1994; 
Park et al. 2011). A major contributor to PM10 are vehicle exhaust emissions, 
including diesel exhaust (Murphy & Richards 1999; Mcclellan 1987). Diesel exhaust 
consists of gaseous and particulate components formed by the combustion of diesel 
fuel (Ono-Ogasawara & Smith 2004). The particulate component, termed diesel 
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exhaust particles (DEP), comprises an elemental carbon core 'soot', to which semi-
volatile or low-volatile organic compounds are adsorbed, including polycyclic 
aromatic hydrocarbons (PAH) and nitro-PAHs (Table 1.1), endotoxin and metals, 
including Na, Mg, Si, Fe, Cu and Ca (Figure 1.1) (Saitoh et al. 2003; Sehlstedt, et al, 
2010). Individual DEP invariably aggregate, and sulphite, water and sulphuric acid 
condense on the particle surface. 
 
                Table 1.1 Aromatic Hydrocarbons Adsorbed on Diesel Soot  
 
 
 
 
 
 
 
 
 
 
 
Adsorbed polycyclic aromatic hydrocarbons (PAHs) and nitro-PAHs on the surface of 
DEP. Table adapted from Chen & Cahill n.d., 2000 and National Institute of 
Standards and Technology (NIST) certificates (See Appendix III). 
 
 
 
 
 
PAHs 
 
Nitro-PAHs 
Phenathrene 1-Nitropyrene 
Fluoranthene 1,6-Dinitropyrene 
Pyrene 3-Nitrophenantherene 
Benzo[a]anthracene 4-Nitropyrene 
Benzo[e]pyrene 6-Nitrochrysene 
Benzo[ghi]perylene 6-Nitrobenzo[a]pyrene 
Benzo[k]fluoranthene 7-Nitrobenz[a]anthracene 
Chrysene 9-Nitroanthracene 
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The mechanisms associated with particle formation in diesel exhaust typically 
involve two 'modes', namely the nucleation mode and the accumulation mode 
(Schneider et al. 2005). The nucleation mode is considered to be liquid particles 
which consist of sulfate, water or semi-volatile organic compounds (Schneider et al. 
2005). These particles are between 5-50nm, and are formed by the high 
temperatures created in the exhaust-pipe of vehicles. At high temperatures, organic 
substances are vaporised and, on cooling, the low-volatile organic components are 
condensed on to the surface of existing carbonaceous particles, leading to the 
formation of particles in the accumulation mode (Ono-Ogasawara & Smith 2004). 
Accumulation mode particles are between 30-500nm, and typically consist of 
carbonaceous soot particles with adsorbed semi-volatile condensates (Figure 1.2) 
Figure 1.1 Diagram of DEP Aggregate 
DEP are composed of carbon particle aggregates which adsorb semi- or low-
volatile organic components, metals or endotoxin, in addition to a layer of 
condensed SO3, H2O and H2SO4. Image adapted from Twigg and Phillips et al. 
2009. 
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(Kittelson et al. 2006; Kittelson et al. 1999; Ma et al. 2008). The chemical 
composition of DEP, is therefore, complex, and is influenced by the formation of 
nucleation mode particles. This is because particles in nucleation mode are indirectly 
dependent on fuel type, engine type (heavy or light) or engine running conditions 
(Rönkkö et al. 2006; Saitoh et al. 2003).  
The physical features of DEP, including size, shape and composition, govern their 
behaviour on respiratory health. DEP are major contributors to PM10, however, 
significant proportions of DEP are typically found in the range PM0.1 - PM2.5 (Ono-
Ogasawara & Smith 2004). The size of DEP enables them to penetrate and deposit 
in the alveolar compartment of the lung, where they impact on the thin alveolar 
epithelium and pass into the circulation (Wichmann 2007). In addition, DEP readily 
bind together forming aggregates of various sizes. Furthermore, the complex shape 
of DEP aggregates may inhibit appropriate phagocytosis, and hence clearance, by 
alveolar macrophages (Champion & Mitragotri 2009). Interference with macrophage 
function could, therefore, have deleterious effects on health, for example in patients 
with COPD. 
 
 
     
 
 
 
 
Figure 1.2 Mechanism of DEP Formation by Nucleation and Accumulation Modes 
 
Primary emissions of diesel exhaust consist of carbon soot particles, semi- or low-
volatile organic components, SO3, H2O and H2SO4. Semi- or low-volatile organic 
components, SO3, H2O and H2SO4 condense on to the surface of existing carbon soot 
particles. During the nucleation process SO3, H2O and H2SO4 also bind to form liquid 
particles. Diagram adapted from Schneider et al. 2005. 
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1.3 Chronic Obstructive Pulmonary Disease 
COPD is an irreversible chronic inflammatory respiratory condition. COPD affects the 
large airways, the peripheral small airways, and the lung parenchyma, leading to 
airway obstruction (Vestbo et al. 2012; GOLD, 2014). Airflow obstruction is 
measured using spirometry, and decreases in forced expiratory volume in 1 sec 
(FEV1), and the ratio of FEV1 to forced vital capacity (FVC), are indicative of 
abnormalities in lung function. For example, FEV1 <80% and FEV1/FVC <0.7 reflect 
impaired lung function in patients with COPD. In addition, lung function reduces 
steadily with disease progression (Figure 1.3). The severity of COPD is correlated 
with a number of factors including length of smoking history, muscle weakness and 
exacerbations (MacNee 2005a; Dourado, et al. 2006; O’Donnell & Parker 2006; 
Barnes 2010). 
 
 
 
 
 
 
 
 
 
    
 
      Figure 1.3 Accelerated Decline in Airflow in Patients with COPD compared with 
Non-smokers and Smokers 
Declined airflow is a normal feature of ageing (blue line). However, 10–20% of smokers 
who are susceptible to COPD, have an accelerated decline in airflow (red line) 
compared to non-smokers and non-susceptible smokers (green line). The length of 
smoking history further declines airflow, and leads to onset of symptoms, disability and 
eventually death. Cessation of smoking slows the rate of decline in airflow reduction, but 
does not reverse it. Diagram adapted from Barnes 2004. 
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COPD is primarily associated with long-term cigarette smoking, as well as inhalation 
of toxic gases/irritants and atmospheric pollutants including DEP (Løkke et al. 2006; 
Hart et al. 2012; Ulvestad et al. 2000). However, only 10-20% of chronic smokers 
develop COPD, and cessation of smoking is associated with lowered disease 
progression (Figure 1.3). Cigarette smoke contains ~4,700 chemicals, many of which 
are noxious, including free-radicals and other oxidants (Rahman 2005). Cigarette 
smoke exposure induces inflammatory responses in the lung and is associated with 
COPD pathophysiology, which comprises chronic bronchitis, small airways disease 
(SAD) and emphysema (Figure 1.4).  
1.3.1 Chronic Bronchitis 
 
Chronic bronchitis is the term used for the hyper-secretion of mucus in the airways 
(Kim & Criner 2013) (Figure 1.4A). Excess mucus production is associated with 
hyperplasia or hypertrophy of goblet cells and submucosal glands (Kim & Criner 
2013; Vestbo, et al. 2006; Saetta, et al. 2000). Excess mucus obstructs the airway 
lumen leading to reduced airflow (Figure 1.3A). The mechanism(s) of cigarette 
smoke-induced increases in mucus secreting tissue is not fully understood, but 
appears to involve upregulation of epidermal growth factor (EGF) signalling 
pathways resulting in the transcription and synthesis of mucins (Kim & Criner 2013). 
Clearance of mucus in chronic bronchitis is suppressed by ineffective mucocilliary 
clearance, which contributes to the characteristic 'cough' observed in many COPD 
patients.  
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1.3.2 Small Airways Disease 
 
Peripheral (i.e. 'small') airways permit laminar movement of inspired air to the 
alveolar compartment of the lung to facilitate effective gas exchange (Burgel 2011). 
Small airways in healthy individuals typically have thin walls and are <2mm in 
diameter and provide no resistance to the flow of air (Burgel 2011). Reduced airflow 
in COPD is associated particularly with structural changes in the small airways 
(Figure 1.4B). These changes include thickening of the airway wall, increased 
smooth muscle mass, peri-bronchial fibrosis and luminal occlusion by mucus plugs. 
 
1.2.2 Small Airways Disease 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Key Features of COPD Pathophysiology  
COPD is a respiratory disorder, characterised by three key features, these include, chronic 
bronchitis, small airways disease and emphysema. (A) Airways from healthy non-smokers do 
not secrete excess mucus compared to airways from patients with COPD. (B) Small airways 
from non-smokers (black arrow) have thin airway walls and are not thickened by fibrosis. The 
airways are held open by alveolar attachments. In COPD the airway walls are thickened by 
fibrosis, resulting in the occlusion of the airway lumen. (C) Emphysema is the destruction of 
the lung parenchyma by proteases produced by inflammatory cells for example neutrophils 
and macrophages. Individual images are adapted from Baraldo et al. 2012;  
http://www.pennmedicine.org/encyclopedia/em_PrintArticle.aspx?gcid=001087; 
http://www.flickr.com/photos/30950973@N03/4858474968. 
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Cigarette smoking is a major contributor to development of small airways disease 
(Churg et al. 2006; Yoshida & Tuder 2007). Inhalation of cigarette smoke triggers an 
inflammatory response by pulmonary cells against the noxious chemicals or debris 
deposited in the peripheral airways (MacNee 2005a). Smoking initiates migration of 
mononuclear cells and lymphocytes into the airway walls, and of macrophages into 
the luminal space (Hogg et al. 2004). Histological examination of lung tissue shows 
that small airways from smokers without COPD have a modest infiltration of immune 
cells compared to patients with disease (Hogg et al. 2004). Cigarette smoke 
activates immune cells and stimulates release of inflammatory mediators which are 
also implicated in small airways disease pathology. For example, activated 
macrophages release transforming growth factor (TGF)-β or fibroblast growth 
factors, which both contribute to fibrosis of airways (Barnes 2008).   
1.3.3 Emphysema  
Emphysema is the destruction of lung parenchyma (Figure 1.4C) leading to 
enlargement of distal airspaces via degradation of small airway walls and capillary 
beds. Emphysema is characterised by decreased elastic recoil of the lung, thereby 
preventing appropriate expulsion of air. The pathophysiology of emphysema involves 
protease-antiprotease and/or oxidant-antioxidant imbalances (MacNee 2005b; 
Abboud & Vimalanathan 2008). Proteases are released from macrophages and 
activated neutrophils that migrate to sites of tissue inflammation or pathogenic 
stimuli. Macrophages and neutrophils release proteases to digest lung tissue 
components such as collagen or elastin, to facilitate movement to sites of 
inflammation (Thorley & Tetley 2007). In addition to secreting proteases, these cells 
also secrete antiproteases to prevent excess damage to the lung tissue. However, in 
COPD this balance is shifted, and levels of proteases overwhelm the level of anti-
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proteases present in the lung. The abundance of proteases in the pulmonary 
environment is thought to lead to the digestion of alveolar attachments, thereby 
causing pre-mature closure of peripheral airways (Abboud & Vimalanathan 2008; 
MacNee 2005a).  
In addition to the protease burden in COPD, levels of oxidants are also elevated and 
overwhelm endogenous anti-oxidants (MacNee 2005b). A major contributor to 
oxidative stress is the oxidant nitric oxide, released from cigarette smoke and 
inflammatory cells (Rytilä et al. 2006). Oxidative stress may perpetuate emphysema 
by inactivating anti-proteases, sequestrating neutrophils, degrading extracellular 
matrix (ECM) and inducing pro-inflammatory mediator release (Rahman 2005).  
1.4 DEP and COPD 
DEP appear to be involved in aggravating the hallmark features of COPD (Lopes et 
al. 2009; Sagai et al. 1996; Churg et al. 2006; Macnee & Donaldson 2003). Inhaled 
DEP deposit on the the airway epithelium leading to the onset of airway hyper-
responsiveness (AHR), emphysematous damage, respiratory toxicity and generation 
of reactive oxygen species (ROS) (Behndig et al. 2006; Nordernhall et al. 2001). As 
well as inducing lung injury and augmenting inflammation, DEP are also involved in 
impairment of cellular defences against respiratory pathogens by inhibiting secretion 
of pro-inflammatory cytokines by alveolar macrophages (Castranova et al. 2001; Yin 
et al. 2005a). The detrimental effects induced by DEP maybe a consequence of the 
noxious composition of these particles (Amakawa et al. 2003). One area where DEP 
appear to be particularly relevant to COPD is in their association with exacerbations 
of the disease. 
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1.4.1 Exacerbations of COPD 
COPD patients are susceptible to exacerbations characterised by augmentation of 
symptoms such as dyspnoea, airway inflammation, mucus purulence and cough 
(Makris & Bouros 2009). The heightened inflammation associated with exacerbations 
leads to a progressive decline in FEV1, resulting in high rates of hospitalization, poor 
quality of life and premature mortality (Wedchiza & Donaldson 2003). Respiratory 
micro-organisms such as viruses (e.g. rhinovirus or respiratory synticial virus) and 
bacteria (e.g. Haemophilus influenzae or Streptococcus pnuemoniae), colonise the 
lung and are major causative agents associated with exacerbations (McManus et al. 
2008; Seemungal et al. 2001). In addition, the incidence of COPD exacerbations is 
increased during episodes of high atmospheric pollution (Lundborg et al. 2006; 
Medina-Ramón et al. 2006; Zanobetti, et al. 2008; Sint, et al. 2008). 
1.5 Pulmonary Inflammation in COPD 
Chronic airway and lung inflammation is a characteristic feature of COPD, and is 
initiated by cigarette smoking (Figure 1.5). Cigarette smoke exposure causes the 
infiltration of a variety of immune cells into the airways and lung, including 
macrophages, neutrophils and CD8+ T-lymphocytes. Activated immune cells release 
pro-inflammatory mediators which are implicated in the pathophysiology of COPD. 
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1.5.1 Alveolar Macrophages 
Alveolar macrophages (AM) are resident at the blood-alveolus interface and are 
pivotal in innate and adaptive immunity (Barnes, 2004; Twigg 2004). These cells are 
placed in the alveolar spaces to maintain sterility of the lungs by engulfing inhaled 
particles, debris, apoptotic cells and pathogens (Barnes, 2004). In addition to their 
phagocytic functions, these cells also release inflammatory mediators (e.g. CXCL8, 
interleukin (IL)-6 or tumour necrosis factor (TNF)α), generate oxidative species 
Figure 1.5 Inflammatory Mechanisms Associated with Cigarette Smoke Exposure 
Contributes to COPD Pathophysiology 
Cigarette smoke stimulates alveolar macrophages to release chemokines for example 
CXCL8, LTB4 and CCL2, which mediate recruitment of neutrophils, CD8
+ T-
lymphocytes and monocytes. Neutrophils and CD8+ T-lymphocytes release proteases 
which degrade lung parenchyma and thereby are associated with mucus 
hypersecretion (chronic bronchitis) and alveolar destruction (emphysema). In addition, 
oxidants released by these cells also contribute to mucus hypersecretion, alveolar 
destruction and small airways disease (chronic bronchiolitis). Cigarette smoke also 
stimulates epithelial cells to release TGF-β, which is associated with the thickening of 
airway walls by fibrosis. Diagram adapted from Barnes 2004.  
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involved in microbial killing, and secrete proteases (Russell et al. 2002; Culpitt et al. 
2003; Barnes, 2004). The role of macrophages in COPD is discussed in more detail 
below (Section 1.6). 
1.5.2 Neutrophils 
Neutrophils are important in defence against infection. In healthy airways, tissue 
invasion by bacterial or viral pathogens is suppressed by non-specific mechanisms, 
for example, the mucocilliary transport system (Sethi 2000). Evasion of these 
barriers results in recruitment of inflammatory cells, including neutrophils from the 
bone marrow, to the site of inflammation (van Eeden et al. 2000; Donnelly & Barnes 
2012). Activation of neutrophils via interaction of surface pattern recognition  
receptors (PRRs) and pathogen-associated molecular patterns (PAMPs) on micro-
organisms, initiates the respiratory burst process which is involved in killing of 
pathogens (Parker et al. 2005).  
In COPD, neutrophils are increased in bronchoalveolar lavage (BAL) and sputum 
samples from patients, although only moderate numbers are observed in lung 
parenchyma or bronchioles (Barnes 2004). The difference in numbers of neutrophils 
between BAL or sputum and lung tissue may indicate the transient nature of these 
cells (Barnes 2004). The movement of neutrophils through lung tissue involves 
secretion of proteases, including matrixmetalloproteases (MMP)-8, MMP-9, 
cathepsin and neutrophil elastase, which digest lung tissue and facilitate migration of 
these cells to sites of inflammation or pathogenic stimuli (Di Stefano et al. 1994). 
Excessive production of neutrophil proteases, such as neutrophil elastase, is 
associated with induction of mucus metaplasia and destruction of alveolar 
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attachments leading to emphysema (Baraldo et al. 2012; O’Donnell & Parker 2006; 
Barnes 2004). 
1.5.3 Lymphocytes 
B and T-Lymphocytes are associated with adaptive immunity, antigenic specificity, 
expansion of antigenic specific daughter cells and immunologic 'memory' (Gadgil & 
Duncan 2008). T-lymphocytes are sub-divided into helper or cytotoxic lymphocytes, 
and are discriminated by the expression of CD4+ or CD8+ glycoproteins respectively 
(Barcelό et al. 2008). CD8+ T-lymphocytes, are one of the predominant cell types, 
along with macrophages, in peripheral airways of patients with COPD (Finkelstein et 
al. 1995; Majo et al. 2001; Hodge et al. 2007; Gadgil & Duncan 2008; Baraldo et al. 
2012). 
Cigarette smoke or irritants stimulate type II pneumocytes to release chemokines 
such as interferon inducible protein (IP)-10 (CXCL10) or monokine induced by 
interferon gamma (MIG) (CXCL9) (Gadgil & Duncan, 2008; Barnes 2008). These 
chemokines are involved in the recruitment of CD8+ T-lymphocytes to the airways, 
by binding to the receptor CXCR3 which is highly expressed on these cells. In turn, 
CD8+ T-cells release interferon (IFN)-ɣ, which further stimulates the release of the 
CXCL9 and CXCL10 (Barnes 2008). In addition to releasing inflammatory mediators, 
CD8+ T-lymphocytes are also involved in the destruction of alveolar wall by releasing 
the cytotoxic enzymes perforin and granzyme B (Barnes 2008).  
B-lymphocytes are observed in severe COPD (GOLD stage IV) and are found in 
peripheral small airways. These cells are present in lymphoid follicles and surround 
T-lymphocytes (Hogg et al. 2004; Barnes 2008). B-lymphocytes are associated with 
production of auto-antibodies in severe stages of COPD (Agusti et al. 2003).   
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1.6 Alveolar Macrophages in COPD 
Macrophages occupy a pivotal role in the pathophysiology of COPD (Figure 1.5), 
and may be considered 'orchestrators' of the disease (Donnelly & Barnes 2012). The 
number of macrophages is increased in BAL fluid and sputum of patients with COPD 
(Retamales et al. 2001; Barnes et al. 2003). They are also increased at sites of 
emphysema and in peripheral airways (Barnes 2004). 
The lung environment of healthy non-smokers is usually sterile. However, in COPD 
patients the lung is often colonised by bacterial pathogens, for example H. influenzae 
or S.pneumoniae (Sethi 2011; Taylor et al. 2010). AM from COPD patients show a 
reduced ability to clear inhaled pathogens compared to non-smoker and smoker 
controls (Berenson et al. 2006; Taylor et al. 2010; Berenson et al. 2013). Parallel 
experiments conducted on primary alveolar macrophages and blood macrophages 
from COPD patients (ex-smokers and current smokers), exposed to respiratory 
pathogens, display inconsistent findings in the clearance of phagocytic prey. For 
example, AM from ex-smoker and current smoking COPD patients, displayed 
reduced clearance of three different strains of non-typeable H.influenzae (NTHI), 
compared with AM from non-smokers. However, identical experiments conducted on 
blood macrophages did not display this defect (Berenson, et al, 2006). In contrast to 
this finding, other in-vitro studies have shown that blood monocyte-derived 
macrophages (MDM) from patients with COPD, are also defective in the clearance of 
NTHI, but not S..pnuemoniae compared to control groups (Berenson, et al. 2006). 
Similar findings are observed in tissue AM, with cells from COPD patients being 
defective in the uptake of NTHI and Moraxella Catarrhalis but not S..pnuemoniae 
(Berenson, et al. 2013). The inability to appropriately clear inhaled pathogens may 
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be responsible for continued colonisation of the airways, a propensity to more 
frequent exacerbations and aggravation of the underlying inflammation seen in 
COPD.  
It has been determined that the extent of defective macrophage phagocytosis is not 
limited to specific respiratory pathogens, but also extends to the ineffective clearance 
of apoptotic cells i.e. airway epithelial cells. Inadequate clearance of apoptotic cells 
may lead to release of intracellular contents which are injurious to surrounding 
tissue; and may be associated with emphysema and pulmonary fibrosis (Hodge et al. 
2003). BAL macrophages from non-smokers or COPD patients incubated with 
apoptotic epithelial cells or fluorescent beads showed that cells from COPD patients 
were defective in the clearance of apoptotic epithelial cells compared to non-smoker 
macrophages. In contrast, macrophages from COPD patients still retained their 
ability to internalise fluorescent beads.     
The mechanism associated with reduced phagocytosis in macrophages is unclear. 
In-vitro studies looking at the effects of MDM from non-smokers, smokers and 
patients with COPD on the clearance of NTHI and S.pnuemoniae, showed a 
reduction in the uptake of pathogens. However, this effect was not associated with 
alterations in macrophage receptor expression for e.g. Toll like receptor (TLR) -2, 
TLR 4, macrophage receptor with collagenous structure (MARCO), cluster of 
differentiation (CD) 163, CD36 or mannose receptors; other studies have showed 
that primary AM from COPD patients and healthy smokers display a reduction in 
CD31, CD91, CD44 and CD71 (Taylor, et al, 2010; Hodge, et al. 2007). Therefore it 
is suggested that impaired macrophage phagocytosis maybe associated with 
alterations in macrophage receptor expression. 
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1.6.1 Mechanisms of Phagocytosis 
Phagocytosis is the actin-dependent process of internalising prey which is >0.5µm in 
diameter (Aderem & Underhill 1999). The phagocytic process can occur via a 
number of mechanisms, but relies on discriminating 'non-self' molecules from 'self' 
molecules. This process involves recognising highly conserved PAMPs, for example 
lipopolysacchrides and formylated peptides by PRRs (Taylor et al. 2005; Ishii et al. 
2008; Rovina et al. 2013). The most common phagocytic process, involves coating 
pathogens or particles with soluble serum proteins, termed 'opsonins', which include 
immunoglobulins (Ig) or complement. The recognition of immunoglobulins or 
complement by macrophage Fc-receptors (e.g. Fc-ɣRIII) or complement receptors 
(e.g. C3b) respectively, increases the susceptibility of phagocytosis (Aderem & 
Underhill 1999; Donnelly & Barnes 2012). In addition, other receptors, namely the 
scavenger receptors (SR) are associated with non-opsonised phagocytosis 
(Donnelly & Barnes 2012; Greenberg & Grinstein 2002).  
Opsonised-mediated phagocytosis involves activation of the Fc-receptor or the 
complement receptor (CR), leading to the rearrangement of the macrophage 
cytoskeleton and finally resulting in particle internalisation. The internalisation of 
particles by macrophages, can occur by two different processes, the first process is 
mediated by the Fc-receptors and involves pseudopodia extending from the surface 
of the cell which encapsulates the particle in a zippering manner (Donnelly & Barnes 
2012). The second process is mediated by CRs and involves the particle 'sinking' 
into the cell with only small protrusions of the cell membrane surrounding the particle 
(Aderem & Underhill 1999; Donnelly & Barnes 2012). The internalised particle is then 
held within a phagosome, to which endosomes bind by a series of fusion and fission 
Chapter 1: General Introduction 
 
39 
 
processes. Maturation of the phagosome eventually leads to the binding of 
lysosomes, thereby creating phagolysosomes. Pathogens contained within the 
phagolysosomes are degraded by reactive oxygen intermediates (Aderem & 
Underhill 1999; Donnelly & Barnes 2012).   
The lung is not a serum-rich environment, for this reason, the primary means of 
engulfing inhaled pathogens or particles is via non-opsonised phagocytosis 
(Donnelly & Barnes 2012). SRs are implicated with non-opsonised phagocytosis, 
with the major SR on the surface of alveolar macrophages being macrophage 
receptor with collagenous structure (MARCO) (Arredouani et al. 2004; Arredouani et 
al. 2005; Donnelly & Barnes 2012). However, the mechanism associated with non-
opsonised phagocytosis by alveolar macrophages is not fully understood 
(Arredouani et al. 2004).  
As mentioned earlier (Section 1.6), alveolar macrophages are defective in the 
clearance of inhaled pathogens and in addition also display reduced efferocytosis, 
which is the clearance of apoptotic cells. Exact mechanisms associated with the 
reduced efferocytosis are not clear, however, it is considered that recognition 
receptors on the surface of cells may play a part. For example, alveolar 
macrophages from smokers and patients with COPD display reduced expression of 
CD receptors including CD31, CD91, CD44 and CD71, suggesting that smoking may 
be correlated to impaired macrophage function (Hodge et al. 2007). However, other 
groups have shown no difference in the mentioned receptors, but have shown 
reductions in the expression of CD80, the human leukocyte antigen DR (HLA-DR), 
CD86 and CD11a (Löfdahl et al. 2006; Pons et al. 2005). It is unclear whether 
defective macrophage phagocytosis is associated with reduced recognition receptor 
expression, or is a feature of cells becoming replete following exposure to inhaled 
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debris or particles such as DEP. The satiation of macrophages may prevent further 
internalisation of other inhaled particles for example respiratory pathogens leading to 
bacterial colonisation of the lung. 
1.6.2 Macrophages and Mediators 
In addition to ingestion of microbes and other particles, macrophages also have a 
secretory role involving release of mediators. Release of mediators serves as a 
means of communicating with other cells to initiate either an inflammatory or anti-
inflammatory response. Activation of macrophages release several mediators, of 
which CXCL8, IL-6 and TNFα predominate, particularly in COPD (Barnes 2009). In 
COPD, these mediators contribute and amplify existing immune responses 
associated with the pathophysiology of the disease.  
Cigarette smoke or pathogenic stimuli such as endotoxin, are responsible for 
stimulating release of macrophage mediators. Stimulation of macrophages activate 
transcription factors that are typically associated with the expression of inflammatory 
genes, for example nuclear factor kappa light chain enhancer of activated B cells 
(NF-κB) or activator protein 1 (AP.1) (Renda et al. 2008). In COPD, activation of NF-
ĸB in macrophages is associated with the increased release of CXCL8, IL-6 and 
TNFα, this is determined by the localisation of cytoplasmic p65 to the nucleus 
(Barnes 2004; Libermann & Baltimore 1990). Activation of these transcription factors 
is associated with the phosphorylation of mitogen activated protein kinases (MAPK) 
(Renda et al. 2008). The MAPKs are serine/threonine protein kinases which are a 
complex network of interacting proteins involved in the communication of 
extracellular signals that lead to phosphorylation of intracellular transcription factors 
to initiate cellular processes (Figure 1.6) (Seger & Krebs 1995). 
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In macrophages, p38, extracellular signal regulated kinase (ERK)-1/2 or c-jun N-
terminal kinases (JNK) signalling are associated with mediator release (Barnes 
2004). In COPD, phosphorylation of p38 is reported to be increased in alveolar 
macrophages compared to non-smoking or smoker controls (Renda et al. 2008). p38 
MAPK has four isomers, namely p38α, p38β, p38Ɣ or p38δ (Smith et al. 2006; 
Nebreda & Porras 2000). These isoforms are encoded by different genes and 
expression of the different isoforms is tissue-dependent. In alveolar macrophages, 
the p38α and p38δ isoforms are abundantly expressed (Smith et al. 2006). The 
isoforms of p38 phosphorylate different substrates, although the effect of the 
individual isoforms on inflammation are unknown (Smith et al. 2006).  
 
 
 
Figure 1.6  MAPK Signalling Pathway 
MAPK are serine threonine kinases and include p38, ERK 1/2 and JNK. The MAPK 
pathway involve enzymes which initiate downstream signalling by regulating 
substrates in a consecutive manner, resulting in the phosphorylation of transcription 
factors which leads to cellular responses.  
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The following mediators have distinct roles in COPD pathophysiology and are 
released via activation of MAPK pathways: 
CXCL8: CXCL8 is a chemokine involved in the recruitment of neutrophils and cells 
that express the G-protein coupled CXCR1 and CXCR2 receptors, to sites of tissue 
injury, inflammation or pathogenic stimuli. CXCL8 is released by numerous 
pulmonary cells including alveolar macrophages. Macrophages from patients with 
COPD, release higher levels of CXCL8 compared to non-smoker and smoker 
controls as determined by levels of chemokine measured in induced sputum 
(Keatings et al. 1996; Culpitt et al. 2003; Nocker et al. 1996). The elevated level of 
CXCL8 is correlated to neutrophil recruitment in the airways of patients with COPD. 
The increased release of TNFα by macrophages in patients with COPD is also 
responsible for the activation of recruited neutrophils. The accumulation and 
activation of neutrophils at sites of inflammation in the peripheral airways may 
perpetuate underlying inflammation in COPD by stimulating mucus hypersecretion 
and releasing proteases thereby prompting tissue destruction (Quint & Wedzicha 
2007). 
Stimulation of macrophages by cigarette smoke or pathogenic stimuli triggers 
downstream signalling events culminating in the activation of the transcription factor 
NF-κB or AP.1, which is associated with CXCL8 production (Drost et al. 2005; 
Murugan & Peck 2009). The activation of these transcription factors are regulated by 
the phosphorylation of the MAPK p38, ERK-1/2 or JNK (Renda et al. 2008). 
IL-6: IL-6 is a pleiotropic cytokine which has been highlighted to mediate several 
inflammatory effects in the respiratory system. Levels of IL-6 are increased in BAL 
samples from patients with COPD and are associated with amplifying inflammation 
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by working in concert with other cytokines (Barnes 2009). IL-6 provides a link 
between innate and adaptive immunity in COPD via the release of acute phase 
proteins from the liver, and has been implicated in fibrotic remodelling in peripheral 
airways. In addition, the increased release of IL-6 has also been linked to airway 
space enlargement, airway inflammation and may mediate systemic co-morbidities 
associated with COPD including diabetes and bone disease (Ochoa et al. 2011; 
Barnes 2010).  
TNFα: In COPD, levels of TNFα are increased and have been implicated in cachexia 
'weight loss' in patients. TNFα, along with IL-6 is responsible for the release of acute 
phase proteins and C-reactive proteins (CRP) from the liver, therefore driving 
systemic inflammation and the activation of immune cells. In addition, acute phase 
proteins are also associated with the activation of complement (Schleimer 2005). 
The release of TNFα by AM, is associated with cigarette smoke induced emphysema 
by increasing the production of MMPs by neutrophils (Cosio et al. 2009; Churg et al. 
2004). The effects of TNFα are mediated on pulmonary cells including macrophages, 
by activating p38 MAPK pathways which activates NF-κB to initiate the transcription 
of inflammatory genes (Barnes 2004).  
The effect of DEP on release of these mediators was investigated in the present 
thesis, using macrophage-like cells, termed, monocyte-derived macrophages 
(MDM). 
1.7 Monocyte-Derived Macrophages 
Understanding the effect of DEP on the respiratory system is incomplete. The 
current thesis attempted to extend previous findings to further understand the 
interrelationship between DEP and macrophage function. The effect of DEP on AM 
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function will be examined on blood macrophages, namely MDM. Comparison of 
primary AM and blood macrophages (Table 1.2), show that despite some differences 
in receptor expression e.g. CD80, CD86, CD163 and CD62L, this does not appear to 
alter the functioning of macrophages to clear respiratory pathogens (Berenson et al. 
2006; Berenson et al. 2013; Taylor et al. 2010, Winkler et al. 2008; Lacey et al. 
2012). Although differences between primary and blood macrophages are evident, 
as described in Table 1.2, the similarities between AM and blood macrophages cells 
outweigh the differences (Taylor et al. 2010). It is reasonable to use MDM in this 
investigation, as these cells are more readily available compared to primary AM, are 
minimally invasive to acquire and allow comparison of the effect of DEP on 
macrophage function from patients with COPD, and non-smoker and smoker 
controls.  
1.8 Inhibitor Compounds Used  
The study herein involved assessing the contribution of MAPK pathways to 
inflammatory mediator release. As part of that investigation, inhibitors of different 
MAPK signalling molecules were used. The characteristics of the inhibitors are 
outlined below: 
p38, ERK 1/2 and c-JNK are involved in the release of mediators by alveolar 
macrophages in COPD. To determine whether DEP stimulate MDM release of 
CXCL8, IL-6 or TNFα by MAPK signalling, the p38 inhibitor, PF755616 and MEK 
inhibitor, PD98059 were used. PF755616 is selective for the p38α and p38β 
isoforms, and have a half-maximal inhibitory concentration (IC50) of 27nM (Iain Kilty 
personal communication). PD98059 inhibits the ERK 1/2 upstream signalling 
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component MEK 1/2. PD98059 has an IC50 of 2µM (Alessi et al. 1995; Tudhope, 
Finney-Hayward, et al. 2008). 
1.9 Hypothesis and Aims 
From the above, the following hypothesis was proposed: ‘DEP modulate 
macrophage and pro-inflammatory mediator release and phagocytosis, and this is 
more prominent in COPD’.  
To examine this hypothesis, the following aims were investigated:  
 Chapter 3: Examination of the physical characteristics and metal composition 
of three different DEP samples. 
 Chapter 4: Examination of the effect of three DEP samples on non-smoker, 
smoker or COPD MDM viability.   
 Chapter 5: Examination of the effect of three DEP samples on non-smoker, 
smoker or COPD MDM release of CXCL8, IL-6 or TNFα. 
 Chapter 6: Examination of the mechanism of DEP on MDM mediator release 
from non-smokers, smokers or patients with COPD. 
 Chapter 7: Examine the effect of DEP on MDM phagocytosis of fluorescent 
beads in non-smokers, smokers or patients with COPD. 
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Table 1.2 Evidence of Similarities between Blood Derived Macrophages and 
Primary Alveolar Macrophages 
 
Function/Marker 
Alveolar 
Macrophages 
Blood 
Macrophages 
 
References 
Morphology 
 
  Becker et al. 1987 
Markers: 
 
 FCү:  
- CD14, CD32, CD64 
 
 Scavenger Receptors: 
- MARCO, CD36, CD206 
- CD163 
 
 Adhesion Molecule: 
- CD11b, CD11c, CD164 
- CD62L 
 
 Inflammatory Receptors: 
- CD14 
 
 Co-Stimulatory Molecules: 
- CD80 
- CD86 
 
 Cigarette Smoke Activates: 
- ERK MAPK 
- p38 MAPK 
 
 Cigarette Smoke Induces: 
- CXCL8 release 
 
 Gene Expression 
 
 
 
 
 
 
 
X 
 
 
 
X 
 
 
 
 
 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
X 
 
 
 
 
 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Winkler et al. 2008 
Phagocytosis: 
 
 Fluorescently-Labelled: 
- H.influenzae 
- S.pnuemoniae  
 
 Fluorescent Beads 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Taylor et al. 2010 
 
Evidence from different studies highlighting the similarities and differences between 
blood derived macrophages and primary alveolar macrophages.  
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2.1 Materials 
 
Material 
 
Supplier 
Albumin, Bovine Fraction V solution (BSA) 
 
Sigma-Aldrich, Poole, UK 
Anti-Mouse IgG HRP-Linked Antibody 
 
New England BioLabs, Hitchen, UK 
Anti-Rabbit IgG HRP-Linked Antibody 
 
New England BioLabs, Hitchen, UK 
Bio-RadTM Protein Assay 
 
BioRad, Munich, Germany 
Cell Dissociation Solution 
 
Sigma-Aldrich,  Poole , UK 
Cell Lysis Buffer (10 X) 
 
New England BioLabs, Hertfordshire, UK 
Cell Scrapers 
 
Sarstedt, Leicester, UK 
Cell-TrackerTM Red 
 
Invitrogen, Paisley, UK 
Centrifuge Tubes (50ml) 
 
Sarstedt, Leicester, UK 
Centrifuge Tubes (15ml) 
 
Sarstedt, Leicester, UK 
Costar 96-Well Black Plates (flat bottom) 
 
Costar, Fisher Scientific, Leicester, UK 
Costar 96-Well Clear Plates (flat bottom) 
 
VWR, Leicester, UK 
 
Costar 24-Well Clear Plates (flat bottom) 
 
VWR, Leicester, UK 
Coverslips 
 
Thermo Fisher Scientific, Leicester, UK 
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Dextran from Leuconostoc spp. 
 
Sigma-Aldrich, Poole, UK 
Diesel Exhaust Particles-N 
(DEP-N) 
Kindly Donated By The Department of 
Mechanical Engineering, Imperial College, 
London, UK 
Dimethyl Sulphoxide 
(DMSO) 
Sigma-Aldrich, Poole, UK 
 
Dulbecco’s Phosphate Buffered Saline (D-
PBS) 
Sigma-Aldrich, Poole, UK 
 
10X Dulbecco’s Phosphate Buffered Saline 
(10 X D-PBS) 
Invitrogen,  Paisley, UK 
 
Hycult Limolas Amebocyte Lysate  Endotoxin 
Kit 
Cambridge Bioscience, Cambridge, UK 
Enhanced Chemiluminesence Substrate 
reagent (ECL) 
GE Healthcare, Chalfont St. Giles, UK 
Ethylene-diamine-tetra-acetic Acid 
(EDTA) 
Sigma-Aldrich, Poole, UK 
Ethanol 
 
BDH, Poole, UK 
Eppendorf Tubes 
(0.5ml) 
Sarstedt, Leicester, UK 
Eppendorf Tubes 
(1.5ml) 
Sarstedt, Leicester, UK 
Eppendorf Tubes 
(2.0ml) 
Sarstedt, Leicester, UK 
FACScanto II flow cytometer Becton Dickinson, Oxford, UK 
 
FACSClean 
 
Becton Dickinson, Oxford, UK 
FACSFlo 
 
Becton, Dickinson, Oxford, UK 
FACSRinse 
 
Becton, Dickinson, Oxford, UK 
Filters (0.2μm pore) 
 
Sarstedt, Leicester, UK 
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Fluospheres ® Carboxylate Modified 
Microspheres (Yellow-green, 2.0µm) 
Molecular Probes, Invitrogen, Paisley, UK 
Fluostar Optima Fluorimeter 
 
BMG LabTech, Aylesbury, UK 
 
Foetal Calf Serum 
 
Gibco, Invitrogen,  Paisley , UK 
Full-range Rainbow Molecular Weight 
Marker 
GE Healthcare, Chalfont St. Giles, UK 
Formvar Coated Copper Grids Agar Scientific, Stanstead, UK 
 
Glucose 
 
Sigma-Aldrich, Poole, UK 
Haemacytometer Neubauer counting 
chamber 
Fisher Scientific, Leicester, UK 
Hanks Balanced Salt Solution 
 
Sigma-Aldrich, Poole, UK 
Hybond ECL 
 
Amersham Pharmacia Biotech, GE 
Healthcare, Chalfont St. Giles, UK 
Hyperfilm TM ECL 
 
Amersham Pharmacia Biotech, GE 
Healthcare, Chalfont St. Giles, UK 
Hybond Nitrocellulose Membrane Amersham Pharmacia Biotech, GE 
Healthcare, Chalfont St. Giles, UK 
Lab-Tek Permanox 8-Well Chamber Slides Costar, Fisher Scientific, Leicester, UK 
 
Laemelli Buffer Sigma-Aldrich, Poole, UK 
 
Launch Vision Works LS (Densitometer 
Software) 
UVP, Cambridge, UK 
 
L-Glutamine Sigma-Aldrich, Poole, UK 
 
Light Green 
 
Sigma-Aldrich, Poole, UK 
Limolas Amebocyte Assay Hycult Biotech, Cambridge Bioscience, 
Cambridge, UK 
LPS from Salmonella enterica Serotype: 
enteritidis (LPS) 
Sigma-Aldrich,  Poole, UK 
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MEK 1/2 Inhibitor (PD98059) 
 
Sigma-Aldrich,  Poole, UK 
 
Methanol Sigma-Aldrich,  Poole, UK 
 
Mini Complete Protease Inhibitor Cocktail 
Tablets 
Roche, Mannheim, Germany 
Mouse (Monoclonal) Anti-Human CXCL8 
Biotin Conjugate 
Invitrogen, Paisley, UK 
Mouse (Monoclonal) Anti-Human IL-6 Biotin 
Conjugate 
Invitrogen, Paisley, UK 
Mouse (Monoclonal) Anti-Human TNFα 
Biotin Conjugate 
Invitrogen, Paisley, UK 
Mouse (Monoclonal) Anti-Human CXCL8 
Capture Antibody 
Invitrogen, Paisley, UK 
Mouse (Monoclonal) Anti-Human IL-6 
Capture Antibody 
Invitrogen, Paisley, UK 
Mouse (Monoclonal) Anti-Human TNFα 
Capture Antibody 
Invitrogen, Paisley, UK 
MTT(3-(4,5-dimethythiazol2-yl)-2,5-
diphenyltetrazolium bromide 
Sigma-Aldrich,  Poole, UK 
 
NUNC Maxisorp Flat Bottomed Plates 
 
Fisher Scientific, Leicester, UK 
 
NuPage 4-12% BIS-TRIS Electrophoresis 
Gels 
Invitrogen, Paisley, UK 
NuPage MOPS SDS Running Buffer (20X) Invitrogen, Paisley, UK 
 
p38 Inhibitor (PF755616) 
 
Pfizer, Kent, UK 
Paraformaldehyde (PFA) 
 
Sigma-Aldrich,  Poole, UK 
PE Annexin V: Apoptosis Detection Kit I 
 
Beckton Dickinson, Oxford, UK 
 
Penicillin 
 
Sigma-Aldrich,  Poole, UK 
 
Percoll 
 
GE Healthcare, Buckinghamshire, UK 
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Pippette Tips With Microcapillary for Loading 
Gels 
VWR, Leicester, UK 
Phosphatase Inhibitor II 
 
Sigma-Aldrich,  Poole, UK 
 
Phosphatase Inhibitor III 
 
Sigma-Aldrich,  Poole, UK 
 
Phosphate Buffered Saline  Tablets 
(PBS) 
Sigma-Aldrich,  Poole, UK 
Phospho-HSP27 Primary Antibody 
 
New England BioLabs, Hitchen, UK 
Phospho-p38α Primary Antibody 
 
New England BioLabs,  Hitchen, UK 
Phospho-p42/44 (ERK 1/2) Primary Antibody New England BioLabs,  Hitchen, UK 
 
Phospho-SAPK/JNK Primary Antibody 
 
New England BioLabs,  Hitchen, UK 
 
Polyoxyethylene-Sorbitan Monolaurate 
(Tween-20) 
Sigma-Aldrich,  Poole, UK 
 
Polymyxin B 
 
Sigma-Aldrich,  Poole, UK 
Polystyrene Round Bottomed (5ml) FACS 
Tubes 
Becton Dickinson, Oxford, UK 
Recombinant Human GM-CSF 
 
R&D systems, Oxford, UK 
 
Recombinant Human CXCL8 Standard 
 
R&D systems, Oxford, UK 
 
Recombinant Human IL-6 Standard 
 
R&D systems, Oxford, UK 
 
Recombinant Human TNFα Standard R&D systems Oxford, UK 
Roswell Park Memorial Institute media 
(RPMI) – 1640 
Sigma-Aldrich,  Poole, UK 
 
Saponin 
 
Sigma-Aldrich,  Poole, UK 
Sodium Azide 
 
Sigma-Aldrich,  Poole, UK 
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Sodium Chloride (0.9%) 
 
Baxter Healthcare, Northampton, UK 
Sodium Chloride 
 
VWR, Leicester, UK 
Sonicator 
 
Fisher Scientific, Leicester, UK 
Streptavidin-conjugated horseradish 
peroxidise 
Invitrogen, Paisley, UK 
SRM-1650B National Institute of Standards & 
Technology, Gaithersburg MD, USA 
SRM–2975 
 
National Institute of Standards & 
Technology, Gaithersburg MD, USA 
Streptomycin Sigma Aldrich, Poole, UK 
 
Sucrose 
 
Fisher Scientific, Leicester, UK 
 
Syringes 
 
3S Healthcare, London, UK 
 
Toludine blue Sigma-Aldrich, Poole, UK 
 
Total- ERK 1/2 primary antibody 
 
New England BioLabs,  Hitchen, UK 
Total- HSP27 primary antibody 
 
New England BioLabs,  Hitchen, UK 
Total-p38α primary antibody New England BioLabs,  Hitchen, UK 
 
Total-SAPK/JNK MAPK primary antibody 
 
New England BioLabs, Hitchen, UK 
 
Trizma base (TRIS) 
 
Sigma-Aldrich, Poole, UK 
 
Trypan blue Sigma-Aldrich, Poole, UK 
 
Tetramethylbenzine Solution 
(TMB) 
B.D Optima,  Oxford, UK 
UVP GelDoc-IT Imaging System 
(Densitometer) 
UVP, Cambridge, UK 
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β-Mercaptoethanol Sigma-Aldrich, Poole, UK 
 
4',6-Diamidino-2-phenylindole 
dihydrochloride (DAPI) 
Sigma-Aldrich, Poole, UK 
0.2µm Sized Inert Beads Sigma-Aldrich, Poole, UK 
 
10µm Sized Inert Beads Sigma-Aldrich, Poole, UK 
 
30µm Sized Inert Beads Sigma-Aldrich, Poole, UK 
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2.2 Methods 
2.2.1 Subject Selection: Blood Sampling and Lung Function 
Measurements 
Whole blood was collected by venepuncture from healthy non-smoker, smoker and 
COPD volunteers recruited from the National Heart & Lung Institute (NHLI), London, 
Royal Brompton Hospital (RBH), London and Wexham Park Hospital, Slough, 
Berkshire. All volunteers gave written and informed consent as approved by the 
Health Research Authority (HRA) Ethics Committee, Chelsea, London (previously 
known as NHS Royal Brompton, Harefield and the NHLI Research Ethics 
Committee) (See Appendix I).  
2.2.1.1 Non-smokers  
Non-smokers aged between 45 - 80 years had normal lung function as predicted by 
age, sex and height, with normal bronchial reactivity (see section 2.2.1.6). 
Volunteers had no history of respiratory disease, no history of cigarette smoking and 
were not taking regular medication. 
2.2.1.2 Smokers 
Smokers aged between 45 - 80 years had normal lung function as predicted by age, 
sex and height, with normal bronchial reactivity, no history of respiratory disease and 
were not taking regular medication. Smokers had a smoking history of at least 10 
pack years (a pack year defined as 20 cigarettes per day for one year). 
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2.2.1.3 COPD Patients 
COPD patients were aged between 45 - 80 years.  Inclusion criteria for patients with 
COPD were in accordance with the Global Initiative for Chronic Obstructive Lung 
Disease guidelines (Vestbo et al. 2012). Patients with COPD had a forced expiratory 
value (FEV1): forced vital capacity (FVC) ratio of <0.7, a post-bronchodilator FEV1 % 
predicted of <85%, and no previous history of other respiratory diseases. Patients 
with COPD also had a smoking history of at least 10 pack years. Patients were 
excluded from the study if they presented with significant findings in medical records, 
or upon examination, apart from symptoms associated with COPD. 
2.2.1.4 Clinical Measurements 
Lung function measurements were undertaken by respiratory nursing staff located at 
the Royal Brompton, Harefield and Wexham Park hospitals. 
2.2.1.5 Spirometry 
FEV1 and FVC were measured using a spirometer. Readings were expressed as 
absolute values or as a percentage of predicted values for age, sex and height. 
Baseline readings were recorded by taking the highest reading following three 
attempts; each attempt was separated by 1min intervals. Predicted values were 
based on calculations derived from Crapo tables, which assign predicted values by 
correlating age, sex and height (Crapo et al. 1981). 
2.2.1.6 Bronchial Reactivity 
Volunteers underwent a bronchial reactivity challenge to assess airway 
responsiveness. The challenge involved inhaling methacholine chloride at increasing 
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doses between 0.0625 - 64mg/ml diluted in 0.9% (W/V) sodium chloride (saline). 
FEV1 was measured (Section 2.2.1.5), following inhalation of each individual dose of 
methacholine chloride. 
On arrival volunteers were asked to rest for 15 min before baseline spirometry was 
measured. Following baseline assessment, volunteers inhaled five deep breaths of 
nebulised saline, delivered via a breath-activated dosimeter (Mefar Dosimeter MB3, 
Brescia, Italy) and held their breath for 6 s. Following inhalation of saline, each dose 
of methacholine was inhaled and FEV1 measurements were recorded at 30 and 180 
s. If FEV1 fell by 20% and was reversible using a bronchodilator (salbutamol), the 
challenge was stopped and the volunteer was excluded from the study. This is 
because any suggested airway hyper-responsiveness is consistent with a diagnosis 
of asthma rather than COPD (Cockroft 2010). 
2.2.2 Isolation of PBMC  
Peripheral blood mononuclear cells (PBMC) were isolated from 60ml whole blood 
obtained from non-smokers, smokers and COPD patients. Blood was collected in 
0.5M of the chelating agent ethylene-diamine-tetra-acetic acid (EDTA), and divided 
into 3 x 20ml aliquots. Red blood cells (RBC) were sedimented using 6% (W/V) 
dextran diluted in 0.9% (W/V) sodium chloride, and further diluted in Hank's balanced 
salt solution (HBSS) to isolate PBMC. In brief, 3 x 20ml aliquots of blood were 
transferred into separate 3 x 50ml centrifuge tubes and mixed with 20ml HBSS and 
10ml of 6% (W/V) dextran solution, giving a total volume of 50ml. Blood was 
sedimented at room temperature (RT) for 20 min, after which the PBMC-rich layer 
was collected and transferred to clean 3 x 50ml centrifuge tubes. PBMC were 
washed twice with 15ml HBSS by centrifuging for 5 min at 400 x g at 22°C. 
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PBMC were separated from granulocytes using a discontinuous Percoll density 
gradient. The discontinuous gradient was prepared by diluting neat Percoll (1:10) 
with 9% (W/V) sodium chloride solution to obtain a 100% working concentration. The 
working concentration of Percoll was further diluted with 0.9% (W/V) sodium chloride 
to obtain the following density fractions: 81% (V/V), 67% (
V/V) and 55% (
V/V). These 
fractions were prepared by diluting 8.1ml, 6.7ml and 5.5ml Percoll with 1.9ml, 3.3ml 
and 4.5ml of 0.9% (W/V) sodium chloride, respectively. Once prepared, 4ml of the 
81% (V/V) fraction was transferred to 15ml centrifuge tubes, followed by carefully 
over-laying 4ml of the 67% (V/V) fraction. The discontinuous Percoll gradient was 
completed by re-suspending pelleted PBMC in 4ml of the 55% (V/V) fraction and 
carefully layering the cells upon the 67% (V/V) fraction. The discontinuous Percoll 
gradient was centrifuged at 750 x g for 30 min at 22°C to separate PBMC from 
granulocytes. PBMC were collected from the 55%/67% interface and were washed in 
50ml HBSS by centrifuging at 400 x g for 5 min at 22°C. PBMC were then re-
suspended in 10ml MDM ‘complete media' (Roswell Park Memorial Institute (RPMI)-
1640, containing 10% (V/V) foetal calf serum (FCS), 10mg/ml (1% (
V/V) 
penicillin/streptomycin (PS), 2mM (1% (V/V)) L-glutamine (LG)), and an aliquot 
withdrawn to perform a cell count. The aliquot of PBMC were diluted 1:10 in Kimura 
dye (0.05% (V/V) toluidine blue, 0.03% (
V/V) light green, 10% (
V/V) saponin, 0.07M 
phosphate buffer pH 6.4) and cells were counted on a haemocytometer. Once the 
cells had been counted the PBMC were centrifuged at 300 x g for   min at 22  and 
re-suspended at 1 x 106 cell/ml in MDM media. 
2.2.3 Monocyte Differentiation to MDM  
PBMC were seeded onto 96-well clear-bottom, black plates at 1 x 105 cells/well and 
incubated for 2h at 37°C, 5% (v/v) CO2 to allow monocytes to adhere to the plastic 
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surface (Tudhope, Finney-hayward, et al. 2008). Following incubation, non-adherent 
cells were aspirated and the attached monocytes were cultured in MDM media 
containing 2ng/ml granulocyte macrophage-colony stimulating factor (GM-CSF). 
Monocytes were incubated for 12d to allow full differentiation into MDM; cells were 
replenished with fresh MDM media containing GM-CSF on days 4 and 7 (Taylor et 
al. 2010). 
2.2.4 DEP Sample Collection  
Three different samples of DEP were used in this project, namely DEP used by 
Nightingale et al. 2000, termed DEP-N herein, and standard reference material 
(SRM)-1650B and SRM-2975 purchased from the National Institute of Standards 
and Technology (NIST) (Gaithersburg, MD, USA). DEP-N was prepared by placing 
cyclone collectors on the exhaust of a stationary diesel engine. The engine was run 
at 3,000 rpm with break pressure applied at 300-500-kPa, with a 20% exhaust-gas 
re-circulation fraction. A heat-exchanger, four cyclones and a standard gas 
recirculation route were used to mimic the use of a light-duty vehicle. DEP-N were 
collected and passed through a 20μm sieve and stored in a tight-lidded container. 
DEP-N were representative of the emissions of a light-duty engine. 
SRM-1650B and SRM - 2975 were reported by NIST to have an average particulate 
diameter of 0.18µm and 11.2µm respectively. SRM-1650B and SRM-2975 particles 
are representative of the emissions from an industrial-forklift truck and a heavy-duty 
engine, respectively. SRM-1650B material was generated by several direct four-
stroke engines operating under different conditions which were representative of 
heavy-duty engine emissions. SRM-1650B were collected from heat exchangers of a 
dilution tube facility following 200 hr of particulates accumulating. SRM-2975 material 
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was collected from a filter system designed for diesel-powered fork-lifts. SRM-2975 
was received by NIST in a 55-gal drum and homogenised using a V-blender before 
packaging in polyethylene bags. Both samples were analysed for adsorbed PAH and 
nitro-PAH constituents, with values given on reference certificates (See Appendix 
III). 
2.2.5 Metal Composition of DEP Samples 
The composition of metals adsorbed to the surface of the DEP samples was 
identified by inductively coupled plasma atomic emission spectroscopy (ICP-OES). 
This assay was kindly performed by Dr J Seiffert and Mr P Maguire, Imperial College 
London. In brief, DEP samples were introduced into flowing argon to form plasma, 
which contained a rich source of both excited and ionized atoms. Light emitted by 
elements in the samples was measured. To determine the elemental composition of 
DEP-N, SRM-1650B or SRM-2975 samples, emission intensities were compared to 
the intensities of five standard solutions of known concentrations. 
2.2.6. Detection of Endotoxin on DEP samples 
DEP and lipopolysaccharide (LPS) were each re-suspended in sterile HBSS (pH 7.5) 
to obtain a concentration range of 1-100µg/ml for DEP and 0.01-100ng/ml for LPS. 
Endotoxin concentrations used to produce the standard curve were prepared by 
diluting 50µl reconstituted stock endotoxin standard (50 EU/ml) with 35µl endotoxin 
free water (EFW) to obtain a concentration of 30EU/ml. 50µl of EFW was pipetted in 
duplicate into wells on the microtitre plate provided with the kit, to which 33µl of the 
30EU/ml concentration was pippetted into the assigned wells to obtain the highest 
concentration for the standard curve of 10EU/ml (Figure 2.1). Serial dilutions were 
then performed by transferring 33µl of the 10EU/ml concentration of endotoxin and 
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pipetting it into subsequent wells; 33µl from this well was then transferred to the next 
well and so on to obtain a range of endotoxin concentrations from 10EU/ml - 0EU/ml. 
50µl DEP (with unknown concentrations of endotoxin), or LPS samples, were 
pipetted to assigned wells on the microtitre  plate, followed by 50µl limolas 
amebocyte lysate (LAL) reagent, and incubated for 45 min at RT to enable the 
reagent to bind to the endotoxin (successful binding of LAL reagent to endotoxin 
produces a yellow colour). Colour formation was closely monitored and the reaction 
was stopped by pipetting 50µl of 'stop' solution (50% (V/V) acetic acid diluted in 15ml 
distilled water). Absorbance was read on a plate reader at λ 405nm. The lower limit 
of detection of the assay was 0.04EU/ml. 
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Figure 2.1 Endotoxin Standard Curve 
Standard curve used to interpolate unknown concentrations of endotoxin on DEP 
and LPS samples. Data are in triplicate and are mean ± SEM, n =1. 
 
Chapter 2: Materials and Methods 
 
62 
 
2.2.7 MDM Treatments 
2.2.7.1 Treatment of MDM with Inert Beads 
Inert, polystyrene-based beads of different sizes (30µm, 10µm or 0.2µm) were 
commercially brought as a suspension in aqueous solution. The beads were further 
suspended in 10x D-PBS to obtain an isotonic solution. Beads were sonicated for 2 
min and aliquoted into 1.5ml Eppendorf tubes and stored at -20˚  until required. 
Prior to MDM treatment, inert beads were sonicated and 300µl of inert beads were 
diluted in 700ml of RPMI-1640 serum-free cell culture media to obtain a stock 
concentration of 30mg/ml. Inert beads were further diluted in cell culture media to 
obtain the concentration range of 1-300 µg/ml (Figure 2.2). MDM were treated with 
the beads (1-300 µg/ml) and incubated for 24h at 37˚  in  % (V/V) CO2. 
2.2.7.2 Treatment of MDM with DEP Samples 
DEP-N, SRM-1650B or SRM-2975 were reconstituted in warmed HBSS at a stock 
concentration of 30mg/ml. DEP-N, SRM-1650B or SRM-2975 were then sonicated 
for 2 min to disaggregate particles, and aliquotted into 0.5ml Eppendorf tubes and 
stored at -20°C until required. Prior to treatment of MDM, DEP were again sonicated 
for 2 min and diluted in RPMI-1640 serum-free cell culture media to give a 
concentration range of 1-300µg/ml (Figure 2.2). MDM treated with DEP were 
incubated for 24h at 37˚  in  % (V/V) CO2.  
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2.2.7.3 Treatment of MDM with DEP or LPS, With or Without 
Polymyxin B 
In order to determine the contribution, if any, of LPS to any MDM responses 
observed, polymyxin B was used to inhibit the activity of LPS via its LPS-binding and 
neutralising activity. Polymyxin B (120mg/ml) was diluted in 12ml filter-sterilised 
double-distilled water (ddH2O), to obtain a stock concentration of 10mg/ml. 50µl 
polymyxin B was aliquoted into 0. ml  ppendorf tubes and stored at 4  until 
Figure 2.2 Dilution of Inert-Beads or DEP Samples  
MDM were treated with increasing concentrations of inert beads or DEP (1-
300µg/ml), to determine their effect on MDM function. To prepare these 
concentrations, particles (30mg/ml) were diluted 1:100 by transferring 50µl of 
particles (30mg/ml) to 4.50ml of cell culture media to obtain the top concentration of 
300µg/ml (blue arrow). Subsequently, a 1:3 dilution of the 300µg/ml concentration 
was prepared by pipetting 1ml particles (300µg/ml) to 2ml cell culture media, to 
obtain a concentration of 100µg/ml (red arrow). In addition, a further 1:10 dilution 
was prepared from the 300µg/ml of particles to obtain a concentration of 30µg/ml 
(black dashed arrow). Serial dilutions were performed by diluting particles 
(100µg/ml) 1:10 by transferring 200µl particles (100µg/ml) to 1.8ml of media (black 
solid arrow) to obtain the following concentrations: 10µg/ml (red dashed arrow) and 
1µg/ml (red arrow).  
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required. Polymyxin B treatment was prepared by diluting polymyxin B 1:1000 in 
serum-free RPMI-1640 cell culture media to obtain a working concentration of 
10µg/ml. DEP-N (1-100µg/ml) (Section 2.2.7.2) or LPS (10ng/ml) (Section 2.2.7.4) 
was prepared in cell culture media with or without polymyxin B and incubated for 1hr 
at RT. Following incubation, 150µl DEP (1-100µg/ml) or LPS (10ng/ml), diluted with 
or without polymyxin B, was pipetted onto MDM. Cells treated with only media or 
media containing polymyxin B (10µg/ml) were used as non-stimulated baseline 
controls and were incubated at 37C, 5% (V/V) CO2 for 24h. Following incubation, 
supernatants were harvested and analysed for release of CXCL8 using enzyme-
immunosorbant assays (ELISA) (Section 2.2.10).  
2.2.7.4 Preparation and Treatment of MDM with LPS with or without 
Polymyxin B 
Lyphophilised LPS was reconstituted by pipetting 1ml of D-PBS to obtain a stock 
concentration of 1mg/ml. 5µl of LPS was then aliquotted into 0. ml  ppendorf tubes 
and stored at -20  until required.  PS was diluted 1 10 000 to obtain a concentration 
of 100ng/ml by pipetting 2.2µl LPS (1mg/ml) into 18.8ml RPMI-1640 cell culture 
media. This was then further diluted 1:10 by adding 200µl of 100ng/ml LPS to 1.8ml 
cell culture media to obtain a concentration of 10ng/ml. For polymyxin B experiments 
MDM cultured at 1x105 cells/well were treated with 100µl LPS (10ng/ml) prepared 
with or without polymyxin B and incubated for 1h as described in Section 2.2.7.3. In 
addition to the polymyxin B experiments, LPS (10ng/ml) was also used as a positive 
control for western blot experiments, including DEP-N concentration response 
(Section 2.2.7.5) and time-course (Section 2.2.7.6) experiments.  
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2.2.7.5 Western Blot: DEP-N Concentration-Response 
MDM were cultured on a 24-well plate at a density of 5x105 cells/well as described in 
Section 2.2.3. Cells were treated with 500µl of either increasing concentrations of 
DEP-N (1-100µg/ml) or LPS (10ng/ml) and incubated at 37    % (V/V) CO2 for 1hr as 
described in Section 2.2.7.2 and Section 2.2.7.4 respectively. Following incubation, 
media was removed and cells were washed using 500µl ice-cold D-PBS. The D-PBS 
was then removed and 15µl lysis buffer containing 10µl protease and phosphatase 
inhibitors was pipetted onto cells as described in Section 2.2.11.1. Cell membranes 
and total protein were collected using a cell scraper and transferred to pre-chilled 
0.5ml Eppendorf tubes. Phosphorylation of either p38 MAPK, or ERK 1/2, or JNK 
was determined by western blotting as described in Section 2.2.11.6. 
2.2.7.6 Western Blot: DEP-N Time-Course Study 
MDM were cultured on 24-well plates at a density of 5X105 cells/well as described in 
Section 2.2.3. MDM were incubated at 37    % (V/V) CO2 with 500µl DEP-N at 0, 5, 
10, 20, 40 and 60 min, or in LPS (10ng/ml) for 60 min. Following incubation, 
supernatants were removed and cells were immediately placed on ice. Cells were 
washed with 1ml ice-cold PBS, and 15µl 1x lysis buffer was pipetted onto MDM as 
described in Section 2.2.11.1. Cell membranes and total protein was collected using 
a cell scraper and transferred to pre-chilled 0.5ml Eppendorf tubes. Phosphorylation 
of p38 or ERK 1/2 was determined by western blotting as described in Section 
2.2.11.6. 
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2.2.7.7 Western Blot: Treatment of MDM with p38 Inhibitor  
Lyphophilised p38 inhibitor (PF755616) was reconstituted in neat dimethyl sulfoxide 
(DMSO) to obtain a stock concentration of 10mM and stored at -20oC until required. 
The p38 inhibitor was diluted in 1:1000 in RPMI-1640 cell culture media to obtain the 
top concentration of 10µM (10-5M) (Figure 2.3). This was performed by transferring 
2µl of the p38 inhibitor to 1.98ml of cell culture media. The top concentration of the 
p38 inhibitor was further diluted to obtain a concentration range of 10-5 - 10-10M, 
performed as serial dilutions. In brief, 200µl of 10-5M was transferred to 1.8ml cell 
culture media, and diluted by 1:10 serial dilutions to obtain a concentration range of 
10-5 - 10-10M. MDM were cultured on 96-well black plates and were treated with 
100µl of 10-5 – 10-10M inhibitor and incubated at 5% (V/V) CO2, 37
oC for 1h. Following 
incubation, supernatants were removed and DEP-N (100µg/ml) was transferred to 
cells and further incubated in 5% (V/V) CO2, 37
o  for 24h. Following incubation  
supernatants were harvested and stored at -20  until required for   ISA (Section 
2.2.10). For western blot experiments, MDM were cultured on 24-well plates at a 
density of 5X106 cells/well as described in Section 2.2.3. MDM were treated with 
500µl increasing concentrations of p38 inhibitor (10-5 - 10-10M) and incubated in 5% 
(V/V) CO2, 37
oC for 30min. Supernatants were removed and 500µl DEP-N was 
applied and further incubated for 1h in 5% (V/V) CO2, 37
oC for 30min. Following 
incubation, cells were lysed and proteins were separated by western blotting as 
described in Section 2.2.11. To determine functionally whether or not p38 had been 
inhibited, phosphorylation of the downstream signalling component heat shock 
protein 27 (HSP27) was examined as described in Section 2.2.11.6.   
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2.2.7.8 Western Blot: Treatment of MDM with MEK 1/2 Inhibitor  
The MEK 1/2 inhibitor (PD98059) was reconstituted in neat DMSO to obtain a stock 
concentration of 30mM and stored at -20  until required. The M   1 2 inhibitor was 
diluted 1:1000 in RPMI-1640 serum-free cell culture media to obtain the top 
concentration of 30µM, by pipetting 3µl stock solution of inhibitor to 2.97ml media. 
The top concentration of the MEK 1/2 inhibitor was further diluted in media as shown 
in Figure 2.4  to obtain the concentration range 30µM - 0.1µM. In brief, 1ml of the 
30µM concentration of MEK 1/2 inhibitor was diluted in 2ml media to obtain a 
concentration of 10µM. The 30µM concentration was again diluted 1:10 by 
transferring 200µl inhibiter to 1.8ml media to obtain the 3µM concentration. Serial 
 
Figure 2.3 Serial Dilution of Stock p38 Inhibitor (PF755616) 
The stock concentration of the p38 inhibitor (10mM) was diluted 1:10 (blue arrow) in 
2ml serum-free cell culture media to obtain a working concentration of 10-5 M. Serial 
dilutions (red arrows) were performed on the working concentration of the p38 
inhibitor by transferring 200µl 10-5 M concentration to 1.8ml cell culture media (black 
arrow); this was repeated to obtain a concentration range of 10-5 – 10-10M.  
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dilutions were then performed on the 10µM inhibitor concentration to obtain the 1µM 
and 0.1µM concentrations. In brief, 200µl of the 10µM concentration was pipetted 
into 1.8ml cell culture media to obtain the 1µM concentration, and subsequently 
200µl of the 1µM concentration was diluted in 1.8ml media to obtain the 0.1µM 
concentration. Once the required concentrations were prepared, 100µl of MEK 1/2 
inhibitor (30µM - 0.1µM) was pipetted on to MDM cultured on 96-well black plates 
and incubated in 5% (V/V) CO2, 37
oC for 1h. Supernatants were aspirated and 150µl 
of DEP-N (100µg/ml) was transferred to MDM and further incubated in 5% (V/V) CO2, 
37oC for 24h. Following incubation, supernatants were harvested and stored at -20oC 
until required for ELISA experiments (Section 2.2.10). For western blot experiments, 
MDM were cultured on 24-well plates at a density of 5X106 cells/well as described in 
Section 2.2.3. MDM were treated with 500µl PD98059 (0.1µM - 30µM) and incubated 
at 37oC, 5% (V/V) CO2 for 30 min. Following incubation, supernatants were aspirated 
and 500µl DEP-N (100µg/ml) was pipetted on to cells and further incubated at 37oC, 
5% (V/V) CO2 for 1 hr. Supernatants were removed and cells were lysed and proteins 
were separated by western blotting as described in Section 2.2.11. To determine 
whether the ERK 1/2 pathway was inhibited by the MEK 1/2 inhibitor, 
phosphorylation of ERK 1/2 was examined as described in Section 2.2.11.6.   
 
 
 
 
 
Chapter 2: Materials and Methods 
 
69 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.7.9 Measurement of Phagocytosis by MDM   
The phagocytic capacity of MDM treated with inert beads of different sizes or DEP 
was assessed by further exposing MDM to carboxylate-based fluorescent beads 
(size: 2µm). Fluorescent beads were suspended in serum free RPMI-1640 cell 
culture media at a concentration of 50x106 beads/ml. 100µl fluorescent beads was 
pipetted onto DEP or inert bead-treated MDM and incubated for 4h at 37˚  in  % 
(V/V) CO2 (Taylor et al. 2010). 
 
 
Figure 2.4 Dilution of Stock MEK 1/2 Inhibitor (PD98059)  
The concentration range of the MEK 1/2 inhibitor (PD98059) required to treat MDM was 
between 0.1µM - 30µM. To prepare these concentrations, the stock concentration of MEK 
1/2 inhibitor (30mM), was diluted 1:10 (blue arrow) in serum-free cell culture media to 
obtain a working concentration of 30µM. The 30µM concentration was further diluted 1:3 
by transferring 1ml of the 30µM inhibitor to 2ml of media to obtain the 10µM concentration 
(red arrow). 200µl of the 30µM concentration of inhibitor was further diluted in 1.8ml of 
media to obtain a concentration of 3µM (black dashed arrow). 200µl of the 10µM 
concentration was pipetted to 1.8ml cell culture media (black solid arrow) to obtain a 
concentration of 1µM (red dashed arrow); subsequently 200µl from the 1µM 
concentration was pipetted to 1.8ml of cell culture media to obtain the final 0.1µM 
concentration (red arrow).  
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2.2.7.9.1 Quantification of Phagocytosis 
MDM were washed with 100µl PBS and any extracellular fluorescence was 
quenched using 1% (V/V) trypan blue for 2 min. Trypan blue was aspirated and 
phagocytosis of fluorescent beads by MDM was measured using fluorimetery 
(Fluostar Optima BMG LabTech  Aylesbury  Buckinghamshire) at excitation λ 480nm 
and emission λ  20nm. Data were expressed as relative fluorescent units (RFU). 
2.2.8 Cell viability 
2.2.8.1 MTT Assay 
MDM viability was determined by the MTT assay which measures mitochondrial 
function. MDM were incubated with 0.1% (W/V) 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium (MTT) and incubated at 37°C, 5% (V/V) CO2 for 1 h at RT. During 
incubation, MTT is reduced to formazan by mitochondrial dehydrogenases of 
metabolically active cells, and is visualised by the formation of an insoluble purple 
precipitate. The MTT was aspirated and cells were lysed by 100µl neat DMSO. To 
avoid interference with the assay by DEP that had been phagocytosed by cells, 
plates were centrifuged at 400 x g for 5 min and lysates were transferred to separate 
clear 96-well plates. Absorbance was measured at λ  70nm by spectrophotometry. 
Results were expressed as a percentage of non-stimulated cells, which were 
considered 100% viable. 
2.2.8.2 Detection of Apoptosis and Necrosis 
Apoptosis and necrosis of DEP-N-treated MDM were determined by staining cells 
with annexin V conjugated to the flurochrome phycoerythrin (PE) and 7-Amino-
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Actinomycin (7-AAD). The Annexin V PE and 7-AAD kit was purchased from BD 
Biosciences  Oxford  U  and the protocol was followed according to manufacturer’s 
instructions. In brief, 100µl DEP-N-treated MDM (1-100µg/ml; 1X106 cells/ml) were 
pipetted directly into FACS tubes and washed with ice-cold D-PBS by centrifugation 
at 400 x g. The cell pellet was re-suspended in 1 X binding buffer (10mM 
Hepes/NaOH (pH 7.4), 140mM NaCl, 25mM CaCl2) and 5µl Annexin PE and 5µl 7-
AAD were pipetted into corresponding FACS tubes. Cells were incubated in the dark 
for 15 min at RT. Following incubation, cells were washed with D-PBS by 
centrifugation at 400 x g and re-suspended in 4% (V/V) paraformaldehyde (PFA). 
Samples were analysed using flow cytometry (BD FACScanto II flow cytometer, UK). 
For each sample processed, doublets (cells stuck together) were selected out from 
the population of single cells being analysed. Doublets were removed by identifying 
where the cells had distributed on a forward and side scatter height vs width dot-plot. 
If cells had distributed away from the main cell population, gates were applied to 
prevent the former data being collected (Figure 2.5).  For each sample processed, 
10,000 events were recorded. The Annexin V kit, quantified the percentage of cells 
undergoing apoptosis or necrosis according to their distribution on a dot plot (Figure 
2.6). Cells which had stained positive with Annexin-PE were considered to be 
undergoing early apoptosis, whereas cells which had stained positive with 7-AAD 
were considered to be undergoing necrosis. Cells which had stained positively for 
both Annexin-PE or 7-AAD were undergoing necrosis, whilst unstained cells were 
considered to be viable (Figure 2.6). Data were analysed using CellQuest software. 
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C. D.
Figure  2.5 Removing Doublets from Single Cell Suspensions 
MDM were treated with 1-100µg/ml DEP and incubated for 24h at 37ºC in 5% CO2. To 
determine whether DEP induced cell apoptosis or necrosis, MDM were analysed using flow 
cytometry. (A) MDM from a smoker were selected by ‘gating’ around the main cell 
population to avoid inclusion of monocytes or debris. To prevent two or more cells from 
being processed at the same time, gates were applied to cells and assessed according to 
their size and granularity on a forward- and side-scatter dot-plot; these cells were termed 
‘doublets’. (B)  ells were examined on a forward-scatter dot-plot according to their height 
and width and large cells were removed by applying a gate on the discrete single-cell 
population and any large cells were excluded. (C) A side-scatter dot-plot was also used, to 
exclude any cells which had an excess granularity according to the height or width of the 
cell, as this was representative of doublets. (D) Following removal of doublets the 
suspension of single cells was processed.  
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Figure 2.6 Dot-Plots of DEP-N-Treated MDM Undergoing Apoptosis or Necrosis 
To differentiate whether DEP or inert bead-treated cells underwent apoptosis or necrosis, 
cells were stained using PE (marker of apoptosis) or 7AA-D (marker of necrosis) and 
analysed according to their location on flow cytometry dot-plots. (A-B) Non-stimulated viable 
cells from a non-smoker and smoker were located in the lower left quadrant. (C) Apoptotic 
cells that had stained positively for PE only, were located in the lower right quadrant, whereas 
necrotic MDM that had stained positively for 7-AAD only, were located in the upper left 
quadrant. (D) Cells which had stained positive for both PE and 7-AAD were located in the 
upper right quadrant and were considered to be undergoing necrosis.  
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2.2.9 Imaging of DEP 
2.2.9.1 Light Microscopy Imaging of DEP  
Stock concentration of DEP-N, SRM-1650B and SRM-2975 (30mg/ml) were 
sonicated for 5 min and diluted in RPMI-1640 media or double-distilled water 
(ddH2O) to obtain a concentration of 300µg/ml. 100µl of each sample was pipetted 
onto a 48-well flat bottom clear plate and viewed under an inverted light microscope 
using a X20 objective lens. Images were captured using an Olympus SLR camera 
fitted with a microscope-compatible adaptor. 
2.2.9.2 Light Microscopy Imaging of MDM Incubated with DEP or 
Inert Beads 
MDM (1 x 105 cells/well) cultured on 96-well flat bottom black plate were treated with 
150µl of D P or inert bead (1-100 g ml) samples and incubated at 37    % (V/V) 
CO2 for 24h as described in Section 2.2.7.1 and Section 2.2.7.2 respectively. Images 
of MDM treated with DEP or inert beads were captured using a X20 objective lens on 
via an Olympus SLR camera fitted with a microscope-compatible adaptor. 
2.2.9.3 Fluorescent Microscopy Imaging of DEP-Treated or Inert-
Bead-Treated MDM Incubated with Fluorescent Beads 
MDM were treated with 150µl of increasing concentrations of DEP or inert beads (1-
100µg/ml) samples as described in Section 2.2.7.1 and Section 2.2.7.2 respectively. 
Following treatments, MDM were incubated at 37oC, 5% (V/V) CO2 for 24h and  
subsequently  supernatants were collected and stored at -20  until required. D P- 
or inert-bead-treated MDM were subsequently incubated with 100µl fluorescent 
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beads (50x106 beads/ml) at 37oC, 5% (V/V) CO2 for 4h as described in Section 
2.2.7.9. Following incubation, supernatants were removed and cells were washed 
with 100µl D-PBS, and extracellular fluorescence was quenched using 100µl 1% 
(V/V) trypan blue. DEP-treated or inert bead-treated MDM were viewed under an 
inverted light microscope using a fluorescent lamp. Images were captured using a 
X20 objective lens via an Olympus SLR camera fitted with a microscope-compatible 
adaptor. 
2.2.9.4 Transmission Electron Microscopy (TEM) 
2.2.9.4.1 TEM: Particle Characterisation    
DEP samples were diluted in ddH2O to obtain a concentration of 300µg/ml. DEP 
were sonicated for 30 min and 15µl of each sample was transferred to formvar-
coated copper grids and incubated overnight at RT. Particles were stained using 1% 
(V/V) uranyl acetate and incubated for 10 min. Grids were washed with ddH2O and 
excess moisture was removed using filter paper. Grids were air dried for 15 min and 
particle morphology and geometric diameters were analysed using TEM.  
2.2.9.4.2 TEM: Internalisation of DEP-N by MDM 
MDM cultured on 24-well plates were treated with 1ml DEP-N at 1-100µg/ml and 
were incubated for 24h at 37°C, 5% (V/V) CO2. Cells were washed three times with 
500µl 0.9% (W/V) NaCl2 and fixed using 2.5% (
V/V) glutaraldehyde in (0.05M) 
cacodylate buffer (pH 5.0-7.4). Following dehydration, cells were incubated at 4oC 
for 2h. Glutaraldehyde was removed and cells were rinsed in cacodylate buffer three 
times prior to overnight incubation at 4oC. Cells were post-fixed in osmium tetroxide 
and incubated for 1h at 4oC. Cells were then washed twice with distilled water and 
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dehydrated by submerging in a series of graded ethanol solutions. Briefly, cells were 
incubated in 70% (V/V) ethanol twice for 10 min each, followed by incubation in 90% 
(V/V) ethanol twice for 10 min and finally incubation in 100% (
V/V) ethanol three times 
for 10 min each. Once cells were fixed, ethanol was removed and replaced with 
araldite resin diluted 50:50 in neat ethanol and incubated for 24h at RT. Tissue 
culture plates were placed on a rotator to facilitate equal infiltration of araldite resin 
between samples. Following incubation, the diluted resin was removed and replaced 
with 100% (V/V) resin and further incubated for 2h. Using a pastette, epoxy resin was 
transferred to wells and precision-moulded embedding capsules (Beem capsules), 
that allow preparation of uniform, pre-shaped blocks, were filled with fresh resin. The 
capsules were inverted and affixed over the wells. Tissue culture plates were placed 
in the oven for 72h at 60oC to harden.  
2.2.9.4.3 TEM: Sectioning 
Once the resin had hardened, the Beem capsules were removed and sections were 
cut on a microtome. Glass knives were aligned to cut 1µm thick sections to 
determine the area of confluent cells. This was done by transferring the 1µm section 
to a glass slide and staining with toulene blue. The area of confluent cells was further 
reduced in size and ultra-thin sections of 75nm were taken. These sections were 
transferred to copper grids and stained using uranyl acetate for 7 min followed by 
washing with methanol. Sections were than submersed in lead citrate for 5 min and 
washed with methanol. Grids were placed on hardened wax paper to remove excess 
methanol before viewing by TEM. 
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2.2.9.5 Confocal Microscopy 
2.2.9.5.1 DEP-N Treatment of MDM  
Peripheral blood monocytes monocytes (2 X 105/well) were cultured on Lab-tek 
permanox 8-well chamber slides in the presence of GMCSF (2ng/ml) for 12 days to 
enable differentiation towards the MDM phenotype (Section 2.2.3). MDM were 
exposed to 200µl DEP-N (1-100µg/ml) and incubated for 24h in 5% CO2 at 37°C. 
MDM incubated in only RPMI-1640 cell culture media served as non-stimulated 
controls. Fluorescent beads were transferred to MDM and incubated for a further 4h. 
Particles which had not been phagocytosed were aspirated and extracellular 
fluorescence was quenched by 1% (V/V) trypan blue followed by repeated washing 
with D-PBS as described in Section 2.2.7.9.1. 
 2.2.9.5.2 Staining 
MDM cytoplasm was stained using a working concentration of 12.5mM Cell 
TrackerTM red, diluted in D-PBS by incubating for 45 min at 37oC. Following 
incubation, cells were further incubated in pre-warmed RPMI-1640 cell culture media 
for 30 min at 37oC. Cells were fixed by incubating with 200µl 4% (W/V) PFA for 10 min 
at RT, followed by repeated washing with D-PBS. The cell nuclei were stained with 
2µM DAPI and incubated for 3 min at RT. Cells were washed again with D-PBS and 
chambers were removed from the microscope slide. Cover-slips were affixed over 
the cells using citifluo and sealed with clear nail varnish. Slides were stored in the 
dark at 4°C.   
 
Chapter 2: Materials and Methods 
 
78 
 
2.2.9.5.3 Visualisation 
Microscope slides were viewed on a Leica SP2 upright confocal microscope. A 
series of 40 sequential, cross-sectional images of cells were taken to visualise the 
internalisation of DEP-N and fluorescent beads. Images were overlaid and 
remodelled using the Volocity ® 3D Imaging Analysis Software (PerkinElmer Inc., 
Massachusetts, USA). 
2.2.10 ELISA 
CXCL8, IL-6 and TNFα were measured by   ISA according to manufacturer’s 
instructions (R&D systems, Oxford, UK). Briefly, capture antibody was coated onto 
Nunc Maxisorp flat-bottom 96-well plates overnight RT. Plates were washed three 
times with wash buffer (0.05% (V/V) Tween-20 in PBS pH 7.1-7.5). Non-specific 
binding was blocked with 100μl blocking buffer ( % (W/V) sucrose, 1% (
W/V) BSA and 
0.01% (W/V) azide pH 7.4) and incubated for 1h at room temperature. Standards and 
supernatants were diluted in reagent diluent (1% BSA (W/V) in PBS) and were 
transferred to the plate and incubated for 2h at RT. Following incubation, plates were 
washed with wash buffer and 100µl detection antibody was transferred to wells and 
incubated for 2h at RT. Plates were washed  and 100μl streptavidin-conjugated-
horse radish peroxidase (HRP) was transferred to wells and incubated at RT for 20 
min. Following incubation  100μl tetramethybenzinidine substrate (1 1 colour 
substrate A (H2O2) and colour substrate B (TMB)) solution was applied and 
incubated until sufficient colour had developed. The reaction was stopped by adding 
 0 l 1M sulphuric acid. Absorbance was set at λ 4 0nm with wavelength correction 
at λ  70nm to determine optical density of each well. To determine the 
concentrations of mediators in unknown samples, readings of individual wells were 
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interpolated from the standard curve (Figure.2.7). The lower limit of detection for 
TNFα and  X  8 was 31.3pg/ml, and for IL-6 was 15.6pg/ml.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7 ELISA Standard Curves for CXCL8, IL-6 and TNFα 
 
Representative standard curves for (A)  X  8 (B) TNFα or ( ) I -6. Unknown 
concentrations of mediators released by DEP- or inert bead-treated MDM were 
interpolated from the curves. Mediator standards were processed in duplicate and 
data are expressed as medians or mean ± SEM, n=1. 
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2.2.11 Western Blotting 
2.2.11.1 Protein Extraction 
Following differentiation, MDM were exposed to various treatments (Section 2.2.7.5; 
Section 2.2.7.6; Section 2.2.7.7; Section 2.2.7.8). Media was removed and cells 
were washed with  00μl ice-cold D-PBS. The D-PBS was then removed and cells 
were lysed by addition of lysis buffer (150mM NaCl, 20mM Tris-HCl (pH 7.5), 1mM 
Na2EDTA,1mM EGTA, 1% (
w/v) Triton X-100, 2.5mM sodium pyrophosphate, 1mM 
beta-glycerophosphate, 1mM Na3VO4, 1µg/ml leupeptin) containing 10µl of protease 
and phosphatase inhibitors. Lysates were collected in pre-chilled Eppendorf tubes 
and centrifuged at 10000 x g, for 10 min at 4˚ . Following centrifugation  
supernatants were removed from sedimented debris and placed directly on ice.  
2.2.11.2 Protein Assay 
To determine protein levels in each sample, a BioRad protein assay was performed. 
In brief, 1mg/ml BSA was used to produce a standard curve in the range 0 - 1mg/ml. 
Samples were transferred in triplicate to a 96-well clear plate and treated with 200μl 
BioRad protein reagent (diluted 1:4 in distilled water). Absorbance was measured at 
ʎ 590nm with a spectrophotometer. Unknown protein concentrations of samples 
were interpolated from the standard curve (Figure 2.8).  
2.2.11.3 Preparation of Samples 
20μg ml protein from each sample was transferred to Eppendorf tubes and diluted 
with Laemelli sample buffer (62.5mM Tris-HCl, 10% (v/v) glycerol, 1% (
w/v) SDS, 1% 
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(v/v) β-mercaptoethanol, 0.01% (
w/v) bromophenol blue (pH 6.8)) to obtain a final 
volume of 30μl. These were then boiled for   min at 9 ˚  to denature proteins. 
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Figure 2.8 BSA Standard Curve for Protein Assay 
Representative BSA protein standard curve used to interpolate the concentration of 
protein in DEP-treated cell lysates. BSA standard samples were processed in 
duplicate. Data are mean ± SEM, n=1. 
 
2.2.11.4 Gel Electrophoresis 
4-12% bis-tris polyacrylamide gels (Invitrogen, Paisley, UK) were used to separate 
proteins according to size. Gels were secured within a glass tank filled with MOPS 
running buffer (250mM MOPS, 250mM Tris, 5mM EDTA, 1% (w/v) SDS, (pH 7.7)). 
Using loading micro-capillary pipette tips   μl of a molecular weight marker was 
transferred to gels along with 22μl sample to individual wells. The lid of the tank was 
Chapter 2: Materials and Methods 
 
82 
 
firmly secured and connected to a power source, and 100V was applied for 2h 
allowing the proteins to resolve. 
2.2.11.5 Transfer of Proteins to Hybond Nitrocellulose Membrane 
Proteins separated by gel electrophoresis were transferred to a Hybond 
nitrocellulose membrane. This involved assembling a transfer cassette containing 
sponge and blotting paper (3MM Chr chromatography paper) soaked in transfer 
buffer (0.191M glycine, 0.02M Tris-HCl, 20% (v/v) methanol, (pH7.4)). The gel and 
nitrocellulose membrane were then placed in between the stacked sponge and 
blotting paper and the cassette was closed. The cassette was then placed within a 
transfer tank along with an ice-pack to prevent the gel from over-heating. Transfer 
buffer was poured into the tank and connected to a power source. Proteins were 
transferred at 200mA and 200mV for 1h.  
2.2.11.6 Immunodetection 
The nitrocellulose membrane was incubated in 12ml blocking buffer (5% (w/v) non-fat 
dried milk dissolved in TBS-Tween 20 (0.5M Tris Base, 9% (w/v) NaCl, 0.5% (
v/v) 
Tween-20, pH 7.4)) for 1h at RT to prevent non-specific antibody binding. The 
primary antibody, against the protein of interest, was diluted 1:1000 in blocking buffer 
and poured over the membrane. The membrane was placed on a rotator and 
incubated at 4˚  overnight. The membrane was washed repeatedly with TBS-
Tween-20 buffer to remove unbound antibody followed by transferring the membrane 
to blocking buffer containing HRP conjugated secondary antibody (1:1000) and 
incubating for 1h at RT.  
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The membrane was then washed with TBS-Tween-20 buffer and incubated in 10ml 
enhanced chemiluminescence (ECL) detection solution (GE Healthcare, 
Buckinghamshire, UK) for 2 min at RT. The membrane was then wrapped in cling 
film and exposed to photographic film for 1-10 min. The film was developed using an 
AFP imaging developer (New York, USA) and the density of bands of interest was 
analysed using UVP GelDoc-IT Imaging System and Labworks Software.   
2.2.12 Statistical Analysis 
Data were compared for statistical significance between subject groups by one-way 
ANOVA followed by Dunnett’s test for multi-group comparisons. Data expressing a P 
value of <0.05, were considered to be statistically significant. Statistical differences 
were calculated using Prism V.5 (GraphPad, San Diego, USA). 
2.2.13 Overarching Timeline of Experiments  
See Figure 2.9. 
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3.1 Introduction  
Atmospheric pollution consists of a complex mixture of heterogeneous particles such 
as soot, dust, pollen and vehicle exhaust emissions. These particles are known as 
PM and are classified according to their size (Backes et al. 2013). For example, 
particles with a diameter <0.1µm, <2.5µm or <10µm are termed PM0.1, PM2.5 and 
PM10 respectively. Epidemiological studies show that increases in PM are associated 
with adverse respiratory health (Bell & Davis 2001; Dockery & Pope 1994). A major 
contributor to PM10 are DEP which are formed by incomplete combustion of diesel 
fuel. DEP consist of an elemental carbon core which binds a number of organic 
compounds, including PAHs and nitro-PAHS, endotoxin and metals including B, Ca, 
Fe and Zn (Wichmann 2007). 
The mechanism involved in the formation of DEP involve two 'modes', referred to as 
the nucleation mode and accumulation mode (Schneider et al. 2005). During the 
nucleation mode, liquid particles consisting of sulfate, water or semi-volatile organic 
components are formed by high temperatures created in the exhaust-pipe, and are 
typically between 5-50nm (Schneider et al. 2005). At high temperatures semi-volatile 
organic components are vaporised and on cooling they condense on to the surface 
of existing carbon particles (Ono-Ogasawara & Smith 2004). These particles 
aggregate leading to the formation of particles in the accumulation mode, and are 
typically between 30-500nm (Kittelson et al. 1999; Kittelson et al. 2006; Ma et al. 
2008). The chemical composition of DEP is complex and is influenced by particles in 
the nucleation mode as they are indirectly dependent on fuel type, engine type 
(heavy, light or industrial fork-lift) or engine operating conditions (Rönkkö et al. 2006; 
Saitoh et al. 2003). 
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Diesel exhaust emissions represent a mixture of fine (<2.5µm) and ultrafine particles 
(<0.1µm). Ultrafine particles are short-lived in the atmosphere and undergo rapid 
aggregation, but remain <2.5µm in diameter (Dockery & Pope 1994; Oberdöster 
2001). The small size of DEP enables them to be inhaled and deposited deep within 
the respiratory tract. In addition, the large surface area of these particles enables 
toxic compounds to condense or bind to their surface. Once inhaled, DEP are in 
direct contact with biological molecules and cells of the lung, and therefore, influence 
respiratory health. It is for this reason that the physical and chemical properties of 
DEP ought to be examined. 
The physical and chemical composition of DEP is dependent on engine type (light 
duty, heavy duty or industrial fork-lift), engine running conditions (idling, accelerating 
or de-accelerating) and fuel type. Standard reference material (SRM), namely diesel 
exhaust matter obtained from the National Institute of Standard and Technology 
(NIST, USA), has been previously characterised. SRM has been examined for 
average size of particles and proportions of organic and inorganic constituents 
adsorbed to the surface of the carbon core (Table 3.1 and Table 3.2). However, 
levels of adsorbed metals on SRM particles have not been characterised. SRM-
1650B is a particle sample from a heavy-duty engine with an average particle size of 
0.18µm. In contrast, SRM-2975 is a particle sample from an industrial fork-lift engine 
with an average size of 11.2µm. SRM-1650B has more PAHs and nitro-PAHs 
compared to SRM-2975 (Table 3.1 and 3.2). The DEP sample used by Nightingale 
et al. 2000 (DEP-N), was obtained from a light duty engine and has not been 
previously characterised. In the present investigation, the physical characteristics of 
DEP-N, SRM-1650B and SRM-2975 were visualised using light and electron 
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microscopy, and the metals adsorbed to their surface were examined using 
inductively-coupled plasma atomic emission spectroscopy (ICP-OES).  
From the above, the following hypothesis was proposed: ‘The three DEP samples 
used herein (DEP-N, SRM-1650B and SRM-2975) will display differences in their 
physical and chemical characteristics’. To examine this hypothesis, the following 
aims were applied:   
 Examine the effect of cell culture media and ddH2O on the aggregation of 
DEP samples using light microscopy  
 Examine particle morphology of DEP samples using TEM 
 Examine metal composition of DEP samples using ICP-OES 
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Table 3.1 Concentrations of PAHs on the surface of SRM-1650B and SRM-2975  
Concentrations of selected PAHs were analysed on the surface of SRM-1650B and 
SRM-2975 by using two or more analytical techniques (NIST certificate) (See 
Appendix III).  
Table 3.2 Concentrations of Nitro-PAHs on the surface of SRM-1650B and 
SRM-2975 
Concentrations of selected nitro-PAHs were analysed on the surface of SRM-1650B 
and SRM-2975 by using two or more analytical techniques (NIST certificate) (See 
Appendix III). 
 
Concentrations of Selected PAHs SRM-1650B (mg/kg) SRM-2975 (mg/kg) 
Phenantherene 70 ± 2 17 ± 3 
1-Methylphenanthrene 28 ± 2 1 ± 0.1 
2-Methylphenanthrene 71 ± 3 2 ± 0.2 
3-Methylphenanthrene 55 ± 2 1+ 0.2 
9-Methylphenanthrene 35 ± 2 - 
Fluoranthene 47 ± 1 27 ± 5 
Pyrene 43 ± 2 1 ± 0.2 
Benzo[ghi]fluoranthene 11 ± 1 - 
Chrysene 13 ± 1 5 ± 0.2 
Concentrations of Selected  
nitro-PAHs  
SRM-1650B 
(mg/kg) 
SRM-2975  
(mg/kg) 
9-Nitroanthracene  5890 ± 310 3 ± 0.5 
1-Nitropyrene 18200 + 200 35 ± 5 
7-Nitrobenz[a]anthracene 967 ± 42 3 ± 1 
6-Nitrochrysene 46 ± 2 2 ± 0.5 
6-Nitrobenzo[a]pyrene 1390 + 100 1 ± 0.3 
1,6-Dinitropyrene 84 ± 3 2 ± 0.4 
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3.2 Methods 
3.2.1 Imaging of DEP by Light Microscopy 
Stock concentrations of DEP-N, SRM-1650B and SRM-2975 (30mg/ml) were 
sonicated for 5 min and diluted in serum-free cell culture media or ddH2O to obtain a 
concentration of 300µg/ml. 100µl of each sample was pipetted on to 48-well plate 
and viewed under an inverted light microscope using a X20 objective lens. Images 
were captured using an Olympus SLR camera fitted with a microscope compatible 
adaptor. 
3.2.2 Imaging of DEP by TEM 
DEP samples were diluted in ddH2O to obtain a concentration of 300µg/ml and 
sonicated for 30 min. 15µl of each sample was transferred to formvar-coated copper 
grids and incubated overnight at RT. Particles were stained with 1% (V/V) uranyl 
acetate and incubated for 10min (Section 2.2.9.4.1). Grids were washed with ddH2O 
and air-dried for 15 min. Particle morphology and geometric diameters were 
analysed using TEM.  
3.2.3 Metal Composition of DEP  
The composition of metal ions adsorbed to the surface of DEP was identified by ICP-
OES. This assay was kindly performed by Dr J Seiffert and Mr P Maguire, Imperial 
College London. In brief, DEP samples were projected into flowing argon to form 
plasma which contained a rich source of both excited and ionized atoms. Light 
emitted by the elements in samples was measured. To determine element 
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concentrations of DEP samples, emission intensities were compared to the 
intensities of five standard solutions of known concentrations. 
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3.3 Results  
3.3.1 Examination of DEP Samples Using Light Microscopy 
DEP have complex physical geometrics and are composed of numerous chemical 
species. Cell culture media is composed of inorganic salts and metabolites. Dilution 
of DEP in cell culture media may lead to the surface chemistry of particles reacting 
with components present in the media, thereby modifying particulate morphology. 
For this reason, it is important to examine DEP morphology when diluted in cell 
culture media and ddH2O (control). DEP morphology was assessed using light 
microscopy.  
DEP-N, SRM-1650B and SRM-2975 were diluted in serum-free cell culture media or 
ddH2O and sonicated prior to visual examination using light microscopy. DEP-N 
(Figure 3.1A) and SRM-1650B (Figure 3.1B) samples diluted in media or ddH2O 
appeared as black solid aggregates held together in various shapes and sizes. SRM-
2975 (Figure 3.1C) sample contained aggregates of smaller size compared to DEP-
N or SRM-1650B. 
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Figure 3.1 Physical Characterisation of DEP Samples in Serum-Free Cell Culture 
Media or ddH2O  
DEP samples were sonicated for 5min and diluted in serum-free cell culture media or 
ddH2O to obtain a concentration of 300µg/ml. Physical characteristics of (A) DEP-N 
(B) SRM-1650B and(C) SRM-2975 samples were examined using a light microscope 
at X20 magnification.  
 
Chapter 3: Characterisation of DEP 
 
94 
 
3.3.2 Examination of DEP Samples Using TEM 
Having established that there was no difference in the morphology of DEP samples 
following dilution in cell culture media and ddH2O, the samples were further 
assessed by TEM. Samples were re-suspended in ddH2O to avoid interference of 
carbon compounds present in cell culture media during examination of DEP. TEM 
was used to determine the morphology and size of individual particles to determine 
how these characteristics may mediate biological effects.   
Analysis of DEP-N showed that primary (non-aggregated) particles encompassed a 
range of sizes between ~30-60nm, were of an irregular shape, and formed 
aggregates of various size (Figure 3.2A). Similar findings were also observed 
following examination of SRM-1650B (Figure 3.2B) and SRM-2975 (Figure 3.2C) 
samples, with individual particles in the size range ~40-60nm. 
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Figure 3.2 TEM of DEP 
 
DEP (300µg/ml) were diluted in ddH2O and sonicated for 30 min. The DEP solution 
was then pipetted on formvar copper grids. Particles were stained using 1% (
V
/
V
) 
aqueous uranyl acetate and incubated for 10 min at RT. (A) DEP-N (left-right), (B) 
SRM-1650B (left-right) and (C) SRM-2975 (left-right). 
 
Chapter 3: Characterisation of DEP 
 
96 
 
3.3.3 Metal Composition of DEP  
Having determined the physical characteristics of DEP samples, the composition of 
adsorbed metals on the surface of these particles was examined. ICP-OES analysis 
showed that DEP-N had a 5% (W/W) and 20% (
W/W) mass of Cu and Fe metals 
whereas SRM-1650B and SRM-2975 did not (Figure 3.3). DEP-N also had higher 
mass of Ca, Ni and Zn metals compared to the other DEP samples. In contrast, 
SRM-1650B and SRM-2975 particles had ~2% mass of B adsorbed to their surface 
compared to DEP-N.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Percentage Mass of Metals Adsorbed to the Surface of DEP 
 
DEP, SRM-1650B and SRM-2975 were analysed for the presence of adsorbed metals on the 
surface of combustion particles by ICP-OES analysis (n=1). This analysis was conducted by Dr J 
Seiffert and Pierce Maguire, Imperial College London, UK. 
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3.4 Discussion  
The laboratory-generated DEP-N used by Nightingale et al. 2000 were not previously 
characterised, but were used as a surrogate of the type of particle produced by a 
light-duty engine, typically found in cars and vans. The standardised samples SRM-
1650B and SRM-2975 used herein were obtained from NIST and were acquired from 
a heavy-duty engine and an industrial forklift engine respectively. The present 
chapter showed that primary particles from all the three samples formed aggregates 
of various sizes and shapes when diluted in both cell culture media and ddH2O 
despite sonication. No differences were observed between the physical 
characteristics of the three DEP samples obtained from the different engines types. 
Similar findings have been reported by others showing that DEP readily aggregates 
in cell culture media and distilled water as determined by light microscopy and TEM 
(Saxena et al. 2008; Holder et al. 2008).  In addition, Müller et al. 2010, used TEM to 
examine lung cells (epithelial cells, MDM and monocyte-derived dendritic cells) 
exposed to DEP (diluted in cell culture media) and observed DEP aggregation, 
similar to the observation herein.  
It was initially speculated that DEP may have aggregated in the cell culture media as 
an effect mediated by the high content of salts. However, DEP diluted in ddH2O also 
aggregated into clumps of variable size and shape. Therefore, it is unlikely that 
media composition alone is involved in particle aggregation but, rather, the surface 
chemistry of particles may drive this effect (Murphy et al. 1999). Layahe & 
Ehrburger-Dolle 1994 describe aggregation of carbon black particles as a process of 
particle collision by Brownian motion and interactions between acetylene and 
unsaturated hydrocarbons, which are responsible for growth of particles. Since DEP 
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consist of carbon, similar mechanisms may be involved in DEP aggregation as 
observed in the present chapter.   
The physical and chemical properties of SRM-1650B and SRM-2975 have been 
characterised by NIST. The average particle size of SRM-1650B and SRM-2975 is 
reported as 0.18µm and 11.2µm respectively, as determined by light scattering 
techniques. Analyses from TEM in the current investigation are in contrast to the 
findings of NIST. TEM analyses showed an average primary particle size for SRM-
1650B and SRM-2975 of ~40-60nm and ~40-50nm respectively. According to 
Kittelson, et al. 2001, DEP are heterogeneous in size, with most particles existing in 
either the nucleation mode (5-50nm), composed of carbon, semi-volatile and metallic 
compounds, and in the accumulation mode (0.05-1.0µm) composed of carbon 
aggregates and adsorbed material. These observations support the data herein as 
individual particulates and aggregates from DEP samples were found to be within 
the range of the nucleation mode.   
ICP-OES analysis indicated that all DEP samples herein had a distinct range of trace 
metals adsorbed on the surface of the DEP carbon core. The samples differed in the 
content of metal ions, which may be an effect of the different engine type, fuel, 
operating conditions and temperature used to generate the samples (Taylor et al. 
n.d.; Mcdonald et al. 2011). Adsorption of metal ions on to DEP are associated with 
differential biological effects on human health, as determined by human exposure 
studies or in-vitro studies on primary cells and cells lines (Chen & Lippmann 2009). 
Baulig et al. 2004 found that exposure of the 16-HBE bronchial epithelial cell line to 
different DEP samples with contrasting levels of Fe and Cu content, stimulated pro-
inflammatory cytokine release and were correlated with hydroxyl radical production. 
A human exposure study by Ghio et al. 2000 revealed that 2h inhalation of 
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concentrated ambient particles (CAPs) in Chapel Hill, North Carolina, resulted in 
pulmonary neutrophillic inflammation and increased blood fibrinogen levels. Further 
examination of the analyses by Huang et al. 2003 showed that sulphate, Fe and Se 
were responsible for increases in neutrophils found in bronchial alveolar lavage 
(BAL) samples, and Cu, Zn and V were related to increased fibrinogen levels (Chen 
& Lippmann 2009). Becker et al. 2005 showed that variations in composition of DEP 
during different seasons were related to different biological responses in human 
alveolar macrophages and bronchial epithelial cells. Exposure of cells to equal 
amounts of coarse (particles >1µm), fine and ultrafine DEP obtained during different 
seasons in Chapel Hill, NC resulted in the differential release and production of 
CXCL8 and IL-6. Analysis of DEP constituents by mass spectroscopy and plasma 
atomic emission spectroscopy indicated that variations in seasonal responses were 
correlated with the metal ions adsorbed to the surface of particles. For example, IL-6 
release was correlated with Fe and Si, whilst CXCL8 release was related to Cr. 
Soluble metals on DEP may also mediate pro-inflammatory effects by depositing in 
the airways and reacting with lung lining fluid. The interaction between soluble metal 
ions and biological molecules present in the airway lining fluid generate reactive 
oxygen species (ROS) which may mediate these biological effects (Park et al. 2006). 
Taken together, the data in this chapter reveal that DEP encompass a wide range of 
particle sizes and readily form aggregates whether diluted in cell culture media or 
ddH2O. The DEP-N, SRM-1650B and SRM-2975 all had particles in the range ~15-
60nm, and formed aggregates of similar sizes. It was also determined that even 
though the different DEP samples were physically similar they differed in metal ion 
composition,  with DEP-N having more Cu, Fe, Ca, Ni and Zn, and the SRM samples 
having more B than DEP-N. In regards to the findings of this investigation, the 
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proposed hypothesis: ‘The three DEP samples used herein (DEP-N, SRM-1650B 
and SRM-2975) will display differences in their physical and chemical characteristics’ 
was rejected, but still requires further examination in regards to the chemical 
characteristics of DEP. 
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 4.1 Introduction  
The previous chapter (Chapter 3) established that DEP-N, SRM-1650B and SRM-
2975 were physically similar, but differed in metal ion composition. The detrimental 
effects of DEP on respiratory health may reflect the noxious composition of these 
particles (Amakawa et al. 2003). As discussed previously, DEP are composed of a 
carbon core and various by-products of incomplete combustion, including PAHs, 
Nitro-PAHs and metals (Cu, B, Fe, Ca and Ni). These by-products have carcinogenic 
effects on human health as determined by both human and animal exposure studies. 
In-vitro studies in cell lines, show that DEP induce oxidative DNA damage (Mcclellan 
1987; Krivoshto et al. 2008; Vattanasit et al. 2013; Attfield et al. 2012). Table 4.1, 
highlights individual components of DEP and the biological effects they may mediate.  
Table 4.1. Classification of Biological Effects Produced by Adsorbed Chemical 
Species on DEP 
Classification of components adsorbed on the elemental carbon core of DEP and 
their biological effect (adapted by Krivoshto et al. 2008). 
Components of DEP Biological effect 
Components 
of Gas-Phase 
Emission 
Nitrogen & sulphuric oxides 
Carbon dioxide 
Carbon monoxide 
 
Respiratory tract irritant 
Respiratory tract irritant 
Asphyxiation 
Hydrocarbons Alkanes  
Alkenes  
 
Respiratory tract irritant 
Respiratory tract irritant,  
mutagenic and carcinogenic         
Aldehydes Formaldehydes  
Monocyclic aromatic hydrocarbons  
Benzene   
Carcinogenic 
Carcinogenic  
Mutagenic and carcinogenic         
Components 
of Particle-
Phase 
Emission 
Elemental carbon 
Inorganic sulphate and nitrate  
PAH (Nitro-PAH) 
Adsorbs organic/inorganic                                          
compounds  
Respiratory tract irritant 
Mutagenic and carcinogenic      
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Inhaled particles are normally cleared by AM (Warheit & Hartsky 1993). Therefore, 
understanding the effects of DEP on macrophage function is important. It is unclear 
whether the toxic effects of DEP are mediated by soluble chemical species adhered 
to the surface of the particle such as PAHs and toxic metals, or whether the particles 
mediate their effects following internalisation by cells (Boland et al. 1999). Inhalation 
and penetration of DEP in the lung leads to apoptosis, inflammation and up-
regulation of antioxidant enzymes, as seen in human exposure studies (Salvi et al. 
1999; Behndig et al. 2006; Nordenhall et al. 2000) and in-vitro studies using primary 
human cells and cell lines (Hiura et al. 2000; Hiura et al. 1999). 
Cell culture studies on human AM, murine macrophage RAW 264.7 and human 
monocyte THP.1 cell lines, established that treatment of cells with DEP 
compromised cell viability via generation of ROS (Hiura et al. 1999). The increase in 
ROS disrupts the intracellular anti-oxidant/oxidant balance and leads to oxidative 
stress, culminating in cellular apoptosis (Hiura et al. 1999). The decline in cell 
viability may be limited to the organic constituents adsorbed to the surface of DEP. 
This is because particulates treated with methanol to extract organic constituents 
from the surface of DEP, do not induce ROS or cellular apoptosis  (Hiura et al. 1999; 
Hiura et al. 2000; Li et al. 2002; Ma & Ma 2002;). In contrast, cells treated with the 
extract of DEP reduced cell viability by the induction of ROS (Hiura et al. 1999).   
Increases in atmospheric DEP contribute to increased hospital admissions and 
mortality in individuals with COPD (Atkinson et al. 2001). To date, the effects of DEP 
in COPD comprise epidemiological studies. Most studies look at the risk associated 
with developing COPD in an occupational setting, or worsening of COPD-related 
symptoms following exposure to DEP. For example, retrospective studies show that 
occupational exposure of individuals to DEP increases risk of developing COPD 
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compared to non-exposed individuals (Anderson et al. 1997; Sunyer et al. 2000). In 
addition, the case-control study conducted by Hart et al. 2006 looking at the effects 
of occupational DEP exposure on rail-road workers, demonstrated the link between 
DEP exposure and COPD-related mortality. However there is a scarcity of 
information on the effects of DEP on pulmonary macrophages, the important innate 
immune cells involved in lung homeostasis, which are also implicated in the 
pathophysiology of lung diseases such as COPD (Barnes 2004). Thus, it is important 
to determine the effects of DEP-related toxicity on macrophages obtained from an 
environment of persistent inflammation, as seen in smokers or patients with COPD 
(Overbeek et al. 2013; Holloway & Donnelly 2013). Primary AM from resected lung 
tissue or cell lines such as RAW 264.7 have been used for in-vitro studies, but these 
studies have not investigated whether disease alters DEP-related toxicity in 
macrophages (Hiura et al. 2000). Hiura et al. 1999 and Kafoury et al. 2005 have 
modelled the effect of DEP on alveolar macrophage toxicity, by using the mouse 
RAW 264.7 macrophage cell line. Hiura et al. 1999 found that DEP induced cellular 
apoptosis which was attributed to PAH compounds bound to DEP. In contrast 
Kafoury et al. 2005 found that DEP treatment did not induce apoptosis in RAW 264.7 
cells, this response was associated to the absence of active PAH bound to DEP.   
The above findings suggest that the relationship between DEP and their effects on 
cellular toxicity are not well understood. In this chapter, the toxicity of the three DEP 
samples was examined on macrophages and the following hypothesis was 
proposed: 'DEP-N, SRM-1650B and SRM-2975 will reduce macrophage viability by 
inducing apoptosis and this effect will be more prominent in macrophages from 
patients with COPD'. To examine this hypothesis the following aims were applied: 
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 The cytotoxic effects of DEP will be examined on human MDM as a model of 
macrophages.  
 The effects of DEP-related cytotoxicity will be examined in MDM from patients 
with COPD and compared to MDM from non-smokers and smoker controls.  
 The effect of DEP on the induction of apoptosis or necrosis in MDM will be 
examined by flow cytometry. 
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4.2 Methods 
4.2.1 Isolation of PBMC 
PBMC were obtained from non-smokers, smokers and patients with COPD as 
described in Section 2.2.2.  PBMC were cultured in MDM complete media (RPMI-
1640, containing 10% (V/V) foetal calf serum (FCS), 10mg/ml (1% (
V/V)) 
penicillin/streptomycin (PS), 2mM (1% (V/V)) L-glutamine (LG)) and seeded onto a 
96-well black plate (1x105 cell/well). Cells were incubated for 2h at 37°C, 5% (V/V) 
CO2 to isolate monocytes by adherence to the plastic tissue culture plate. Monocytes 
were cultured in MDM complete media containing 2ng/ml GM-CSF and incubated for 
a further 12 days at 37°C, 5% (V/V) CO2 to derive MDM (Section.2.2.3). 
4.2.2 Treatment of MDM with Inert Beads 
Inert beads of 0.2µm, 10µm or 30µm diameter were re-suspended in 10X D-PBS at 
a concentration of 30mg/ml. Beads were sonicated for 2 min to disaggregate them 
and were diluted in RPMI-1640 media in the concentration range 1-300µg/ml. MDM 
were treated with 1-300µg/ml inert beads and incubated for 24h at 37°C, 5% (V/V) 
CO2. Non-stimulated MDM were incubated in media alone and were used as 
baseline controls (Section 2.2.7.1). 
4.2.3 Treatment of MDM with DEP 
DEP-N, SRM-1650B and SRM-2975 were suspended in warmed HBSS at a stock 
concentration of 30mg/ml. DEP samples were sonicated for 2 min to break up large 
aggregates of particles and were diluted in RPMI-1640 media at the concentration 
range 1-300µg/ml. MDM were treated with these particles at 1-300µg/ml and 
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incubated for 24h at 37°C, 5% (V/V) CO2. Non-stimulated (NS) cells were incubated in 
media alone and were used as baseline controls (Section 2.2.7.2).  
4.2.4 Light microscopy of Inert-Bead- and DEP-Treated-MDM 
Images of MDM treated with increasing concentrations (1-100µg/ml) of inert beads or 
DEP samples, were captured on an inverted light microscope using X20 objective 
lens. Pictures were taken with an Olympus SLR camera fitted with a microscope 
compatible adaptor.   
4.2.5 Cell Viability 
Cell viability was assessed as described in Section 2.2.8.1 
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4.2.6 Assessment of MDM internalisation of DEP-N by TEM 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Flow Chart of TEM Methodology, to Examine DEP-N Internalisation by MDM  
The methodology of preparing DEP-N-treated MDM samples, prior to TEM examination.  
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4.2.7 Detection of Apoptosis and Necrosis 
MDM were treated with DEP-N (1-100µg/ml) as described in Section 2.2.7.2. Non-
stimulated (NS) cells were used as baseline controls. Cells were transferred to 
polystyrene FACS tubes at 100µl and stained with 5µl of Annexin-PE and 7-AAD as 
described in Section 2.2.8.2. Cells staining positive with either Annexin-PE/7-AAD 
flurochromes were analysed using FACS Diva software (Figure 4.2). The percentage 
of apoptotic or necrotic cells were analysed as described in Section 2.2.8.2. 
 
 
 
 
 
 
 
 
 
4.2.8 Statistics 
Data were compared for statistical significance between subject groups by one-way 
ANOVA followed Dunnett’s test for multi-group comparisons. Data expressing a P 
value of <0.05, were considered to be statistically significant. Statistical differences 
were calculated using Prism V.5 (GraphPad, San Diego, USA). 
 
NECROSIS 
 APOPTOSIS 
Figure 4.2. Distribution of DEP-N-Treated MDM Stained with Annexin-PE and 7-
AAD  
  
DEP-N-treated MDM (1-100µg/ml) were stained with Annexin-PE and 7-AAD, and 
analysed using flow cytometry. Cells undergoing (A) apoptosis had stained positively 
with Annexin-PE and were present in the lower right quadrant of the dot plot. Cells 
undergoing (B) necrosis had stained positively with 7-AAD and were present in the 
upper right quadrant of the dot plot. 
A. B. 
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4.3 Results  
4.3.1 Volunteer Demographics 
Characteristics of volunteers recruited for the study are shown in Table 4.2. Patients 
with COPD were significantly older than either non-smoker or smoker volunteers; 
however there were no differences in smoking history between smokers and COPD 
patients. Patients with COPD had significantly reduced FEV1, FEV1 % predicted, FVC 
and FEV1: FVC ratio compared to either non-smokers or smokers. There were no 
differences in lung function between non-smokers and smokers.  
Table 4.2 Volunteer Demographics 
 
 
 
 
 
 
 
 
 
 
Data are mean ± S.E.M. **p<0.01, ***p<0.001 vs non-smokers, # p<0.05, ## p<0.01 
vs smokers, ### p<0.001 vs smokers. 
 
4.3.2 Monocyte Differentiation to MDM 
To examine the interaction of DEP-N, SRM-1650B or SRM-2975 on macrophage 
function, it was necessary to establish an acute exposure model. MDM were 
 Non-Smokers 
n=28 
Smokers 
n=18 
COPD 
n=49 
Age (Years) 57 ± 2 58 ± 2 67 ± 1*** ## 
Gender (M:F) 12:16 7:11       27:22 
FEV1 (L) 2.9 ± 0.2 2.7 ± 0.2 1.3 ± 0.1
***### 
FEV1  
(% Predicted) 
100 ± 3 98 ± 4 51 ± 3***### 
FVC (L) 4 ± 0.2 4 ± 0.3 3 ± 0.1***## 
FEV1:FVC 0.8 ± 0.02 0.7 ± 0.02 0.5 ± 0.02
***### 
Smoking 
History 
(Pack Years) 
- 34 ± 5*** 39 ± 4*** 
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selected as a replacement for macrophages due to their availability, acquisition 
through minimally-invasive techniques, ability to compare effects in individuals with 
different health status, and similarities to primary AM (Winkler et al. 2008). 
MDM were derived by isolating monocytes and culturing these cells in the presence 
of GM-CSF for 12d. To determine whether these cells had fully differentiated into 
MDM, photomicrographs were taken at days 0, 3, 6, 9 and 12 to assess their 
morphology (Figure 4.3). Monocytes at day 0 were small and round compared to 
cells which had been incubated in GM-CSF at day 3-12. Other morphological 
changes observed throughout the incubation time period included cells becoming 
flatter and having a larger cytoplasmic volume (compared to monocytes on day 0). 
Cells undergoing differentiation also had a granular appearance and extending 
pseudopodia (indicated by red arrows in Figure 4.3), suggesting a macrophage-like 
phenotype. 
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Figure 4.3 Effect of GM-CSF on Monocyte Differentiation into MDM 
 
Whole blood monocytes from a smoker subject were isolated by adherence. Cells were incubated 
in the presence of GM-CSF (2ng/ml) for 12 days to enable differentiation of monocytes into MDM. 
Photomicrographs of cells undergoing differentiation were taken at days 1, 3, 6, 9 and 12. Red 
arrows indicate extending pseudopodia by MDM. Cells were viewed using light microscopy at X 20 
magnification. 
DAY 1 DAY 3
DAY 6 DAY 9
DAY 12
50µm 50µm
50µm50µm
50µm
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4.3.3 Effect of DEP on MDM Viability and Morphology  
MDM from non-smokers, smokers and COPD patients were exposed to increasing 
concentrations of DEP-N, SRM-1650B and SRM-2975 for 24h and changes in cell 
viability and morphology were assessed. Increasing concentrations of DEP-N 
decreased cell viability in a concentration-dependent manner, with a significant 
decrease in cell viability of ~50% at 300µg/ml for MDM from non-smokers and COPD 
patients (Figure. 4.4A). Similar data was observed from MDM from smokers, but did 
not reach statistical significance. Cell viability was not reduced when cells were 
exposed to either SRM-1650B (Figure. 4.4B) or SRM-2975 (Figure 4.4C). However, 
there was a significant reduction of viability by ~35% in MDM from COPD patients 
exposed to 300µg/ml SRM-1650B (Figure. 4.4B). As 300µg/ml of DEP decreased 
cell viability, this concentration was excluded from further analyses. 
The next question was whether or not MDM from different subject groups 
internalised DEP (1-100µg/ml). In order to address this, photomicrographs of cells 
exposed to the different DEP were examined. MDM from non-smokers, smokers and 
COPD patients appeared to show internalisation of DEP-N at concentrations of 10 – 
100 µg/ml, with no difference between subject groups (Figure 4.5). Similar data were 
seen with MDM exposed to SRM-1650B and SRM-2975, with internalisation of 
particles seen at concentrations of 30–100µg/ml (Figures 4.6 and Figure 4.7).   
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A. 
B. 
C. 
Figure. 4.4  Effect of DEP on MDM Viability. 
 
MDM from non-smokers () (n=5), smokers () (n=3) and patients with COPD () (n=4; ex-
smoker n=2, current smoker n=1, unknown n=1) were treated with 1-100µg/ml of (A) DEP-N, (B) 
SRM-1650B or (C) SRM-2975. DEP-treated cells were incubated for 24h followed by treatment with 
MTT to determine cell viability. Non-stimulated (NS) cells were used as baseline controls and 
represented 100% cell viability (normalised data). Data are mean ± SEM % cell viability (relative to 
control).  *p<0.05, **p<0.01 vs NS.  
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Figure 4.5 Photomicrographs of DEP-N-Treated MDM 
 
MDM from Non-smokers (A), Smokers (B) and COPD (C) patients were treated with DEP-N (1-
100µg/ml) and incubated for 24h. Non-stimulated (NS) cells were used as a baseline control. Red 
arrows indicate DEP aggregates. Cells were viewed by light microscopy and images were taken at 
X 20 magnification.   
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Figure 4.6 Photomicrographs of SRM-1650B-Treated MDM 
 
MDM from Non-smokers (A), Smokers (B) and COPD (C) patients were treated with SRM-
1650B (1-100µg/ml) and incubated for 24h. Non-stimulated (NS) cells were used as a baseline 
control. Red arrows indicate DEP aggregates. Cells were viewed by light microscopy and 
images were taken at X 20 magnification.   
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Figure 4.7 Photomicrographs of SRM-2975-Treated MDM 
 
MDM from Non-smokers (A), Smokers (B) and COPD (C) patients were treated with SRM-2975 
(1-100µg/ml) and incubated for 24h. Non-stimulated (NS) cells were used as a baseline control. 
Red arrows indicate DEP aggregates. Cells were viewed by light microscopy and images were 
taken at X 20 magnification.   
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4.3.4 Effect of Inert Beads on MDM Viability and Morphology 
The effect of DEP on MDM viability and morphology might be due merely to 
ingestion of particles rather than elemental composition. To determine whether 
particle size altered viability and morphology, MDM were exposed to inert beads of 
different sizes in order to mimic the size distribution of the samples of DEP used 
herein.  
MDM from non-smokers, smokers and COPD patients were exposed to inert beads 
with diameters of 0.2µm, 10µm or 30µm. Increasing concentrations of beads of any 
size did not significantly decrease cell viability of MDM from the different subject 
groups (Figure 4.8), although MDM from COPD patients treated with the highest 
concentration of 0.2µm beads showed decreased cell viability by ~30%, albeit not 
significant (Figure 4.8A).  MDM from COPD patients treated with 300µg/ml of 30µm 
beads significantly increased viability compared to non-smoker MDM (Figure 4.8C). 
Having demonstrated that inert beads did not reduce MDM viability, it was unclear 
whether cells had actually internalised the beads, which may be responsible for the 
lack of effect on cell viability. It was also important to determine whether the size 
distribution of particles altered cellular morphology. Photomicrographs of MDM from 
non-smokers, smokers and COPD patients exposed to increasing concentrations of 
0.2µm beads, did not show any alteration of cellular morphology (Figure 4.9). 
Internalisation of the 0.2µm beads by MDM was not visible, although aggregates 
were observed at 30 - 100µg/ml concentrations (indicated by red arrows in Figure 
4.9).  
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Figure. 4.8 Effect of Inert beads on MDM Viability.  
 
MDM from non-smokers () (n=4), smokers () (n=2-4) and patients with COPD () 
(n=3-4; ex-smokers n=2, current-smokers n=1, unknown n=1) were treated with 1-
100µg/ml of (A) 0.2µm beads, (B) 10µm beads or (C) 30µm beads. MDM were 
incubated at 5% (V/V) CO2, 37̊C for 24h, followed by treatment with MTT to determine 
cell viability. Non-stimulated (NS) cells were used as baseline controls and represented 
100% cell viability (normalised data). Data are mean ± SEM of % cell viability (relative 
to NS).  # p<0.05 non-smokers vs COPD 
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Figure 4.9 Photomicrographs of 0.2µm Inert Bead-Treated MDM 
 
MDM from Non-smokers (A), Smokers (B) and COPD patients (C) were treated with 
0.2µm polystyrene beads (1-100µg/ml) and incubated for 24h. Non-stimulated (NS) 
cells were used as a baseline control. Red arrows indicate artefacts. Cells were 
viewed by light microscopy and images were taken at X 20 magnification.   
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The 10µm and 30µm inert beads were spherical and were observed across 1-
100µg/ml concentrations (indicated by red arrows in Figure 4.10 and Figure 4.11). 
MDM exposed to increasing concentrations of 10µm beads did not alter cellular 
morphology in the different subject groups when compared to non-stimulated 
controls. The 10µm beads appeared to have been ingested by cells at 10-100µg/ml 
concentration, with some cells displaying internalisation of two beads (Figure 4.10). 
MDM exposed to increasing concentrations of 30µm sized inert beads, altered 
cellular morphology. MDM treated with the 30µm beads had aggregated around the 
bead, which appeared as a ‘group effort’ by the cells, to internalise the prey 
(indicated by white arrows in Figure 4.11).  
4.3.5 TEM: Internalisation of DEP-N by MDM 
Since MDM were more susceptible to DEP-N related toxicity, it was still unclear 
whether the decrease in viability was an effect of particle ingestion or chemical 
composition. In order to further determine whether particulates were being 
internalised by cells, TEM was used.   
The TEM images show that MDM have characteristic features typical of 
macrophages, such as extending pseudopodia (indicated by red arrows) and the 
presence of cellular vesicles (indicated by yellow arrows) (Figure 4.12A, Figure 
4.12B). It also confirms that MDM were capable of ingesting DEP-N, as particulates 
were seen in membrane-bound vesicles located in the cytoplasm of the cell (Figure 
4.12B).  
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Figure 4.10 Photomicrographs of 10µm Inert Bead-Treated MDM 
 
MDM from Non-smokers (A), Smokers (B) and COPD patients (C) were treated with 10µm 
polystyrene beads (1-100µg/ml) and incubated for 24h. Non-stimulated (NS) cells were used as a 
baseline control. Red arrows indicate inert beads bound/internalised by MDM. Cells were viewed by 
light microscopy and images were taken at X 20 magnification.   
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Figure 4.11 Photomicrographs of  30µm Inert Bead-Treated MDM 
 
MDM from Non-smokers (A), Smokers (B) and COPD (C) patients were treated with 30µm 
polystyrene beads (1-100µg/ml) and incubated for 24h. Non-stimulated (NS) cells were used as a 
baseline control. Red arrows indicate the 30µm inert bead and white arrows indicate the 
assembly of cells around the inert beads. Cells were viewed by light microscopy and images 
were taken at X 20 magnification.   
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Figure 4.12. TEM: Internalisation of DEP-N by MDM  
MDM from a non-smoker subject was treated with DEP-N (30µg/ml) for 24h. TEM 
image shows typical features of MDM such as pseudopodia (red arrow) and cellular 
vesicles (yellow arrow). (A) TEM image of MDM showing DEP-N internalised by MDM 
(B) Detailed view of DEP-N internalised within membrane bound vesicles.  
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4.3.6 Effect of DEP-N on MDM Apoptosis and Necrosis 
Since MDM were susceptible to DEP-N related toxicity, it was unclear whether DEP-
N treatment induced cellular apoptosis or necrosis. To assess this further, DEP-N 
treated cells were stained with Annexin-V and 7-AAD as markers of apoptosis or 
necrosis respectively and analysed using flow cytometry.  
Flow cytometry plots show that DEP-N induced both apoptosis and necrosis in MDM 
from all subject groups as indicated by the shift of unstained viable cells to the upper 
and lower right quadrant (Figure 4.1A and Figure 4.1B in section 4.2.7). The shift in 
viable cells undergoing necrosis was greater in MDM from non-smokers and patients 
with COPD (Figure 4.13A and Figure 4.13C); however cells from smokers were 
resilient to this effect and ~34% of these cells were apoptotic (Figure 4.13B). Data 
from the flow cytometry plots were translated to graphs and, from these analyses, it 
was observed that DEP-N significantly induced apoptosis in a concentration-
dependent manner in MDM from non-smokers and smokers by ~20% and ~13% 
respectively, at the highest concentration. Cells from patients with COPD were also 
apoptotic at 100µg/ml DEP-N by ~15%; however statistical significance was not 
reached (Figure 4.14A). DEP-N significantly induced necrosis in a concentration-
dependent manner in MDM from non-smokers and smokers by ~66% and ~27% at 
100µg/ml respectively. Cells from patients with COPD also showed a trend towards 
concentration-dependent necrosis following DEP-N treatment. MDM from patients 
with COPD were ~55% necrotic at the highest concentration of DEP-treatment 
(Figure 4.14B). Despite data being significant, MDM from smokers appeared less 
susceptible to the effects of DEP-N induced necrosis at 1-100µg/ml compared to 
non-smokers and patients with COPD. 
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Figure 4.13. Flow Cytometry Dot Plots Showing the Effect of DEP-N on Apoptosis and 
Necrosis of MDM. 
 
MDM from (A) non-smokers, (B) smokers and (C) COPD were treated with 1-100µg/ml DEP-N and 
incubated at 37̊C, 5% (V/V) CO2 for 24h. Following incubation, cells were stained with Annexin-V and 
7-AAD (bind cells undergoing apoptosis or necrosis) for 15 min at RT. Data are dot plots from a 
individual experiments. 
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Figure 4.14 Distribution of MDM Undergoing Apoptosis or Necrosis Induced by DEP-N  
 
MDM from non-smokers () (n=3), smokers () (n=4) and patients with COPD () (n=3; ex-smoker 
n=2, current smoker n=1) were treated with 1-100µg/ml DEP and incubated for 24h. Following 
incubation DEP-N-treated MDM were stained with Annexin-V and 7-AAD, and then analysed by flow 
cytometry to determine whether cells underwent (A) apoptosis or (B) necrosis.  Data are mean ± SEM. 
# p< 0.05 non-smokers vs smokers. 
 
 
NS 1 10 30 100
0
20
40
60
80
[DEP] g/ml
N
e
c
ro
s
is
 (
%
)
NS 1 10 30 100
0
5
10
15
20
25
#
[DEP] g/ml
A
p
o
p
to
s
is
 (
%
)
Chapter 4: Effect of DEP on MDM Viability 
 
128 
 
4.4 Discussion  
MDM were used in the present chapter to model alveolar macrophages due to their 
ready availability, acquisition through minimally-invasive techniques, and ability to 
compare effects in individuals with different health status. Monocytes were incubated 
in the presence of GM-CSF for 12 days and had differentiated into macrophage-like 
cells (Winkler et al. 2008; Taylor et al. 2010; Tudhope et al. 2008). 
In this investigation the toxicity of three different DEP samples were examined using 
MDM viability and morphology as outputs and compared to the effects of cells 
treated with commercial inert beads of different sizes. The DEP samples had 
variable effects on cell viability, with DEP-N being more toxic than SRM-1650B or 
SRM-2975 at high concentrations, with no visible effect on cellular morphology. It 
was unclear whether composition or ingestion of particles by cells was driving 
toxicity, therefore inert beads with a size distribution of 0.2µm - 30µm were used. 
The inert beads did not reduce viability, as seen with DEP-N and SRM-1650B, 
suggesting that the effects of DEP on MDM may have been driven by their 
composition, and not size. 
The in-vitro study conducted by Xia et al. 2004, showed similar findings to the 
present data, highlighting that composition of DEP may be responsible for 
cytotoxicity. In this study the RAW 264.7 macrophage cell line was exposed to 
different chemicals fractionated from DEP such as aliphatic, aromatic and polar 
organic components. Fractionated chemicals induced variable toxic effects on RAW 
264.7 cells, with quinone-enriched polar chemicals being potent inducers of ROS, 
thereby perturbing mitochondrial function and initiating apoptosis. Hiura et al. 2000 
also showed that treatment of primary alveolar macrophages and RAW 264.7 cells 
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with DEP extracts perturbed mitochondrial function via ROS generation, leading to 
cellular apoptosis. These observations may explain the increased susceptibility of 
MDM to DEP-N related toxicity compared to the SRM-1650B or SRM-2975 samples. 
For instance, DEP-N has trace metals (chapter 3) and may also have a higher 
content of adsorbed aromatic organic compounds such as quinones which are ROS 
generators that may initiate mitochondrial damage leading to cellular apoptosis and 
necrosis (Park et al. 2011; Hiura et al. 1999; Castranova et al. 2001; Block et al. 
2004). This could be determined by pre-treating MDM with anti-oxidants such as N'-
acetylcysteine (NAC) or glutathione to reverse ROS production, thereby preserving 
viability. Detection of anti-oxidant transcription factor up-regulation, such as Nrf2, 
may also confirm whether DEP is an inducer of oxidative stress, as DEP stimulates 
anti-oxidant and cytoprotective responses at low concentrations of exposure in 
macrophages (Xiao et al. 2003; Li et al. 2000). 
Even though MDM were more susceptible to DEP-N-related toxicity, SRM-1650B 
also reduced cell viability at the highest concentration of treatment, whereas SRM-
2975 exposure did not. The variability between these samples may be reflected in 
the increased number of PAH and nitro-PAH adsorbed on the surface of SRM-1650B 
compared to SRM-2975 (Chapter 3). Taken together with the findings mentioned 
above, the increased toxicity of SRM-1650B may be associated with the increased 
number of adsorbed chemicals on the surface of the particles. 
MDM from smokers, despite being significant, appeared less susceptible to DEP-N-
induced necrosis when compared to cells obtained from non-smokers or COPD 
patients. Data from flow cytometric analyses shows that MDM from smokers may 
already have cytoprotective responses (such as anti-oxidants) in place to protect 
cells against exposure to noxious chemicals. The study conducted by McCusker & 
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Hoidal 1990, showed that BAL macrophages from smokers have a higher level of 
superoxide dismutase and catalase activity compared to macrophages from non-
smokers. This may be similar in MDM from smokers and may explain why MDM from 
different subject groups are inclined to undergo different processes culminating in 
cell death, as MDM from smokers may have a number of anti-oxidant defences in 
place to balance oxidants released in the circulatory system by cigarette smoke. 
Therefore increases in ROS production by DEP exposure may be counteracted by 
the excess anti-oxidative enzymes in smoker macrophages.   
In summary, the current chapter reveals that DEP-N treated MDM show reduced 
viability in non-smokers and patients with COPD. DEP-N related toxicity initiated 
necrosis in MDM from non-smokers and patients with COPD; however MDM from 
smokers appeared less susceptible to this form of cell death. Findings from this 
chapter supported the hypothesis, suggesting that DEP will reduce macrophage cell 
viability; however mechanism of cellular demise requires further examination. 
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5.1 Introduction  
Findings from Chapters 3 and 4 established that the DEP samples (DEP-N, SRM-
1650B and SRM-2975) used herein were physically and morphologically similar, but 
displayed differences in their surface chemistry. It was also established that the 
composition of the DEP samples induced cytotoxicity in MDM from non-smokers and 
COPD patients at 100µg/ml as determined by flow cytometric analyses. Having 
determined the physical properties, metal composition and toxicity of DEP, the next 
step was to determine the effect of these particles on macrophage function, including 
pro-inflammatory cytokine release and phagocytosis. In this chapter, the effect of 
DEP on cytokine release from MDM will be examined, comparing the effects of DEP 
between MDM from non-smokers, smokers and patients with COPD. 
Macrophages are the ‘janitors’ of the lung with their overall function being to maintain 
pulmonary homeostasis. Macrophages respond to inflammatory cues which initiate 
these cells to phagocytose inhaled particles or pathogens and secrete mediators 
(Barnes 2004). In COPD, macrophages are implicated in the inflammatory processes 
associated with the disease, and are activated by a number of stimuli including, 
DEP, endotoxin, and inflammatory cytokines (Barnes 2004; Vogel et al. 2005). 
Macrophages from COPD patients release pro-inflammatory cytokines such as 
CXCL8, IL-6 and TNFα which are associated with perpetuation of airway 
inflammation typically seen in COPD. These cytokines are increased in COPD as 
determined by analysis of sputum or BAL (Keatings et al. 1996). As mentioned 
previously, DEP comprise an elemental carbon core which binds a number of 
components including organic and inorganic compounds, metals (Cu and Fe) and 
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endotoxin. The composition of DEP has been reported to mediate pro-inflammatory 
cytokine release from macrophages (Imrich et al. 2007).  
In addition, metals bound to the surface of these DEP may also have a role. Huang 
et al. 2003 exposed the airway epithelial cell line BEAS-2B and mouse 
macrophages, RAW 264.7, with ultrafine particles, fine and coarse PM samples and 
cytokine release was measured. BEAS-2B treated with ultrafine particles released 
higher levels of CXCL8 compared to cells exposed to fine and coarse PM. The 
increase in CXCL8 release from BEAS-2B cells was associated with Cr and Mn 
adsorbed to the surface of ultrafine particles. In contrast, RAW 264.7 cells released 
significantly higher levels of TNFα when exposed to ultrafine particles compared to 
particles of larger diameters.  
Endotoxin is found in the environment and is adsorbed on the surface of DEP. 
Endotoxin is a microbial stimulus and inhalation is associated with changes in lung 
function and exacerbation of pulmonary diseases (Arimoto et al. 2005). 
Administration of DEP in combination with endotoxin (lipopolysacchride) is 
associated with neutrophillic lung inflammation and increased chemokine release in 
mice (Takano et al. 2002). The in-vitro study conducted by Huang et al. 2002 
examined the effect of fine or coarse DEP on the release of TNFα from RAW 264.7 
cells. Coarse DEP significantly increased TNFα release, and also contained a higher 
content of endotoxin than fine particles. Polymyxin B is as antibiotic that binds to and 
inactivates endotoxin (Cardoso et al. 2007). Treatment of DEP with polymyxin B 
reduced TNFα release in RAW 264.7 cells by 32% and 42% in the coarse and fine 
fraction of DEP samples. For this reason it was suggested that the endotoxin 
component of DEP, was in part involved in the stimulation of TNFα release by 
macrophages. 
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From the above discussion, it is hypothesised that 'Treatment of MDM with DEP-N, 
SRM-1650B or SRM-2975 will stimulate release of CXCL8, IL-6 and TNFα, and 
release of these mediators will be more profound in MDM from patients with COPD'. 
To examine this hypothesis, the following aims were investigated: 
 Determine whether particle size and/or surface chemistry stimulated CXCL8, 
IL-6 and TNFα release by MDM treated with 0.2µm, 10µm and 30µm inert 
beads.  
 Determine whether DEP surface chemistry stimulated CXCL8, IL-6 and TNFα 
release by MDM treated with DEP-N, SRM-1650B or SRM-2975. 
 Determine the involvement of endotoxin in DEP induced cytokine release by 
using the limolas amebocyte lysate (LAL) assay and the endotoxin 
‘scavenger’ polymyxin B.  
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5.2 Methods 
5.2.1 Treatment of MDM with DEP or Inert Beads 
MDM were treated with DEP (DEP-N, SRM-1650B or SRM-2975) or inert beads with 
different size diameters (0.2µm, 10µm and 30µm) and incu ated at  7 ,     V/V) 
CO2 for 24h as described in Section 2.2.7.1 and Section 2.2.7.2. Following 
incu ation, supernatants were harvested and stored at -    until assayed.  
5.2.2 Measuring Release of Cytokines from DEP- or Inert Bead-
Treated MDM 
Concentrations of CXCL8, IL-6 and TNFα were measured in supernatants collected 
from DEP-or inert bead-treated MDM. Cytokines were measured using ELISA as 
described in section 2.2.10. The limit of detection for  X L  or TNFα was  1. pg/ml 
and IL-6 was 15.6pg/ml. 
5.2.3 Measuring Endotoxin Content of DEP Samples  
5.2.3.1 Measuring Endotoxin Content on DEP Samples Using 
Limolas Amebocyte Lysate Assay 
The endotoxin content of the DEP-N, SRM-1650B and SRM-2975 samples was 
measured using the LAL assay. LPS was used as a positive control. Reagents 
provided in the assay kit were prepared as described in Section 2.2.6. DEP (1-
00µg/ml) samples (with unknown amounts of endotoxin content) were diluted in 
HBSS (pH 7.5).  
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To determine the endotoxin content of the DEP samples, a series of endotoxin 
concentrations (provided in the kit) were used to produce a standard curve (Figure 
5.1). Serial dilutions of standard endotoxin concentrations were prepared in the 
range 0-10 EU/ml (Figure 5.1). 50µl of DEP samples (1-100µg/ml) with unknown 
concentrations of endotoxin were pipetted on to a micro-titre plate (provided with kit) 
followed by addition of 50µl of LAL. Samples were incubated for 45 min at room 
temperature to allow the LAL reagent to bind to endotoxin to produce a yellow 
colour. This reaction was stopped by pipetting 50µl of ‘Stop solution’ (50% (V/V) 
acetic acid diluted in 15ml distilled water) and the absorbance was read on a plate 
reader at λ 4  nm. The limit of detection of the assay was 0.04EU/ml. 
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Figure 5.1 Endotoxin Standard Curve 
 
Standard curve used to interpolate unknown concentrations of endotoxin on DEP 
and LPS samples. Data are in triplicate and are mean ± SEM, n =1. 
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5.2.3.2 Treatment of DEP-N with Polymyxin B 
To determine if the antibiotic, polymyxin B, would inhibit LPS activity in DEP-induced 
MDM release of CXCL8, DEP-N and the positive control LPS was prepared in 
polymyxin B treated media. In brief, DEP-N (1-100µg/ml) and the positive control 
LPS (10ng/ml) were prepared in cell culture media as described in Section 2.2.7.2 
and Section 2.2.7.4. DEP-N (1-100µg/ml) and LPS (10ng/ml) were also prepared in 
cell culture media containing the antibiotic polymyxin B (10mg/ml). MDM were 
treated with DEP-N or LPS with or without polymyxin B as described in Section 
2.2.7.2 and Section 2.2.7.4. Cells were incu ated at  7 ,     V/V) CO2 for 24h and 
supernatants were collected. Supernatants were analysed for release of CXCL8 from 
MDM treated with DEP-N or LPS samples with or without polymyxin B.  
5.2.4 Cell Viability 
Cell viability of MDM treated with DEP-N or LPS, with or without polymyxin B was 
assessed by MTT assay as described in section 2.2.8.1. 
5.2.5 Statistics 
Data sets were compared for statistical significance between subject groups by one-
way ANOVA followed  y Dunnett’s test for multi-group comparisons. A P value 
<0.05, was considered statistically significant. Data were analysed using Prism V.5 
(GraphPad, San Diego, USA).  
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5.3 Results 
5.3.1 Effect of Inert Beads on MDM Cytokine Release 
To determine whether the composition or size of particles were associated with the 
release of pro-inflammatory mediators, namely CXCL8, IL-6 or TNFα, MDM were 
treated with inert beads of different sizes.  
MDM from non-smokers, smokers and patients with COPD treated with 0.2µm, 
10µm or 30µm diameter beads did not significantly stimulate release of CXCL8 
(Figure 5.2), IL-6 (Figure 5.3) or TNFα (Figure 5.4) compared to non-stimulated 
controls, and were below the limit of detection for these assays. 
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Figure 5.2. Effect of Inert Bead-Treated MDM on CXCL8 Release. 
 
MDM from non-smokers (●) (n=4), smokers (■) (n=5) and patients with COPD (▲) (n=4; ex-smokers 
n=1; current-smokers n=1; unknown n=2) were treated with 1-100µg/ml of (A) 0.2μm, (B) 10μm or (C) 
30μm inert beads and incubated at 5% (
V
/
V
) CO
2
, at  7  for 24h. Following incu ation, supernatants 
were harvested and CXCL8 release was measured using ELISA. Data are expressed as medians. No 
significant differences were found. 
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Figure 5.3. Effect of Inert Bead-Treated MDM on IL-6 Release. 
 
MDM from non-smokers (●) (n=2), smokers (■) (n=4) and patients with COPD (▲) (n=2; ex-
smokers n=1; current-smokers n=1) were treated with 1-100µg/ml of (A) 0.2μm, (B) 10μm or (C) 
30μm inert beads and incubated at 5% (
V
/
V
) CO
2
, at  7  for 24h. Following incubation, 
supernatants were harvested and IL-6 release was measured using ELISA. Data are expressed as 
medians. No significant differences were found. 
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Figure 5.4. Effect of Inert Bead-Treated MDM on TNFα Release. 
 
MDM from non-smokers (●) (n=1), smokers (■) (n=4) and patients with COPD (▲) (n=2; ex-
smokers n=1; current-smokers n=1) were treated with 1-100µg/ml of (A) 0.2μm, (B) 10μm or (C) 
30μm inert beads and incubated at 5% (
V
/
V
) CO
2
, at  7  for 24h. Following incu ation, 
supernatants were harvested and TNFα release was measured using ELISA. Dotted line 
represents limit of detection. Data are expressed as medians. No significant differences were 
found. 
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5.3.2 Effect of DEP on MDM Cytokine Release 
Having determined that inert beads did not stimulate cytokine release, the next step 
was to determine whether the three DEP samples (DEP-N, SRM-1650B and SRM-
2975) would induce MDM release of CXCL8, IL-6 or TNFα. MDM treated with DEP-N 
released CXCL8 in a concentration-dependent manner, with cells from smokers 
releasing less CXCL8 than non-smokers, or patients with COPD. The maximal 
release of CXCL8 from smoker MDM was ~8ng/ml compared to cells from non-
smokers and patients with COPD which released ~16ng/ml (Figure 5.5A). MDM from 
smokers released CXCL8 in a concentration-dependent manner when treated with 
SRM-1650B, albeit significance was not reached (Figure 5.5B). SRM-2975 also did 
not induce CXCL8 release from MDM (Figure 5.5C). MDM from non-smokers, 
smokers or patients with COPD treated with increasing concentrations of DEP-N, 
SRM-1650B or SRM-2975 did not release IL-6  Figure  .6) or TNFα  Figure  .7) 
compared with non-stimulated controls. 
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Figure 5.5. Effect of DEP-Treated MDM on CXCL8 Release. 
 
MDM from non-smokers (●) (n=7-10), smokers (■) (n=6-11) and patients with COPD (▲) (n=6-13: ex-
smokers n=3-5; current-smokers n=2-7; unknown n=1) were treated with 1-100µg/ml of (A) DEP-N, (B) 
SRM-1650B or (C) SRM-2975 and incubated at 5% (
V
/
V
) CO
2
, at  7  for 24h. Following incu ation, 
supernatants were harvested and CXCL8 release was measured using ELISA. Data are expressed as 
medians. *p<0.05, **p<0.01, p<0.001 vs non-stimulated controls. #p<0.05, ##p<0.01 smokers vs patients 
with COPD. 
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Figure 5.6. Effect of DEP-Treated MDM on IL-6 Release. 
 
MDM from non-smokers (●) (n=2-9), smokers (■) (n=4-10) and patients with COPD (▲) (n=4-11; 
ex-smokers n=3-6; current-smokers n=1-3; unknown n=2) were treated with 1-100µg/ml of (A) 
DEP-N, (B) SRM-1650B or (C) SRM-2975 and incubated at 5% (
V
/
V
) CO
2
, at  7  for 24h. 
Following incubation, supernatants were harvested and IL-6 release was measured using ELISA. 
Data are expressed as medians. No significant differences were found. 
NS 1 10 30 100
0
1
2
3
4
5
[DEP] g/ml
IL
 - 
6 
(n
g/
m
l)
NS 1 10 30 100
0.0
0.1
0.2
0.3
0.4
0.5
1
2
3
4
5
[DEP] g/ml
IL
-6
 (n
g/
m
l)
NS 1 10 30 100
0.0
0.1
0.2
0.3
0.4
0.5
1
2
3
4
5
[DEP] g/ml
IL
-6
 (n
g/
m
l)
A 
B 
C 
DEP-N 
SRM-1650B 
SRM-2975 
Chapter 5: Effect of DEP on Cytokine Release by MDM 
 
145 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7. Effect of DEP-Treated MDM on TNFα Release. 
 
MDM from non-smokers (●) (n=6-10), smokers (■) (n=6-9) and patients with COPD (▲) (n=3-11; 
ex-smokers n=1-4; current-smokers n=2-6; unknown n=1) were treated with 1-100µg/ml of (A) 
DEP-N, (B) SRM-1650B or (C) SRM-2975 and incubated at 5% (
V
/
V
) CO
2
, at  7  for 24h. 
Following incubation, supernatants were harvested and TNFα release was measured using ELISA. 
Data are expressed as medians. Dotted line represents limit of detection. Data are expressed as 
medians. No significant differences were found 
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5.3.3 Endotoxin Content of DEP samples 
DEP bind a number of components to their surface, including endotoxin. As DEP-N 
and SRM-1650B were associated with release of CXCL8 by MDM, the DEP samples 
were examined for endotoxin content using the LAL assay. There was no significant 
difference in endotoxin content across 1-100µg/ml in DEP-N (Figure 5.8A) or SRM-
1650B (Figure 5.8B) samples when compared to vehicle alone. SRM-2975 showed a 
higher endotoxin level at 100µg/ml compared to vehicle alone, albeit not significant.  
To validate the findings of the LAL assay, DEP-N or LPS (control) was treated with 
or without the endotoxin scavenger polymyxin B and applied to MDM and CXCL8 
output measured. Treatment of MDM with increasing concentrations of DEP-N with 
or without polymyxin B, did not significantly differentially release CXCL8. In contrast, 
MDM treated with LPS (10ng/ml) significantly released ~40ng/ml of CXCL8 
compared to MDM treated with LPS and polymyxin B, which had released ~1ng/ml of 
CXCL8 (Figure 5.9). Treatment of MDM with DEP significantly reduced cell viability 
at 100µg/ml, but did not reduce viability in MDM treated in combination with DEP and 
polymyxin B, compared to non-stimulated controls (Figure 5.10). These data validate 
the findings of the LAL assay and also show that DEP-N has not adsorbed endotoxin 
which is therefore, unlikely to be responsible for the CXCL8 release. 
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Figure 5.8. Endotoxin Content Adsorbed to the Surface of DEP 
 
The endotoxin content of DEP samples (1-100μg/ml) was examined using LAL assay (n=1). (A) 
DEP-N (■), (B) SRM-1650B (■) or  (C) SRM-2975 (■) were treated with LAL reagent and the 
reaction between endotoxin and LAL reagent produced a yellow colour, this was stopped by the 
addition of acetic acid. Absorbance was measured at 540nm. DEP-N, SRM-1650B and SRM-2975 
samples were performed in triplicate, Data are mean ± SEM and no significant differences were 
found. 
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Figure 5.9. Effect of DEP-N Treatment With or Without Polymyxin B on MDM CXCL8 Release 
 
MDM were treated with 1-100µg/ml of DEP-N (■) or LPS (10ng/ml) (■), with (■) or without 
polymyxin B (n=4). MDM were then incu ated at  7 ,     
V
/
V
) CO
2
, for 24h. Following incubation, 
supernatants were harvested and CXCL8 release was measured using ELISA. Data are mean ± 
SEM. * p<0.05 vs NS, *** p<0.001 LPS vs LPS + polymyxin B. 
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Figure. 5.10  Effect of DEP-N Treatment with or without LPS on MDM Cell-Viability.  
 
MDM were treated with 1-100µg/ml of DEP-N (■) or LPS (10ng/ml) with or without polymyxin 
B (■) (n=4).  ells were incu ated for  7 ,     
V
/
V
) CO2 for 24h following incubation, 
supernatants were harvested and MTT was applied to determine cell viability. Non-
stimulated (NS) cells were used as baseline controls and represented maximum cell viability 
(normalised data). Data are mean ± SEM of % cell viability (relative to control).  No 
significant differences were found. * p<0.05 vs NS.  
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5.4 Discussion  
In the present chapter the effect of DEP on MDM cytokine release was investigated 
and compared to release of cytokines from MDM treated with inert beads of different 
sizes. Treatment of MDM with inert beads, SRM-1650B or SRM-2975 did not 
stimulate cytokine release. MDM treated with DEP-N stimulated CXCL8 release, with 
no effect on IL-6 or TNFα release. The effect of DEP-N on CXCL8 release was not 
attributed to the presence of endotoxin on the particles, as determined by the use of 
LAL assay or polymixin B. Thus, the effect of DEP-N on CXCL8 release is 
associated with the composition, rather than size, of DEP-N particles. 
The cytokines released from macrophages exposed to different samples of DEP vary 
from study to study (Huang et al. 2003; Becker et al. 2005; Amakawa et al. 2003), 
which is similar to the differential response seen herein between MDM treated with 
DEP-N or the SRM particles. It is considered that the difference in cytokine profile 
from macrophages in DEP exposure studies is attributable to the surface chemistry 
of the particles. Amakawa et al. 2003 showed that DEP suppress spontaneous 
release of IL-6 and TNFα from human and murine alveolar macrophages, which 
could not be attributed to loss of cell viability. To determine whether the suppression 
of IL-6 and TNFα was correlated to the chemical species adsor ed on the surface of 
the particles, macrophages were exposed to elemental carbon. Treatment of cells 
with carbon alone did not replicate the initial suppression of IL-6 and TNFα. 
However, cells treated with DEP extract suppressed IL-6 and TNFα release, 
suggesting that the soluble organic fraction of DEP was responsible for the effect 
observed. 
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In contrast to the findings mentioned above, other groups have suggested that 
release of cytokines by DEP-treated macrophages is associated to particle size 
(Becker et al. 2003; Hetland et al. 2005). For example Becker et al. 2003, showed 
that exposure of human AM to fine (<PM2.5) particles induced a ten-fold higher 
release of IL-6, than macrophages exposed to ultra fine particles (<PM0.1). In 
addition, Hetland et al. 2005 also showed that human AM exposed to coarse (<PM10) 
fractions of PM induced higher levels of IL-6 and TNFα release compared to both 
ultrafine particles and fine particles. It was determined that even though the coarse 
fraction of PM had high levels of Cu, Fe, organic PAH and endotoxin, these 
components did not correlate to IL-6 and TNFα output. The analyses from Hetland et 
al. 2005 are in contrast to the findings in the present chapter. This is because, even 
though DEP-N, SRM-1650B and SRM-2975 displayed similar physical 
characteristics such as size and morphology (as determined in Chapter 3), only 
DEP-N was capable of stimulating the release of CXCL8, thereby suggesting that 
DEP size was not associated with cytokine release.  
The association of DEP-N with MDM release of CXCL8 may be correlated to the 
metal species adsorbed on the surface of the particles. Findings from chapter 3 
show that DEP-N had a high content of Cu and Fe, compared to SRM-1650B and 
SRM-2975. This may in part be related to the increased CXCL8 release from MDM 
exposed to DEP-N, rather than SRM-1650B and SRM-2975.  
In addition, health effects are also associated with PM seasonal variation, with 
heterogeneous cytokine release being associated to the composition of DEP. For 
example, Becker et al. 2005, showed that treatment of human bronchial epithelial 
cells and AM with PM collected during winter, spring, summer and autumn, 
differentially induced cytokine release. PM samples collected during October were 
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potent inducers of IL-6 in AM, whereas PM collected in January were potent inducers 
of CXCL8 in bronchial epithelial cells. Analyses from Becker et al. 2005 highlight that 
metals such as Cu, Fe, Cr, Al and Ti were correlated to the release of IL-6 and 
CXCL8, which may in part reflect the findings in the present chapter. To establish 
whether metals bound to DEP-N were associated with the release of CXCL8, metal 
chelators such as ethylenediaminetetraacetic acid (EDTA), desferrioxamine (DFOA) 
or 2,3-dimercaprol could be used to treat DEP-N prior to MDM exposure.  
The present chapter showed similarities in the release of CXCL8 between MDM from 
non-smokers and patients with COPD. It was speculated originally that MDM from 
patients with COPD would have been more sensitive to DEP-treatment and would 
have released a higher level of cytokines. This is because BAL macrophages from 
patients with COPD show a higher release of cytokines compared to healthy non-
smokers (Culpitt et al. 2003; Cosio et al. 2004; Barnes 2009). It is possible that the 
similarity in CXCL8 response between non-smokers and patients with COPD is an 
effect of MDM being cultured in an external environment where they are not 
constantly exposed to inflammatory stimuli. The use of BAL macrophages from 
COPD patients maybe used to determine whether these cells are more sensitive to 
DEP-N exposure, as they would be acquired from an inflammatory environment. 
MDM from smokers were resistant to DEP-N exposure with regards to CXCL8 
release, when compared to cells obtained from non-smokers or patients with COPD. 
Even though statistical significance was not reached, the data herein showed that 
MDM from smokers were less susceptible to DEP-N stimulation. It is possible that 
MDM from smokers were ‘protected’ against exposure to noxious chemicals typically 
found in cigarettes by having augmented levels of antioxidant enzymes (McCusker & 
Hoidal, 1990). 
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Taken together, the data from this chapter reveal that DEP-N stimulated the release 
of CXCL8 in MDM from non-smokers, smokers and patients with COPD. Differences 
in response were observed in MDM from smokers, as this group was more resistant 
to DEP-N stimulation. Inert beads of different sizes, did not mediate similar effects, 
suggesting that the composition of DEP but not endotoxin was responsible for the 
release of CXCL8. For these reasons, the proposed hypothesis: 'Treatment of MDM 
with DEP will stimulate release of IL-6, TNFα and  X L , and the release of these 
mediators is more profound in MDM from patients with COPD' was not supported as 
only DEP-N and not SRM-1650B or SRM-2975 stimulated CXCL8 release and this 
effect was not greater in MDM from COPD patients. 
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6.1 Introduction  
The previous chapter (Chapter 5) established that DEP-N, but not SRM 1650B or 
SRM-2975 stimulated MDM release of CXCL8. This effect was observed in cells 
from non-smokers, smokers and patients with COPD. However, differences in the 
release of CXCL8 were observed in cells from smokers. In the present chapter the 
mechanism(s) associated with release of CXCL8 from DEP-N-treated MDM were 
examined.  
DEP stimulates pulmonary cells to release pro-inflammatory mediators such as 
CXCL8, IL-6 and TNFα (Schwarze et al. 2013). Release of these mediators, is 
triggered by activation of signal transduction pathways or phosphorylation of the 
MAPK family. MAPK are serine/threonine protein kinases which direct extracellular 
signals to intracellular targets such as the transcription factor, NF-kB or AP.1, via 
interacting proteins to elicit appropriate biological responses (Hashimoto et al. 2000; 
Kawasaki et al. 2001). The MAPK family encompasses p38, ERK 1/2, and JNK 
pathways. p38 and JNK kinases are involved in the transmission of signals induced 
by environmental stress, heat or oxidative stress. p38 MAPK are sub-divided into 
four isoforms, namely p38α, p38β, p38γ or p38δ, of which p38α and p38δ are 
expressed in lung macrophages (Smith et al. 2006). In addition, the ERK 1/2 
pathway is involved in directing mitogenic signals to intracellular targets (Chung 
2011). 
The composition of DEP is associated with generation of ROS in macrophages 
(Hiura et al. 1999). The main constituent of DEP involved in ROS production is the 
organic fraction which includes PAHs, nitro-PAHs and oxygenated PAHs (ketones, 
quinones and diones) (Li et al. 2002; Sagai et al. 1993; Kumagai & Taguchi 2007). 
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ROS generated by DEP are associated with MAPK signalling which leads to release 
of inflammatory mediators, for example, CXCL8. Methanol extraction of native DEP 
has shown that the organic extract and benzene components of DEP activate 
pathways leading to the phosphorylation of various MAPK in human airway epithelial 
and aortic endothelial cells (Bonvallot et al. n.d.; Tudhope et al. 2008; Li et al. 2009; 
Kawasaki et al. 2001). For this reason, it is hypothesised that 'DEP-N-treated MDM 
from patients with COPD will demonstrate, MAPK signalling leading to release of 
CXCL8'. 
 To examine this hypothesis, the following aims were investigated: 
 Examine the phosphorylation of p38, ERK 1/2 and JNK in MDM treated with 
increasing concentrations of DEP-N. 
 Examine the kinetics of DEP-N-induced phosphorylation of p38, ERK 1/2 and 
JNK, by conducting time course experiments. 
 Examine the relationship between DEP-N induction of MAPK signalling 
pathways and CXCL8 release using MAPK inhibitors.   
 Examine the effect of MAPK inhibitors and DEP-N treatment on MDM cell 
viability. 
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6.2 Methods 
6.2.1 Treatment of MDM and Protein Collection for MAPK Analysis 
In order to examine whether DEP-N induced MAPK phosphorylation in MDM, cells 
were treated with increasing concentrations of DEP-N and the phosphorylation of 
p38, ERK 1/2 and JNK was measured.   
MDM were cultured in 24-well clear plates as described in Section 2.2.7.5     
 r      wi h          -N   -         , c    c    r     i    o     o -  i        
co  ro   or              po i i   co  ro  ,     w r  i c          3  ,     V/V) CO2 
for 1h. Following incubation, supernatants were removed and cells were immediately 
placed on ice. Cells were washed with 1ml ice-cold PBS followed by 15µl of 1X lysis 
buffer and were transferred to the MDM as described in section 2.2.13.1. Cell 
membranes were lysed and total protein was transferred to pre-chilled 0.5ml 
Eppendorf tubes. Lysates were stored at -80°C to limit protein degradation.  
6.2.2 Time-Course of DEP-N on MAPK Phosphorylation 
MDM were cultured in 24-well clear plates as described in section 2.2.7.6      
w r  i c          3  ,     V/V) CO2 in 500µl DEP-N for 0, 5, 10, 20, 40 and 60 min 
or LPS (10ng/ml) for 60 min. Following incubation, supernatants were removed and 
cells were immediately placed on ice. Cells were washed with 1ml of ice-cold PBS, 
followed by 15µl of 1x lysis buffer as described in Section 2.2.13.1. Cell membranes 
were lysed and total protein was collected using a cell scraper and transferred into 
pre-chilled 0.5ml Eppendorf tubes. Lysates were stored at -80°C to limit protein 
degradation 
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6.2.3 Western Blot 
Total protein from cell lysates was measured using the BioRad assay as described in 
Section 2.2.13.2. Phosphorylation of MAPK protein by DEP-N or LPS in the 
concentration and time-course experiments were examined by western blot as 
described in Section 2.2.7.6. Blots were probed for the following MAPK: p38, ERK1/2 
and JNK as described in section 2.2.13.6.   
6.2.4 Effect of p38 (PF755616) Inhibiter on DEP-N induced HSP27 
Phosphorylation 
PF755616 (p38 inhibitor) was prepared in neat DMSO as described in Section 
2.2.7.7. The p38 inhibitor was diluted by 1:10 serial dilutions to obtain a 
concentration range 10-5–10-10        w r  c    r   i      -w    c   r p         
w r  pr - r      wi h       of p38 i hi i or     i c          3  ,     V/V) CO2 for  
30 min. Following pre-treatment, 10X DEP-N (          w   pip      i  o w     
co   i i    h  p38 i hi i or     i c          3  ,     V/V) CO2 for 1h. Cells were 
then lysed as described in Section 2.2.13.1 and the downstream p38 MAPK 
signalling protein HSP27 was examined by western blot as described in section 
2.2.13. Blots were probed for phosphorylated HSP27 as described in section 
2.2.13.6. 
6.2.5 Effect of MEK 1/2 (PD98059) Inhibitor on ERK 1/2 Phosphorylation  
PD98059 (MEK 1/2 inhibitor) was prepared in neat DMSO as described in Section 
2.2.7.8 to obtain a stock concentration of 30mM. The MEK 1/2 inhibitor was diluted 
1:10 in RPMI 1650 cell culture media to obtain a working concentration of 30µM and 
then diluted appropriately to obtain a concentration range 0.1µM – 30µM. MDM were 
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pre-treated with 500µl 0.1mM - 30mM MEK 1/2 i hi i or     i c          3  ,    
(V/V) CO2 for 30 min. 500µl cell culture media was transferred to MDM (non-
stimulated controls) and cells pre-treated with the MEK 1/2 inhibitor were further 
exposed to 10x DEP-N (              i c       for  h    3  ,     V/V) CO2.  
Supernatants were removed and cells were immediately placed on ice and washed 
with 1ml ice-cold PBS. Cells were lysed as described in section 2.2.13.1 and western 
blots were probed for phosphorylated ERK 1/2 and total ERK 1/2 as described in 
Section 2.2.13.6. 
6.2.6 Effect of p38 Inhibitor or MEK 1/2 Inhibitor on DEP-N Induced CXCL8 
Release by MDM  
Inhibitor compounds were prepared as described in Section 2.2.7.7 and 2.2.7.8. 
MDM were cultured in a 96-well black plate and were pre-treated with 150µl of the 
p38 or MEK 1/2 i hi i or     i c       for  h    3  ,     V/V) CO2.150µl of cell 
culture media (non-stimulated control) or DEP-N (100µg/ml) was transferred to cells 
with or wi ho   i hi i or pr - r        c     w r  i c       for   h    3  ,     V/V) 
CO2. Supernatants were collected and analysed for CXCL8 release by ELISA as 
described in Section 2.2.12. 
6.2.7 Effect of p38 Inhibitor or MEK 1/2 Inhibitor of Cell Viability of MDM 
Treated with DEP-N 
Viability of MDM treated with DEP-N with or without pre-treatment with inhibitors was 
assessed using the MTT assay as described in Section 2.2.10.1. 
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6.2.8 Statistics 
Data were compared for statistical significance between subject groups by one-way 
ANOVA followed by        ’       for     i-group comparisons. Data expressing a P 
value of <0.05, were considered to be statistically significant. Statistical differences 
were calculated using Prism V.5 (GraphPad, San Diego, USA). 
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6.3 Results 
6.3.1 Effect of DEP-N on MAPK Phosphorylation  
To determine whether DEP-N stimulated the MAPK pathway in MDM, cells were 
treated with increasing concentrations of DEP-N (1-100µg/ml) for 60 min and p38, 
ERK1/2 or JNK phosphorylation was measured.    
DEP-N-treated (1-100µg/ml) MDM showed a trend to increase phosphorylation of 
p38 in a concentration-dependent manner in MDM from patients with COPD (Figure 
6.1). Treatment of MDM with LPS (10ng/ml) increased phosphorylation of p38 in 
smokers only, but not in MDM from non-smokers or patients with COPD. A trend to 
increase phosphorylation of ERK 1/2 in a concentration-dependent manner, was also 
observed in MDM from non-smokers (10-100µg/ml) and patients with COPD (1-
100µg/ml) although effects were not significant (Figure 6.2). MDM treated with LPS 
(10ng/ml) increased phosphorylation of ERK 1/2 (p44) in non-smokers and smokers. 
In contrast, DEP-N (1-100µg/ml) did not have any discernible effect on the 
phosphorylation of JNK in MDM, but did phosphorylate JNK in cells treated with LPS 
(10ng/ml), although effects were not significant (Figure 6.3). Since DEP-N induced 
phosphorylation of only p38 and ERK 1/2, examination of JNK was excluded from 
subsequent experiments. 
6.3.2 Time Course of DEP-N on p38 and ERK 1/2 MAPK Phosphorylation 
Having determined that MDM treated with DEP-N (100µg/ml) induced 
phosphorylation of p38 and ERK 1/2, the next step was to determine the kinetics of 
MAPK phosphorylation. Therefore, time-course exposure experiments were 
performed, whereby MDM were exposed to DEP-N (100µg/ml) for 0, 5, 10, 20, 40 or 
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60 min and p38 or ERK 1/2 phosphorylation was measured. LPS (10ng/ml) was 
used as a positive control. DEP-N induced maximal phosphorylation of p38 and ERK 
1/2 at 40 min (Figure 6.4; Figure 6.5). MDM treated with LPS (10ng/ml) also induced 
phosphorylation of p38 and ERK 1/2 MAPK at 60 min. 
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Figure 6.1 Effect of DEP-N on p38 Phosphorylation in MDM  
MDM from non-smokers (■) (n=3), smokers (■) (n=2) and patients with COPD (■) (n=4; ex-smokers 
n=1, unknown n=3) were treated with increasing concentrations of DEP-N (1-100µg/ml) or LPS 
(10ng/ml) for 60 min and phosphorylation of p38 was determined by western blot. Blots of (A) non-
smoker, (B) smoker and (C) COPD patients showing phosphorylated and total p38 MAPK. (D) 
Densitometry was used to measure the phosphorylation of p38 compared to non-stimulated controls. 
Data are mean ± SEM. No significant differences were found.  
 
Chapter 6: Investigation of MAPK Signalling Pathways in DEP-
Induced Cytokine Release 
 
164 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E. 
Figure 6.2 Effect of DEP-N on ERK 1/2 (p44/p42) Phosphorylation in MDM  
MDM from non-smokers (■) (n=2), smokers (■) (n=2) and patients with COPD (■) (n=3; ex-
smokers n=1; unknown n=2) were treated with increasing concentration of DEP-N (1-100µg/ml) 
or LPS (10ng/ml) for 60 min and the phosphorylation of p42/44 was determined by western blot. 
(A) Blots from non-smokers, (B) smokers or (C) patients with COPD showing phosphorylation of 
p44/p-p42 and total p44/p42. (B) Densitometry was used to measure the phosphorylation of (D) 
p-p44/p42 and (E) p-p42/p42 compared to non-stimulated controls. Data are mean ± SEM. No 
significant differences were found.  
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Figure 6.3 Effect of DEP-N on Phosphorylation of JNK (p54/p46) 
MDM from smokers (■) (n=2) were treated with increasing concentration of DEP-N (1-
100µg/ml) or LPS (10ng/ml) and the phosphorylation of p54/46 was determined by western 
blot. (A) Blot from smoker subject showing phosphorylation of p54/46 and total p54/46. (B) 
Densitometry was used to measure the phosphorylation of (B) p-p54/t-p54 and (C) p-p46/t-
p46 compared to non-stimulated controls. Data are mean ± SEM.  
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Figure 6.4 Effect of DEP-N on Kinetics of p38 Phosphorylation  
The kinetics of p38 phosphorylation induced by DEP-N (100µg/ml) in MDM (■) (n=2) were 
determined by incubating cells at 5% (V/V) CO2, 3   wi h    -N (100µg/ml) for 0, 5, 10, 20, 40 
and 60 min. MDM treated with LPS (10ng/ml) were also incubated for 60 min. Phosphorylation of 
p38 by DEP-N-treated MDM was determined using western blot. Blots from a (A) non-smoker and 
(B) COPD patient showing phosphorylated and total p38. Densitometry was used to measure the 
phosphorylation of (C) p-p38/t-p38 compared to non-stimulated controls. Data are mean ± SEM.  
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Figure 6.5 Effect of DEP-N on Kinetics of ERK 1/2 (p4/42) Phosphorylation  
The kinetics of  ERK 1/2 (p42/44) phosphorylation induced by DEP-N (100µg/ml), in MDM from 
COPD patients (■) (n=3; ex-smoker n=1, unknown n=2), were determined by incubating cells at 
5% (V/V) CO2, 3   wi h    -N (100µg/ml) for 0, 5, 10, 20, 40 and 60 min. MDM treated with LPS 
(10ng/ml) were also incubated for 60 min. Phosphorylation of (p42/44) by DEP-N treated MDM 
was determined using western blot. (A) Blots from a COPD patient showing phosphorylated and 
total p42/44. (B) Phosphorylation of p44 was normalised to total p44 and measured by 
densitometry. (C) Phosphorylation of p42 was normalised to total p42 and measured using 
densitometry. Data are mean ± SEM. *p<0.05. No significant differences were found.  
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6.3.3 Effect of a p38 Inhibitor (PF755616) on Phosphorylation of HSP27 in DEP-
N-Treated MDM 
To further determine whether DEP-N phosphorylates p38 to induce CXCL8 release, 
MDM were pre-treated with the p38 inhibitor, PF755616. Following pre-treatment, 
MDM were stimulated with DEP-N (100µg/ml) for 60 min and phosphorylation of 
HSP27 (downstream of p38) was assessed (Figure 6.6). DEP-N stimulated 
phosphorylation of HSP27 in MDM, and this signal was significantly inhibited at the 
highest concentration of PF755616 treatment in cells from patients with COPD 
(Figure 6.6). PF755616 pre-treated cells from non-smokers and smokers also 
showed a trend towards a concentration-dependent inhibition of HSP27 
phosphorylation. 
6.3.4 Effect of the p38 Inhibitor (PF755616) on DEP-N-Induced Release of 
CXCL8 
Having determined that the PF755616 compound inhibited DEP-N induced p38 
signalling, the next step was to determine whether this compound inhibited release 
of CXCL8 from DEP-N-treated MDM. Cells were pre-treated with the p38 inhibitor 
prior to stimulation with DEP-N and CXCL8 release was measured using ELISA.   
DEP-N significantly induced CXCL8 release by MDM from smoker subjects and 
patients with COPD. DEP-N also increased the release of CXCL8 by non-smoker 
MDM, albeit not significantly (Figure 6.7A). PF755616 significantly inhibited release 
of CXCL8 in a concentration dependent manner by MDM from non-smokers, 
smokers and patients with COPD (Figure 6.7B). The reduction of CXCL8 release by 
MDM was not correlated with a reduction in cell viability (Figure 6.8). No difference 
was seen between MDM treated with DEP-N alone or with the p38 inhibitor and 
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DEP-N, with the exception of MDM from smokers pre-treated with 10-8 M of the 
PF75616 compound. 
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Figure 6.6 Effect of p38 Inhibitor on DEP-N Induced Phosphorylation of HSP27 in MDM 
MDM from non-smokers (●) (n=3), smokers (■) (n=1) and patients with COPD (▲) (n=4; ex-smoker n=2, 
ex-smoker n=2) were pre-treated with increasing concentrations of the p38 inhibitor (PF755616) for 30 
min. MDM were then exposed to DEP-N                i c          3  ,     V/V) CO2 for 1h. 
Following incubation, cells were lysed and phosphorylation of HSP27 was assessed. (A) Blots from a 
non-smoker subject showing phosphorylated and total HSP27. (B) Densitometry was used to measure 
phosphorylation of HSP27 in DEP-N-treated MDM (C = control and D= DEP-N). (C) Densitometry was 
also used to measure the effect of increasing concentrations of the p38 inhibitor on DEP-N 
phosphorylation of HSP27. Data are normalised to total HSP27 and are mean ± SEM. * p<0.05 vs DEP-
N stimulation. 
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Figure 6.7 Effect of p38 Inhibitor on DEP-N-Induced Release of CXCL8 by MDM 
MDM from non-smokers (■) (n=4), smokers (■) (n=7) and patients with COPD (■) (n=2; ex-
smoker n=1; unknown n=1) were pre-treated with increasing co c   r  io   of   p38 
i hi i or   F            i c       3  ,     V/V) CO2 for  h      w r   h     po     o 
   -N                i c          3  ,     V/V) for 24h. Following incubation 
supernatants were collected and CXCL8 was measured by ELISA. (A) DEP-N stimulated 
release of CXCL8. (B) Release of CXCL8 from MDM pre-treated with the p38 inhibitor, 
followed by DEP-N stimulation, was inhibited in a concentration-dependent manner. Data 
are relative to controls and are mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 vs DEP-N 
stimulation.  
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Figure 6.8 Effect of DEP-N and p38 Inhibitor on MDM Viability  
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6.3.5 Effect of a MEK Inhibitor (PD98059) on Phosphorylation of ERK 1/2 in 
DEP-N-Treated MDM 
To further determine whether DEP-N induced ERK 1/2 (p42/p44) MAPK 
phosphorylation, MDM were pre-treated with the MEK inhibitor PD98059 to inhibit 
the up-stream signalling protein MEK 1/2, thereby preventing the phosphorylation of 
ERK 1/2. Cells were pre-treated with the MEK 1/2 inhibitor prior to stimulation with 
DEP-N (100µg/ml) for 60 min and phosphorylation of ERK 1/2 measured (Figure 
6.9). DEP-N stimulated ERK 1/2, albeit not significantly (Figure 6.9B), and this 
response showed a trend towards inhibition in concentration-dependent manner, in 
cells pre-treated with the MEK 1/2 inhibitor (Figure 6.9C, Figure 6.9D). 
6.3.6 Effect of the ERK 1/2 inhibitor (PD98059) on DEP-N-Induced Release of 
CXCL8 
Having determined that the MEK 1/2 inhibitor compound inhibited phosphorylation of 
ERK 1/2, the next step was to determine the effect of the inhibitor on CXCL8 release. 
Cells were pre-treated with the MEK inhibitor, followed by stimulation with DEP-N 
(100µg/ml) and release of CXCL8 was measured using ELISA.  
DEP-N significantly induced CXCL8 release from all subject groups (Figure 6.10A). 
Pre-treatment of MDM with the MEK 1/2 inhibitor reduced CXCL8 release in a 
concentration-dependent manner, with no significant difference between MDM from 
non-smokers, smokers and patients with COPD (Figure 6.10B). The reduction of 
CXCL8 by MDM pre-treated with the MEK 1/2 inhibitor and DEP-N, was not an effect 
of reduced cell viability in MDM from non-smokers and smokers when compared to 
DEP-N alone. Viability of MEK 1/2 pre-treated cells from patients with COPD, was 
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significantly reduced compared to DEP-N alone at 10-30M, suggesting the 
combination of DEP-N and MEK 1/2 was killing the cells (Figure 6.11). 
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Figure 6.9 Effect of MEK 1/2 Inhibitor on DEP-N-induced Phosphorylation of ERK 1/2 (p44/p42) by 
MDM 
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Figure 6.10 Effect of MEK 1/2 Inhibitor on DEP-N-Induced Release of CXCL8 by MDM 
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Figure 6.11 Effect of DEP-N and MEK 1/2 Inhibitor on MDM Viability  
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6.4 Discussion  
The previous chapter (Chapter 5) showed that DEP-N, but not SRM-1650B or SRM-
2975, induced MDM to release CXCL8. The present chapter examined the 
mechanism of DEP-N induced CXCL8 release by MDM from non-smokers, smokers 
and patients with COPD. Cells were stimulated with DEP-N, and phosphorylation of 
JNK, p38 and ERK 1/2 kinases was examined. 
DEP-N induced phosphorylation of p38 and ERK 1/2 but not JNK in MDM from non-
smokers and COPD patients. This effect was not observed in MDM from smokers. 
Treatment of cells with DEP has been reported to release pro-inflammatory 
mediators by activating specific MAPK pathways. For example, DEP treatment of the 
murine JB6 P+ epidermal cell line, phosphorylated JNK but had no effect on p38 or 
ERK 1/2 (Ma et al. 2004), which is in contrast to the findings presented herein. 
Nonetheless, exposure of healthy volunteers to DEP resulted in phosphorylation of 
p38 and JNK, but not ERK 1/2 (Pourazer et al. 2008). The differential activation of 
MAPK by DEP may be associated with the complex composition of DEP. For 
example, the BEAS-2B bronchial epithelial cell line was exposed to different 
components extracted from DEP to determine activation of the CXCL8 gene. The 
benzene-constituent of DEP, activated p38 in a manner typically seen in cells treated 
with native DEP, thereby suggesting that the specific fractions of DEP composition 
are associated with phosphorylation of specific MAPK pathways (Kawasaki et al. 
2001).  
Although the composition of DEP is involved in driving phosphorylation of specific 
MAPK pathways, in-vitro studies have findings similar to the data presented herein. 
 
Chapter 6: Investigation of MAPK Signalling Pathways in DEP-
Induced Cytokine Release 
 
179 
 
For example, normal human bronchial epithelial cells (NHBEC) treated with ultrafine 
carbon particles, released CXCL8 via phosphorylation of p38 (Kim et al. 2005). 
Similarly, inhibition of p38 activity by the kinase inhibitor SB-202190 partially 
attenuated ultrafine carbon particle induced release of CXCL8 from NHBEC, thereby 
suggesting that p38 signalling is, at least in part, associated with CXCL8 production 
(Kim et al. 2005). Treatment of the THP.1 (monocyte) or RAW 264.7 (macrophage) 
cell lines with DEP extract also induced phosphorylation of p38 and JNK, further 
confirming the direct effects of DEP on macrophage functioning being associated 
with p38 signalling (Hiura et al. 1999). 
MDM treated herein with increasing concentrations of DEP-N induced 
phosphorylation of p38 and ERK 1/2 pathways, although this effect was observed 
only in MDM from non-smokers or patients with COPD. MDM from smokers 
appeared less sensitive to DEP-N-induced phosphorylation of p38 and ERK 1/2. This 
finding reflects the data presented in Chapter 5, whereby MDM from smokers did not 
release similar levels of CXCL8 compared with cells from non-smokers or patients 
with COPD.  This finding may be explained by the ROS generating capacity of DEP, 
on the induction of pro-inflammatory mediators (Schwarze et al. 2013). For example, 
it is reported that cigarette smoke exposure of primary lung macrophages or the 
THP.1 cell line, stimulates release of CXCL8 via pho phory   io  of  A K’   Birr    
et al. 2008). These effects, may in part, be reversed by the antioxidant glutathione, 
thereby suggesting that ROS generated by DEP can be inhibited by antioxidants, 
thereby preventing MAPK activity and CXCL8 release. Therefore it is speculated that 
MDM from smokers herein, may have protective anti-oxidative mechanisms in place 
to clear excess ROS produced by DEP-N, thereby limiting p38 or ERK 1/2 
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stimulation. Nevertheless, the data suggests that the attenuated response to DEP-N 
by MDM from smokers is mediated upstream of p38 or ERK1/2 activation and is 
consistent with the reduced effect of DEP-N on CXCL8 release reported in Chapter 
5. Whether this protective effect is mediated by anti-oxidants or another mechanism 
remains unclear but warrants further investigations. 
Experiments herein investigating the kinetics of DEP-N induced phosphorylation of 
p38 and ERK 1/2 by time course experiments showed that maximal stimulation of 
p38 and ERK 1/2 was observed at 40 min. To confirm whether the trend observed 
for both MAPK were reproducible in cells from all subject groups, this experiment 
would need to be replicated.  
DEP induces phosphorylation of p38 and ERK 1/2 kinases, which are involved in 
regulation of CXCL8 transcription factors such as NF-kB or AP.1. To determine 
whether p38 or ERK 1/2 signalling were involved in DEP-N -induced release of 
CXCL8, cells were pre-treated with either PF755616 (p38 inhibitor) or PD98059 
(MEK 1/2 inhibitor) prior to exposure to DEP-N. Inhibition of both p38 and ERK 1/2 
phosphorylation, resulted in similar levels of reduction in CXCL8 suggesting that the 
mechanism involving DEP-N induced CXCL8 release relies equally on p38 and ERK 
1/2. However, it is of interest to determine which component of DEP-N is responsible 
for activating these kinases. Other studies have attempted to investigate this 
(Bonvallot et al. n.d.) For example, treatment of the 16HBE bronchial epithelial cell 
line with native DEP, organic extracts of DEP (OE-DEP), stripped DEP (SDEP) or 
carbon black (CB) particles resulted in only some components activating 
phosphorylation of MAPK (Bonvallot et al. n.d.). Cells treated with OE-DEP or native 
DEP activated the ERK 1/2 and p38 pathways. However, pre-treatment of cells with 
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the SB203580 p38 inhibitor reduced p38 phosphorylation but did not reduce cytokine 
release; thereby suggesting that other signalling pathways may be involved 
(Bonvallot et al. n.d.). To determine which components of DEP-N activate the p38 or 
ERK 1/2 kinase pathways, particles could be stripped of their surface-bound organic 
or metal fractions using methanol or metal chelators (i.e. EDTA) respectively. Effects 
between stripped and non-stripped particles on p38 or ERK 1/2 kinase pathways can 
then be examined by the Western blot technique.  
In summary, the present chapter found that DEP-N stimulated p38 and ERK 1/2 but 
not JNK pathways in MDM from non-smokers and COPD patients but not cells from 
smokers. These two MAPK signalling pathways appear to be involved in release of 
CXCL8, as determined by inhibiting p38 or ERK 1/2, leading to CXCL8 release. 
How   r,   c     of  h   ow ‘ ’ of   p ri     ,  h    i     i   io   r q ir  f r h r 
examination. Findings from the present chapter support the hypothesis that 'DEP-N 
treated MDM from patients with COPD will phosphorylate MAPK signalling pathways 
leading to MDM release of CXCL8'. 
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7.1 Introduction  
The results presented in Chapters 5 and 6 showed that DEP-N, but not SRM-1650B 
or SRM-2975, stimulated MDM release CXCL8 by MAPK pathways in cells from 
non-smokers and patients with COPD. This differential effect of the DEP appeared to 
be associated with composition of particles rather than size. The next step was to 
determine whether DEP-N, SRM-1650B or SRM-2975 had effects on any other 
macrophage functions therefore, the effect on phagocytosis was examined. 
Inhaled DEP are targets for alveolar macrophages and may therefore, influence the 
capacity of macrophages to phagocytose other inhaled particles or pathogens in the 
lung. DEP impair phagocytosis in primary human and murine macrophages, and also 
macrophage cell lines (Zhou & Kobzik 2007; Lundborg et al. 2006; Yang et al. 2001). 
Impairment of phagocytosis may be related to the internal volume occupied by DEP, 
thereby inhibiting the macrophages from internalizing any further particles (Morrow et 
al. 1988; Tran et al. 2000). DEP also compromise the integrity of the macrophage 
cytoskeleton by inducing endogenous ROS. The macrophage cytoskeleton is 
sensitive to oxidative stress due to the presence of thiol groups leading to oxidation 
of cytoskeleton proteins. Cytoskeleton dysfunction impairs phagocytosis of particles 
and bacteria, thereby perpetuating inflammation and susceptibility to respiratory 
infections (Castranova et al. 2001; Möller et al. 2005; Yang et al. 2001; Li et al. 
2010). 
Macrophages treated with DEP of fine (<2.5µm) or ultrafine particles (<0.1µm) 
diameters, have elevated ROS production (Li et al. 2003). The large surface area of 
DEP may catalyse chemical reactions, thereby inducing ROS production, leading to 
oxidation of the cyotoskeleton proteins in macrophages. In addition, ultrafine 
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particles are not internalised by phagocytosis, and are thereby are not digested in 
phagolysosomes, but are retained in the cytoplasm. Retention of ultrafine particles 
may cause the macrophages to become replete, which prevents further ingestion of 
inhaled particles (Morrow et al 1988). It is unknown if impaired phagocytosis is a 
generic effect of DEP size or whether composition of particles may be driving this 
response. Therefore, examination herein of the three different DEP samples on 
MDM phagocytosis will be compared to MDM treated with inert beads of different 
sizes.  
Airways are normally cleared of inhaled particles or debris by alveolar macrophages, 
however, in COPD macrophage phagocytosis is defective (Taylor et al. 2010; Hodge 
et al. 2003; Hodge et al. 2007; Berenson et al. n.d.; Donnelly & Barnes 2012) for this 
reason it is hypothesised that 'DEP-N, SRM-1650B or SRM-2975-treated MDM from 
patients with COPD will further reduce phagocytosis of fluorescent beads, compared 
to MDM from non-smokers or smokers'.  
To examine this hypothesis, the following aims were investigated: 
 Determine the effect of DEP-N, SRM-1650B or SRM-2975 on MDM 
phagocytosis of fluorescent beads by light microscopy. 
 Determine the effect of DEP-N, SRM-1650B or SRM-2975 on MDM 
phagocytosis of fluorescent beads by fluorimetry. 
 Examine the combination of DEP-N, SRM-1650B or SRM-2975 and 
fluorescent beads on MDM cell viability. 
 Examine the internalisation of DEP-N-treated MDM on the phagocytosis of 
fluorescent beads using confocal microscopy. 
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 Determine the effect of 0.2µm, 10µm or 30µm sized inert beads on MDM 
phagocytosis of fluorescent beads by light microscopy. 
 Determine the effect of 0.2µm, 10µm or 30µm sized inert beads on MDM 
phagocytosis of fluorescent beads by fluorimetry. 
 Examine the combination of 0.2µm, 10µm or 30µm and fluorescent beads on 
MDM cell viability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7: Effect of DEP on MDM Phagocytosis 
 
185 
 
7.2 Methods  
7.2.1 Isolation of PBMC 
PBMC were isolated from whole blood obtained from non-smokers, smokers and 
patients with COPD (Section 2.2.2). Cells were cultured in MDM complete media 
(RPMI-1640, containing 10% (V/V) FCS, 10mg/ml (1% (
V/V)) penicillin/streptomycin 
(PS), 2mM (1% (V/V)) L-glutamine) and seeded onto a 96-well black plate (1x10
5 
cells/well). PBMC were incubated for 2h at 37°C, 5% (V/V) CO2 to isolate monocytes 
by adherence to the plastic tissue culture plate. Monocytes were cultured in MDM 
complete media containing 2ng/ml GM-CSF and incubated for a further 12 days at 
37°C, 5% (V/V) CO2 to differentiate to MDM (section. 2.2.3). 
7.2.2 Treatment of MDM with DEP-N, SRM-1650B or SRM-2975 
DEP-N, SRM-1650B or SRM-2975 were suspended in warmed HBSS to obtain a 
stock concentration of 30mg/ml. DEP were sonicated for 2 min to break up large 
aggregates and were diluted in RPMI-1640 serum-free cell culture media to obtain 
the concentrations of 1-100µg/ml. MDM were treated with DEP and incubated for 
24h at 37°C, 5% (V/V) CO2. MDM incubated in media alone were used as baseline 
controls (Section 2.2.7.2). 
 7.2.3 Treatment of MDM with Inert Beads 
0.2µm, 10µm and 30µm sized inert beads were re-suspended in 10X D-PBS to 
obtain a stock concentration of 30mg/ml. Beads were sonicated for 2 min to break up 
aggregates. The beads were diluted in RPMI-1640 serum-free cell culture media, to 
concentrations of 1-100µg/ml. MDM were treated with 1-100µg/ml inert beads and 
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incubated for 24h at 37°C, 5% (V/V) CO2. MDM incubated in media alone were used 
as baseline controls (section 2.2.7.1). 
7.2.4 Imaging of DEP- or Inert Bead-Treated MDM Incubated With Fluorescent 
Beads 
DEP-or inert bead (1-100µg/ml)-treated MDM were incubated with fluorescent beads 
(phagocytic prey) and viewed under an inverted light microscope using a fluorescent 
lamp. Images were captured using an Olympus SLR camera fitted with a microscope 
compatible adaptor (Section 2.2.9.3).  
7.2.5 Phagocytosis Assay 
DEP-or inert bead (1-100µg/ml)-treated MDM were incubated at 37°C, 5% (V/V) CO2 
for 24h. Cells were then further exposed to 100µl fluorescent beads (50x106 
beads/ml) and incubated for 4h at 37°C, 5% (V/V) CO2 (Section 2.2.7.9). Following 
incubation, cells were washed with PBS and extracellular fluorescence was 
quenched with 1% (V/V) trypan blue for 2 min. Trypan blue was aspirated and 
phagocytosis of fluorescent beads by DEP-or inert bead-treated MDM was analysed 
by fluorimetry (Section 2.2.7.9.1).  
7.2.6 Confocal Microscopy 
PBMC (2X105 cells/well) were seeded onto 8-well chamber slides and incubated for 
12d in the presence of GM-CSF to allow cells to fully differentiate into MDM (section 
2.2.3). Cells were treated with DEP-N (1-100µg/ml) and incubated for 24h at 37°C, 
5% (V/V) CO2. Non-stimulated cells cultured in media were used as controls. DEP-N-
treated MDM were incubated with fluorescent beads for 4h at 37°C, 5% (V/V) CO2 
(section 2.2.7.9). Cells were fixed by incubation in 4% (W/V) paraformaldehyde (PFA) 
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for 10 min at RT. The cell nuclei were stained with 2µM DAPI and incubated for 3 
min at RT and the cytoplasm of cells was stained using 12.5mM Cell TrackerTM Red. 
Chambers were removed from the slide and coverslips were affixed over the cells 
using citifluo and sealed with clear nail varnish. Slides were stored in the dark at 4°C 
(section 2.2.9.5.2). 
7.2.7 Cell Viability 
Viability of MDM treated with DEP or inert beads and incubated with fluorescent 
beads was assessed using the MTT assay (section 2.2.8.1). 
7.2.8 Statistics 
Data were compared for statistical significance between subject groups by one-way 
ANOVA followed by Dunnett’s test for multi-group comparisons. Data with a P value 
of <0.05, were considered to be statistically significant. Statistical analysis was 
performed using Prism V.4 and V.5 (GraphPad, San Diego, USA). 
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7.3 Results 
7.3.1 Imaging the effect of DEP-N, SRM-1650B or SRM-2975 on MDM 
Phagocytosis of Fluorescent Beads  
One of the major functions of macrophages is to clear particles and debris; however, 
it is unknown whether cells which have been previously exposed to DEP still retain 
their ability to clear phagocytic prey. To examine this possibility, MDM treated with 
increasing concentrations of the three samples of DEP (1-100µg/ml) were further 
exposed to fluorescent beads, and phagocytic capacity was assessed by fluorescent 
microscopy. MDM that had not been previously exposed to DEP were the baseline 
controls. 
DEP-N (Figure 7.1), SRM-1650B (Figure 7.2) or SRM 2975 (Figure 7.3) reduced 
phagocytosis of fluorescent beads by MDM from non-smokers, smokers and patients 
with COPD in a concentration-dependent manner compared to unexposed controls. 
At the higher concentration of DEP, large aggregates of particles could be observed 
within the MDM, with markedly reduced number of fluorescent beads. 
7.3.2 Determining the effect of DEP-N, SRM-1650B or SRM-2975-Treated MDM 
on the Phagocytosis of Fluorescent Beads by Fluorimetry 
Images taken using fluorescent microscopy showed that DEP-laden MDM displayed 
reduced phagocytosis of fluorescent beads (section 7.3.1). Fluorimetry was next 
used to validate these analyses, by measuring the fluorescence emitted by DEP (1-
100µg/ml)-treated MDM, incubated with fluorescent beads. Base-line phagocytosis 
was determined in MDM not exposed to DEP but with fluorescent beads alone. DEP-
N-treated MDM showed significantly reduced phagocytosis of fluorescent beads in 
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MDM from non-smokers, smokers and patients with COPD at the highest 
concentration of treatment (100µg/ml) (Figure 7.4A). 
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Figure 7.1. Effect of DEP-N on MDM Phagocytosis of Fluorescent Beads 
DEP-N-treated MDM (1-100µg/ml) from Non-smokers (A), Smokers (B) and COPD (C) 
patients were incubated with fluorescent beads (50x10
6 
beads/ml) for 4h. Non-stimulated 
(NS) cells were used as baseline controls and represented maximum phagocytosis by the 
different subject groups. A reduction in fluorescent beads (green) with increasing 
concentrations of DEP-N was observed in MDM from all subject groups. Red arrows 
indicate DEP-N-laden MDM. Cells were viewed by fluorescent microscopy and images were 
taken at X 20 magnification.   
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Figure 7.2 Effect of SRM-1650B on MDM Phagocytosis of Fluorescent Beads 
SRM-1650B-treated MDM (1-100µg/ml) from Non-smokers (A), Smokers (B) and COPD 
(C) patients were incubated with fluorescent beads (50x106 beads/ml) for 4h. Non-
stimulated cells were used as baseline controls (control) and represented maximum 
phagocytosis by the different subject groups. A reduction in fluorescent beads (green) with 
increasing concentrations of SRM-1650B was observed in MDM from all subject groups. 
Red arrows indicate SRM-1650B-laden MDM. Cells were viewed by fluorescent 
microscopy and images were taken at X 20 magnification.   
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Figure 7.3 Effect of SRM-2975 on MDM Phagocytosis of Fluorescent Beads 
SRM-2975-treated MDM (1-100µg/ml) from Non-smokers (A), Smokers (B) and COPD (C) 
patients were incubated with fluorescent beads (50x106 beads/ml) for 4h. Non-stimulated 
cells were used as baseline controls (control) and represented maximum phagocytosis by 
the different subject groups. A reduction in fluorescent beads (green) with increasing 
concentrations of SRM-2975 was observed in MDM from all subject groups. Red arrows 
indicate SRM-2975-laden MDM. Cells were viewed by fluorescent microscopy and images 
were taken at X 20 magnification.   
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However, MDM treated with SRM-1650B (Figure 7.4B) or SRM-2975 (Figure 7.4C), 
significantly reduced phagocytosis of fluorescent beads in non-smokers or patients 
with COPD but not smokers. Significant differences in phagocytosis were seen 
between SRM-2975-treated MDM from non-smokers and patients with COPD at 1-
100µg/ml. The difference in phagocytosis between the subject groups may be 
associated to the high baseline values observed in non-smoker MDM. 
7.3.3 Confocal imaging of the effect of DEP-N, SRM-1650B or SRM-2975 on 
MDM phagocytosis of Fluorescent Beads  
Confocal microscopy was used to validate the fluorescent microscopy observations 
(section 7.3.1) and fluorimetry findings (section 7.3.2). This technique was used to 
differentiate whether beads were adhered to the outside of MDM or had been 
internalised. As DEP-N had significantly reduced phagocytosis of fluorescent beads 
in MDM from all volunteer groups, DEP-N was selected for confocal analysis.  
DEP-N (1-100µg/ml) treated MDM from a smoker subject were exposed to 
fluorescent beads, and images were captured using a confocal microscope and 
compiled to form a z-stack (Figure 7.5). The cross hairs established that DEP-N 
(black pigmented material) were surrounded by cytoplasm and, thereby internalised 
by MDM. It was also observed that MDM were capable of internalising aggregates of 
various sizes as demonstrated by the areas of black pigmentation within the cell 
cytoplasm (Figure 7.5). In addition, MDM containing DEP-N retained the phagocytic 
capacity to further internalise fluorescent beads, although this became reduced as 
the concentration of DEP-N increased; thereby, confirming the reliability of the light 
microscopy images and fluorimetry data. 
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Figure. 7.4  Effect of DEP-N, SRM-1650B or SRM-2975 on MDM Phagocytosis of Fluorescent 
Beads.  
MDM from non-smokers () (n=6-11), smokers () (n=7-12) and patients with COPD () (n=13-22; 
ex-smoker n=11, current smoker n=9, unknown n=2) were treated with 1-100µg/ml of (A) DEP-N, 
(B) SRM-1650B (0.2µm) or (C) SRM-2975 (11.2µm). Particle-treated cells were incubated for 24h 
followed by further exposure to fluorescent beads (phagocytic prey) for 4h. Phagocytosis was 
measured using fluorimetry. Non-stimulated (NS) cells were baseline controls. Data are mean ± 
SEM of relative fluorescence units (RFU). *p<0.05, **p<0.01, ***p<0.001 vs non-stimulated controls. 
† p<0.05, †† p<0.01 non-smoker vs COPD.  
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Figure 7.5 Confocal Images of DEP-N-Treated MDM Internalising Fluorescent Beads  
MDM from a smoker subject were cultured on 8-well chamber slides and exposed to 100µg/ml 
DEP-N for 24h and viewed using confocal microscopy. Sequential images were taken through 
a single MDM and compiled together to form a z-stack.  The nuclei is stained with DAPI (blue), 
the cytoplasm is stained with Cell Tracker Red (Red), fluorescent beads (green) and DEP-N 
(black pigmented material). Cross hairs demonstrate internalised fluorescent beads or DEP-N 
and white arrows indicate the bead or aggregate of DEP-N internalised by MDM.  
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7.3.4 Effect of DEP Samples and Fluorescent Beads on MDM Viability 
Having determined that increasing concentrations of DEP-N, SRM-1650B or SRM-
2975 reduced MDM-phagocytosis of fluorescent beads, the next step was to 
determine whether this effect was related to cell viability. MDM were incubated with 
DEP-N (1-100µg/ml) for 24h followed by exposure to fluorescent beads for 4h; cells 
were then assessed for viability by MTT assay. Cell that had not previously been 
exposed to DEP were the baseline controls and were considered to be 100% viable. 
DEP-N (Figure 7.6A) treated MDM from COPD patients exposed to fluorescent 
beads significantly reduced cell viability at 1 - 100µg/ml by ~50% at the highest 
concentration. DEP-N also significantly reduced viability in cells from smokers at 
100µg/ml by ~40%. SRM-1650B (Figure 7.6B) treated MDM exposed to fluorescent 
beads significantly reduced viability at 30µg/ml -100µg/ml in COPD patients by ~20% 
at the highest concentration. However, SRM-2975 treated MDM from COPD patients 
only reduced viability by ~30% at 100µg/ml (Figure 7.6C). The combination of DEP 
treatment and fluorescent beads did not significantly alter viability in non-smoker 
MDM. 
7.3.5 Imaging the effect of 30µm, 10µm or 0.2µm Sized Inert Beads on MDM 
Phagocytosis of Fluorescent Beads  
Having determined that MDM exposed to DEP-N, SRM-1650B or SRM-2975 
reduced phagocytosis of fluorescent beads, the next step was to determine whether 
this effect was associated with DEP composition and/or size. To address this 
question, MDM were incubated with inert beads (1-100µg/ml) of different sizes, 
followed by incubation with fluorescent beads, and assessed by light microscopy and 
fluorimetry.  
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Unlike the effect of DEP on phagocytosis of fluorescent beads (Figure 7.1 -7.3), 
MDM from non-smokers, smokers or patients with COPD treated with increasing 
concentrations (1-100µg/ml) of 0.2µm (Figure 7.7), 10µm (Figure 7.8) or 30µm 
(Figure 7.9) sized beads did not exhibit a reduced capacity to further internalise 
fluorescent beads. No difference in response was observed between MDM from non-
smokers, smokers or patients with COPD. 
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Figure. 7.6  Effect of DEP Samples and Fluorescent Beads on MDM Viability. 
MDM from non-smokers () (n=5-6), smokers () (n=7-9) and patients with COPD () (n=11-13; 
ex-smokers n=7, current smokers n=3-4, unknown n=3) were treated with 1-100µg/ml of (A) DEP-
N, (B) SRM-1650B and (C) SRM-2975. DEP-treated cells were incubated for 24h followed by 
further exposure to fluorescent beads for 4h. Cell viability was assessed by MTT assay. Non-
stimulated (NS) cells were baseline controls and represented 100% viability (normalised data). 
Data are mean ± SEM. * p<0.05, ** p<0.01, *** p<0.001 vs non-stimulated controls. # p<0.05 
smokers vs COPD.  
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Figure 7.7 Effect of 0.2µm Sized Inert beads on MDM Phagocytosis of Fluorescent Beads  
0.2µm-treated MDM (1-100µg/ml) from (A) non-smokers, (B) smokers and (C) COPD patients were 
incubated with fluorescent beads (50x106 beads/ml) for 4h. Cells that have not been treated with 
0.2µm inert beads were used as baseline controls (controls) and represented maximum 
phagocytosis by the different subject groups. Cells were viewed by fluorescent microscopy and 
images were taken at X20 magnification. No reduction in phagocytosis of fluorescent beads (green) 
was observed. 
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7.3.6 Determination of the Effect of the 0.2µm, 10µm or 30µm Sized Inert Beads 
on MDM Phagocytosis of Fluorescent Beads by Fluorimetry 
Images captured using fluorescent microscopy showed that inert bead of different 
sizes did not alter the phagocytic ability of MDM, to further ingest fluorescent beads 
(section 7.3.5). Fluorimetry was now used to validate these analyses by measuring 
the fluorescence emitted by inert-bead treated MDM exposed to fluorescent beads. 
MDM treated with media alone represented base-line phagocytosis. 
 
 
 
 
 
Figure 7.8 Effect of 10µm Sized Inert beads on MDM Phagocytosis of Fluorescent 
Beads  
10µm-treated MDM (1-100µg/ml) from (A) non-smokers, (B) smokers and (C) COPD 
patients were incubated with fluorescent beads (50x106 beads/ml) for 4h. Cells that had not 
been treated with 10µm inert beads were used as baseline controls (controls) and 
represented maximum phagocytosis by the different subject groups. Cells were viewed by 
fluorescent microscopy and images were taken at X20 magnification. No reduction in 
phagocytosis of fluorescent beads (green) was observed. 
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MDM treated with increasing concentrations of 0.2µm (Figure 7.10A), 10µm (Figure 
7.10B) or 30µm (Figure 7.10C) inert beads did not effect phagocytosis of fluorescent 
beads when compared to non-stimulated controls. No difference between response 
was observed in MDM from non-smokers, smokers or patients with COPD.  
7.3.6 Effect of Inert Beads and Fluorescent Beads on MDM Cell Viability 
Although increasing concentrations of 0.2µm, 10µm or 30µm sized inert beads did 
not alter subsequent MDM phagocytosis of fluorescent beads, for completeness, the 
effect of the combination of inert and fluorescent beads on MDM viability was 
assessed. Cells were incubated with increasing concentrations of 0.2µm, 10µm or 
30µm inert beads for 24h and further exposed to fluorescent beads for 4h; cell 
viability was assessed using MTT assays. MDM treated with media alone were used 
as baseline controls and represented 100% viability. As might have been expected, 
neither 0.2µm (Figure 7.11A), 10µm (Figure 7.11B) nor 30µm (Figure 7.11C) sized 
beads effected MDM viability compared to baseline controls.   
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Figure 7.9 Effect of 30µm Sized Inert beads on MDM Phagocytosis of Fluorescent 
Beads  
30µm-treated MDM (1-100µg/ml) from (A) non-smokers, (B) smokers and (C) COPD 
patients were incubated with fluorescent beads (50x106 beads/ml) for 4h. Cells that 
had not been treated with 30µm inert beads were used as baseline controls (control) 
and represented maximum phagocytosis by the different subject groups. Cells were 
viewed by fluorescent microscopy and images were taken at X20 magnification. No 
reduction in phagocytosis of fluorescent beads (green) was observed. 
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Figure. 7.10  Effect of Inert Beads on MDM Phagocytosis of Fluorescent Beads. 
MDM from non-smokers () (n=5), smokers () (n=8) and patients with COPD () (n=10; ex-
smokers n=5, current smokers n=3, unknown n=2) were treated with 1-100µg/ml of (A) 0.2µm 
beads, (B) 10µm beads and (C) 30µm beads. Inert bead treated cells were incubated for 24h 
followed by further exposure to fluorescent beads (phagocytic prey) for 4h. Phagocytosis was 
measured using fluorimetery. Non-stimulated (NS) cells were baseline controls. Data are mean 
± SEM relative fluorescence units (RFU).    
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Figure. 7.11  Effect of Inert Beads of Different Sizes and Fluorescent Beads on MDM 
Viability. 
MDM from non-smokers () (n=5), smokers () (n=8) and patients with COPD () (n=10; ex-
smokers n=5, current smokers n=3, unknown n=2) were treated with 1-100µg/ml of (A) 0.2µm 
beads, (B) 10µm beads and (C) 30µm beads. Inert bead treated cells were incubated for 24h 
followed by further exposure to fluorescent beads (phagocytic prey) for 4h. Phagocytosis was 
measured using fluorimetry, followed by treatment with MTT to determine cell viability. Cells 
treated with media alone were baseline controls. Data are mean ± SEM % cell viability (relative to 
control).    
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7.4 Discussion  
Chapter 5 and 6 showed that DEP stimulate MDM from non-smokers and COPD 
patients to activate p38 and ERK 1/2 MAPK, and release CXCL8. The present 
chapter investigated the effect of DEP-N, SRM-1650B or SRM-2975, on MDM 
phagocytosis of fluorescent beads and the impact of these treatments on cell 
viability. Inert-bead treated MDM were also investigated for their effect on 
subsequent phagocytosis of fluorescent beads and cell viability, to determine 
whether the composition and/or size of particles effected internalisation of phagocytic 
prey.  
The current study used qualitative (fluorescent microscopy) and quantitative 
(fluorimetry) techniques to validate whether cells exposed to DEP or inert beads 
affected the phagocytic capacity of MDM. Data from both fluorescent microscopy 
and fluorimetry showed that DEP-treated MDM from all subject groups reduced 
phagocytosis of fluorescent beads. To determine whether these analyses reflected 
internalisation of fluorescent beads and not fluorescence emitted by beads attached 
to the cell membrane, confocal microscopy was used. Sequential imaging of DEP-
treated MDM showed that fluorescent beads were indeed internalised by the cells, 
therefore validating the data obtained using fluorescence microscopy and 
fluorimetry.   
DEP-N significantly reduced phagocytosis of fluorescent beads in MDM from non-
smokers, smokers and patients with COPD. However, MDM treated with SRM-
1650B or SRM-2975 reduced phagocytosis of fluorescent beads only in non-
smokers or patients with COPD. Differences in response were also observed 
between SRM-2975-treated MDM from non-smokers compared to cells from patients 
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with COPD. It is suggested that differences in phagocytosis between non-smokers 
and patients with COPD are associated with the viability of cells. It is possible that 
MDM from COPD patients are already fragile from the pre-treatment with DEP, 
therefore further exposing the cells to fluorescent beads will increase the burden of 
toxicity leading to reduced cell viability, and in part reduce phagocytosis. However, 
MDM from non-smokers pre-treated with SRM-2975 did not show a difference in cell 
viability compared to COPD patients, therefore it is suggested that the reduction of 
phagocytosis seen between the two subject groups is an effect of non-smokers 
having a higher overall baseline response compared to patients with COPD. Since 
non-smokers had a higher baseline phagocytic response, it is difficult to determine 
whether SRM-2975 induced greater inhibition of phagocytosis in patients with COPD 
and therefore this experiment requires further examination. 
The composition of the different samples of DEP-N, SRM-1650B and SRM-2975 
may be associated to the differences in phagocytic response observed in MDM. The 
findings observed herein are similar to findings from other in-vitro studies. For 
example, rat AM macrophages exposed to native DEP, DEP extracts (DEP-E), 
washed DEP (DEP-W) or carbon black (CB) were examined for their effect on 
phagocytic and bactericidal function on Listeria monocytogenes. Only native DEP or 
DEP-E significantly supressed AM phagocytosis and inhibited bactericidal function in 
these cells, whereas DEP-W reduced phagocytosis and bacterial killing to a lesser 
extent. In contrast, AM treated with carbon black reduced phagocytosis but did not 
alter bactericidal functions (Yin et al. 2007). These findings suggest that the organic 
components of DEP may drive suppression of phagocytosis by macrophages.  
Suppression of phagocytosis following treatment of MDM with DEP may be related 
to a number of causes, these include, down regulation of phagocytic receptors (i.e. 
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MARCO) that are involved in the recognition of inhaled prey particles (Becker & 
Soukup, 1998; Kobzik, 1995; Palecanda et al. 1999). The occupation of macrophage 
cytoplasm, termed 'overload', may also prevent further internalisation of inhaled 
particles. For example, a particle-burden of ~2.6 - 6% of the internal volume of 
macrophages suppresses the clearance mechanisms of these cells (Oberdorster et 
al. 1994; Renwick et al. 2001; Morrow et al. 1988; Lundborg et al. 2006). In addition, 
occupation of 7-8% of the macrophage volume may affect the integrity of the 
cytoskeleton, thereby preventing clearance of particles, whilst occupation of 60% 
macrophage volume completely inhibits clearance (Lenhert, 1990, Dorries and 
Valberg, 1992, Möller, et al, 2002; Möller, et al, 2005, Lundborg, et al, 2006). 
Similarly, confocal microscopy images herein, show large aggregates of DEP-N 
occupying MDM volume at the highest concentration of DEP-N treatment (Figure 7.1 
and Figure 7.3). However, these cells were still capable of internalising fluorescent 
beads, albeit less effectively compared to cells treated with low concentrations of 
DEP-N. In contrast to the findings of other groups (Oberdoster, et al. 1992; Dorries & 
Valberg 1992), the data presented herein showed that suppression of phagocytosis 
was not merely an effect of cells becoming replete; as inert-bead treated MDM did 
not reduce subsequent phagocytosis, thereby suggesting that DEP specifically inhibit 
phagocytosis. It was speculated (Renwick et al. 2001) that ultrafine particles 
(<0.1µm) and fine (<2.5µm) particles reduce macrophage phagocytosis because the 
larger surface area of smaller particles introduces a higher proportion of organic 
compounds and transition metals to cells. The DEP samples herein formed 
aggregates within the fine particle range. Internalisation of these particles will enable 
the complex composition of DEP to interact with the intracellular cytoskeleton of 
macrophages, thereby preventing further ingestion of fluorescent beads. Rats 
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instilled with a single dose of 5mg/kg of DEP or CB, followed by inoculation with 
Listeria monocytogenes demonstrated that macrophage clearance of Listeria was 
suppressed by DEP administration and not CB (Yang et al. 2001). This suggests that 
chemicals adsorbed on the surface of DEP are responsible for reduced 
phagocytosis. 
Treatment of MDM with DEP did not supress cell viability as previously seen in 
Chapter 3. However, MDM treated with both DEP and fluorescent beads significantly 
reduced viability in smokers or patients with COPD but not cells from non-smokers. 
This effect suggests that treatment of MDM with DEP samples and fluorescent 
beads may have burdened the cells and damaged membrane integrity which may 
have an effect on phagocytosis. 
Taken together, the findings from the present chapter data show that DEP-N, SRM-
1650B or SRM-2975 pre-treatment of MDM reduce clearance of phagocytic prey. 
These effects are not apparently related to the DEP-treated MDM being replete, but 
are rather associated with the composition of the DEP-samples. Data from this 
Chapter does not support the hypothesis 'DEP-N, SRM-1650B or SRM-2975-treated 
MDM from patients with COPD will reduce phagocytosis of fluorescent beads, 
compared to MDM from non-smokers or smokers'. Even though MDM from COPD 
patients treated with SRM-2975, appeared to have reduced phagocytosis compared 
to MDM from non-smokers, this effect was not evident with other DEP samples. 
Furthermore, it is suggested that non-smoker MDM had a higher baseline 
phagocytosis compared to MDM from COPD patients; therefore it is difficult to 
discern whether SRM-2975 is responsible for the difference observed in 
phagocytosis between these two subject groups and requires further examination. 
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8.1 General Discussion  
The overall general hypothesis of this thesis was: 
 “DEP modulate macrophage pro-inflammatory mediator release and phagocytosis, 
and this is more prominent in COPD.” 
The data presented herein support the first part of the hypothesis, namely that DEP 
modulate MDM inflammatory mediator release and phagocytosis. However, the 
present data did not support the second part of the hypothesis, whereby MDM from 
patients with COPD were not more susceptible to the effects of DEP compared with 
cells from non-smokers or smokers. In addition, the effects of DEP were confined to 
DEP-N rather than SRM-1650B and SRM-2975 particles. These observations merit 
some general discussion.  
8.2. DEP Composition and Relevance of In Vitro and In Vivo 
Experiments  
The composition of DEP is dependent on many factors including engine type, 
operating conditions or fuel type (Ono-Ogasawara & Smith 2004; Mcdonald et al. 
2011). The effects observed in the experimental system used in this thesis may not 
reproduce similar effects in-vivo. This is because the composition of DEP differs 
between samples, and many of the cellular effects are attributed to the ROS-
generating capacity of the high percentage of surface-adsorbed organics, including 
PAHs and nitro-PAHs (Baulig et al. 2003; Schwarze et al. 2013; Totlandsdal et al. 
2013). In addition, metals, including Fe and Cu, and endotoxin adsorbed on the 
surface of DEP are also associated with mediating cellular effects (Imrich et al. 2007; 
Totlandsdal et al. 2013). The variable composition of DEP may be responsible for 
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activating different intracellular signalling pathways to stimulate the release of pro-
inflammatory mediators, for example activation of the p38 MAPK pathway, to 
stimulate macrophage IL-6 release (Li et al. 2002; Totlandsdal et al. 2010; Schwarze 
et al. 2013).  
It is also speculated that findings presented herein may differ from in-vivo responses 
as inhalation of DEP would deposit predominantly on the surface of type II 
pneumocytes which are covered by a layer of surfactant (Schurch et al. 1992). 
Surfactant proteins (SP)-A and SP-B are associated with enhancing macrophage 
phagocytosis by acting as opsonins (Hohlfeld et al. 1997; Benne et al. 1997). 
Surfactant also contains non-enzymatic anti-oxidants for example uric acid, 
glutathione and α-tocopherol, which protect the lung from ROS generated by DEP 
(Thorley & Tetley, 2007). Therefore, responses between the experiments of the 
present thesis may not reflect those that occur in-vivo. 
The concentration range of DEP samples used in the experiments herein, were 
delivered to cells as particulate suspensions. Typical environmental levels of PM10 
are 5-10µg/m3, whereas biologically relevant levels are 0.2 - 20µg/cm
2 (Donaldson et 
al. 2005; Li et al. 2002; Li et al. 2003; Totlandsdal et al. 2010) which are comparable 
to those used in this thesis. It is difficult to relate inhalable doses typically found in 
the environment to cells treated with particulate suspensions, this is because cell 
culture media used to suspend particles may interfere with properties of the DEP 
overtime (Teeguarden et al. 2007). For example, the surface charge or chemistry, 
aggregation of particles and rate at which suspended particles settle on cells may be 
affected by the content of salts in media. To this end, it would not be feasible to 
determine the actual dose 'concentration' of DEP used to treat cells, as the cells 
would only be exposed to deposited aggregates which are large in size, but not small 
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particulates which would remain suspended in media (Teeguarden et al. 2007; 
Totlandsdal et al. 2010). The biologically relevant concentration of particulate matter 
is in the range of 0.2-20µg/cm2 as determined by the calculations in Li et al. 2003 
and Li et al. 2002. The biological relevance of the concentration of DEP used herein, 
were calculated according to the surface area of in 96-well and 24-well tissue culture 
plates, which are 0.32cm2 and 3.2 cm2 respectively. The concentration range of DEP 
used herein are comparable with DEP concentrations used by other groups 
(Chaudhuri et al. 2012; Zhou & Kobzik 2007; Saxena et al. 2008) but maybe high to 
be compared to exposure levels in the atmosphere. Although the findings herein 
cannot be extrapolated to in-vivo inhalation studies directly, this exposure system is 
effective in providing a means of testing the effect of DEP on biological parameters 
(Totlandsdal et al. 2012). To this end, the use of particulate suspensions allows 
examination of different DEP samples on macrophage function, and also allows 
exploration of DEP on the activation of different signalling pathways (Totlandsdal et 
al. 2010). 
8.3. Modulation of mediator release and phagocytosis 
DEP-induced release of CXCL8 by MDM from all subject groups and, contrary to the 
overall thesis hypothesis, this was similar between non-smokers and patients with 
COPD. However, in contrast, DEP-induced release of CXCL8 by MDM from smokers 
was reduced compared with that from MDM from non-smokers or COPD patients. 
DEP-N also failed to activate p38 and ERK 1/2 in MDM from smokers. Furthermore, 
these cells were also protected against the cytotoxic effects of DEP-N. These 
observations are unlikely to be a result of direct, prior cigarette smoke exposure, as 
MDM were differentiated outside the lung environment, thereby suggesting that this 
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response maybe linked to an epigenetic or genetic predisposition of these cells. 
Cigarette smoke consists of ~4,700 noxious chemical species, (Rahman & Macnee, 
1996; Wright et al. 2012). Exposure of circulating monocytes to these chemicals may 
lead to activation of several anti-oxidant genes and stress related genes (Totlandsdal 
et al. 2012). For this reason, it is speculated that the reduced CXCL8 release, MAPK 
activation and cytotoxicy in MDM from smokers may be associated with increased 
production of anti-oxidants (Li et al. 2000). Production of these anti-oxidants may 
protect the cell from excess exposure to DEP-generated oxidants (Hiura et al. 1999).  
However, the effect of DEP-N to suppress phagocytosis was similar across MDM 
from all subject groups thereby suggesting the effects of DEP-N to mediate CXCL8 
release and alter phagocytosis maybe via different mechanisms.  
Primary BAL macrophages from COPD patients release increased levels of 
mediators at baseline (for example CXCL8, IL-6 or TNFα) compared to cells from 
non-smokers or smokers (Barnes 2009; Culpitt et al. 2003). In addition, DEP also 
induce release of inflammatory mediators, for example IL-6 or TNFα, by various 
pulmonary cells, including macrophages (Hetland et al. 2005; Totlandsdal et al. 
2010; Shaw et al. 2011; Schwarze et al. 2013; Becker et al. 2005). For this reason, it 
was suggested that treatment of MDM with DEP would amplify release of the typical-
macrophage mediators, namely CXCL8, IL-6 or TNFα, in the present experimental 
system. However, the findings of this thesis suggested that mediator release by 
DEP-treated MDM from COPD patients were not increased compared to MDM from 
non-smokers. It is speculated that this maybe because MDM are cultured in-vitro and 
are not constantly exposed to the underlying inflammation seen in the lungs of 
COPD patients (Barnes 2004; Barnes 2009). If MDM were exposed to similar 
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inflammatory processes present in the COPD lung, and also exposed to DEP, MDM 
may have further enhanced release of CXCL8, IL-6 or TNFα compared to controls.  
The findings presented in this thesis may not reflect the effect of inhaled DEP on 
alveolar macrophages in-vivo. The alveolar compartment of the lung consists of 
numerous cells including type I/II pneumocytes, macrophages and dendritic cells. In 
the present in-vitro model of macrophage function, the effects of DEP were 
examined only on MDM, thereby excluding interactions of DEP with different cell 
types, which may in turn influence functioning of macrophages. Exposure of various 
cell types in the lung to DEP may stimulate immune responses and produce pro-
inflammatory mediators which may go on to stimulate release of mediators by 
macrophages, for example IL-6 or TNFα. To investigate whether pulmonary cells 
exposed to DEP would modulate macrophage responses, a double cell co-culture 
system could be used instead of a mono-cell culture system. This could include 
primary human type II pneumocytes and alveolar macrophages to mimic the lung 
environment (Lehmann et al. 2009). A co-culture system would provide insight to the 
interaction of other pulmonary cells on the effect of macrophage function following 
DEP treatment.  
Lungs of COPD patients are commonly colonised by bacteria including Haemophilus 
influenzae, Streptococcus pneumoniae or during an exacerbation infection with 
respiratory synticial virus (Donnelly & Barnes 2012; Sikkel et al. 2008). The 
persistence of these micro-organisms in the lung may be related to defective 
macrophage phagocytosis (Taylor et al. 2010; Berenson et al. 2006). The data 
presented herein concluded that DEP-treated MDM from COPD patients did not 
show reduced phagocytosis of fluorescent beads compared to non-smoker or 
smoker subjects. Similarly, findings by Taylor et al. 2010 also demonstrated that 
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MDM from COPD patients also successfully phagocytose fluorescent beads 
compared to non-smoker or smoker controls, but are defective in clearing 
fluorescently-labelled H.influenzae or S.pneumoniae. In-vitro experiments examining 
the effect of DEP on clearance of Listeria monocytegenes by alveolar macrophages 
also showed that cells were defective in internalising pathogens (Yin et al. 2007). For 
this reason, it is speculated that even though phagocytosis of fluorescent beads by 
DEP-treated MDM was similar in all subject groups, this response may be altered if 
DEP-treated cells were exposed to fluorescently-labelled bacteria. The latter 
investigation would allow examination of whether DEP reduce MDM phagocytosis 
significantly in patients with COPD compared to non-smoker or smoker controls. In 
addition, this investigation would also contribute to understanding relationship 
between inhalation of DEP and increased bacterial colonisation and exacerbations in 
COPD patients. 
8.4. Clinical Implications 
The data presented herein show that DEP increase pro-inflammatory mediator 
release and reduced phagocytosis in alveolar macrophages. These observations 
may explain, at least in part, the association between inhalation of DEP and their 
adverse effects on adverse respiratory symptoms in patients with COPD. The clinical 
implications associated with inhalation of DEP include deposition of these particles in 
the alveolar compartment of the lung where they become targets for alveolar 
macrophages (Figure 8.1A; Figure 8.1B). The complex composition of DEP may 
amplify release of the chemokine CXCL8, which is already increased in COPD 
(Bildberg, et al, 2012). The increased levels of CXCL8, may drive recruitment of 
neutrophils and monocytes (Behndig, et al, 2006), and via this mechanism, DEP may 
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increase the number of cells present in the peripheral airways (Figure 8.1D). In 
addition DEP are also internalised by macrophages (Figure 8.1C). The composition 
of DEP may prevent the clearance of other inhaled particles and bacteria, for 
example S.pneumoniae or H.influenzae. The defective clearance of these pathogens 
leads to bacterial colonisation of the lung, which contributes to the inflammatory 
responses observed in COPD. The combined effect of DEP on stimulation of pro-
inflammatory mediator release and decreased phagocytosis of bacterial pathogens 
may contribute to the underlying inflammation observed in COPD, and may increase 
the risk of COPD exacerbations (Figure 8.1D).  
The findings presented herein require further investigation to determine the 
mechanisms underlying DEP modulation of macrophage function. The composition 
of DEP-N, rather than size, is responsible for driving the increased levels of CXCL8 
by activating MAPK signalling pathways, and may also be involved in the inability of 
macrophages to internalise fluorescent beads. This is because MDM treated with 
SRM-1650B or SRM-2975 and inert beads of different sizes did not replicate the 
increase in CXCL8. Therefore suggesting that the composition of DEP-N is 
associated in stimulating CXCL8 release, but this requires further examination. 
Findings from the data herein and other in-vivo or in-vitro studies show that DEP are 
variable in composition, and health effects associated with inhalation are related to 
the complex constituents of these particles. Data from this study and others, show 
that treatment of macrophages with DEP samples stimulate the release of distinct 
pro-inflammatory mediator profiles. In areas of high pollution, Inhalation of DEP by 
healthy non-smokers may induce an inflammatory response, but these effects may 
not appear to damage the health of individuals. However, inhalation of DEP by  
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Figure 8.1 DEP-Treated Macrophages Increase CXCL8 Release and Reduce 
Phagocytosis 
(A) AM located deep in the lung were exposed to (B) inhaled DEP. (C) AM internalise DEP, 
but lose their ability to internalise bacterial pathogens (curved arrow). Ineffective clearance 
of bacteria leads to colonisation of the lung which may (D) increase susceptibility to COPD-
related exacerbations in patients. DEP also stimulate macrophages to release the 
chemokine, CXCL8, which is involved in the recruitment of neutrophils. 
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smokers or patients with COPD may aggravate the underlying inflammation seen in 
these individuals, which may lead to the onset symptoms (Behndig et al. 2006; 
Sehlstedt et al. 2010; Salvi et al. 2000). 
8.5 Future Work 
The observations in the present thesis indicate a number of directions for future 
work, as discussed below. 
 MDM appear to be a suitable model of alveolar macrophage function in terms of 
examination and assessment of the effects of DEP in non-smokers, smokers and 
patients with COPD. However, it would be desirable to use primary 
macrophages from resected lung tissue or from BAL samples. This is because 
blood monocytes are differentiated into MDM by GM-CSF, meaning these cells 
have not been exposed to the lung environment, as would be the case if primary 
macrophages were used. Furthermore, using primary macrophages would mimic 
the effects of DEP on cells already exposed to inhaled particles or debris.  
 
 In the present thesis, MDM from non-smokers, smokers or patients with COPD 
were treated with DEP and further exposed to fluorescent beads to assess the 
phagocytic capacity of these cells (Taylor et al. 2010). However, MDM from 
COPD patients are capable of internalising fluorescent beads but are defective in 
clearing fluorescently-labelled bacterial pathogens. To test the effect of DEP on 
MDM phagocytosis by COPD patients, cells could be treated with DEP and then 
further exposed to H.influenzae or S.pneumoniae. This experiment would 
examine whether DEP are capable of further reducing baseline phagocytosis by 
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MDM from patients with COPD, and allow comparison of data with non-smokers 
and smokers. 
 
 Findings from the present thesis suggest that the composition of DEP is 
responsible for the increase in CXCL8 release and possibly the reduction in 
phagocytosis. To determine whether the composition of DEP is associated with 
the induction of CXCL8 or reduced phagocytosis, the samples of DEP-N could 
be washed with methanol to extract the adsorbed chemical species from the 
surface of the carbon particle. Subsequent investigations could then be 
performed where MDM from non-smokers, smokers or patients with COPD were 
treated with native-DEP, carbon black or the DEP extract, and pro-inflammatory 
mediator release and phagocytic ability of MDM investigated. The toxicity 
associated with native-DEP, carbon black or DEP extract on MDM from the 
different subject groups could also be assessed using MTT or flow cytometry. 
 
 To determine whether adsorbed metals on the surface of DEP were responsible 
pro-inflammatory mediator release, metal chelators could be used. Subsequent 
experiments involving the treatment of MDM with native-DEP, carbon black or 
DEP-extract following metal chelation could be used to assess the effects of 
metals on MDM pro-inflammatory mediator release or phagocytosis. Types of 
metal chelators that could be used are EDTA, DFOA or 2,3-dimercaprol, which 
are responsible for chelating lead, iron or cadmium metals respectively (Flora 
and Pachauri, 2010). 
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 Inhaled DEP deposit in the alveolar compartment of the lung. The lung contains 
a number of cell types including type II pneumocytes, dendritic cells and 
macrophages which all will be exposed to the inhaled particles. To mimic the 
effects of DEP in the lung a double (i.e. MDM or macrophages with type II 
pneumocytes) co-culture could be used to examine the effects of DEP on type II 
epithelial cells, monocyte-derived dendritic cells and MDM. This will provide 
insight on the interaction and cross-talk between the individual cells and how this 
may impact the functioning of macrophages in regards to pro-inflammatory 
mediator release and phagocytosis.  
 
 The effects of DEP on MDM, for example CXCL8 release, may be attributed to 
the generation of ROS by these particles. To determine whether DEP released 
CXCL8 via an oxidative effect, MDM can be treated with DEP in combination 
with anti-oxidants such as NAC. Following incubation, release of CXCL8 in the 
supernatant would be measured by ELISA.  
 
 To examine whether reduced MDM phagocytosis by DEP was associated with 
cytoskeletal dysfunction, cells could be probed for actin integrity using phalloidin 
stains. Also, to assess whether DEP interfere with the cytoskeletal structure of 
MDM, confocal microscopy could be used. 
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         AGE SEX FEV1 FEV1 % FVC  FEV1:FVC 
JiM050912 62 F 2.1 79 2.78 0.755396 
MaGO120612 76 M 2.87 90.50 3.67 0.78 
CLC 66 F 2.28 97 3.2 0.71 
GiD 51 F 3.23 118.50 4.09 0.789731 
JeL270912 64 f 2.53 94.5 3.67 0.689373 
STJ260912 63 M 3.1 103.5 4.55 0.681319 
ToK141009 38 M 3.34 98.6 3.26 1.02454 
ChB020811 62 M 3.42 114.9 4.68 0.730769 
JuB030310 54 F 1.69 94.9 2.26 0.75 
NeA 44 M 3.18 79.5 3.76 0.845745 
JAW161112 56 F 4.17 151.2 5.16 0.81 
MaGO120612 76 M 2.87 90.50 3.67 0.78 
MaBa070110 53 F 1.66 74 2.31 0.718615 
LiH230311 56 F 2.6 116.2 3.28 0.792683 
PaB231009 42 M 3.80 95.00 4.40 0.86 
PeF181109 42 M 4.54 106.00 6.14 0.74 
AnR230410 71 F 1.97 97.2 3.02 0.65 
DaL211009 56 M 3.28 86.30 5.01 0.65 
LaU271009 59 F 1.96 115 2.45 0.8 
liF200410 63 F 2.22 90 2.81 0.790036 
LoD301009 46 F 3.10 103.00 3.42 0.91 
GeC 59 m 3.51 97.00 4.38 0.80 
LaU021109 46 M 3.55 93 4.74 0.74 
DoP040510 72 F 1.23 68.8 1.61 0.763975 
MaT 70 f 2.73 112.30 3.50 0.78 
MOC 57 F 2.69 103 3.49 0.770774 
JAB220413 48 M 4.53 120.1 5.84 0.78 
TEL230611 44 F 2.49 106.4 2.92 0.85 
GAW unknown  unknown unknwon unknown unknown unkown 
 
Appendix II Table 1: Basic Demographics of Non-Smoker Participants 
Recruited for the Study. 
Basic lung function data of non-smoker volunteers recruited for the study. Patient 
identification is anonymised. No lung function data provided for volunteer highlighted 
in yellow. 
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  AGE SEX FEV1 FEV1 % FVC  FEV1:FVC p/y 
Current 
Smokers 
AnH070311 54 F 3.18 121.9 4.41 0.7210884 40 y 
AnM 56 M 3.27 118.4 3.89 0.840617 15 y 
MIK110912 64 m 3.22 105.7 4.7 0.6851064     
PeC010311 63 F 1.92 98.30 2.58 0.74 68.00 y 
MiV 51 M 2.4 73.8 2.4 1 24 Y 
ELM190712 44 F 2.35 87.9 3.28 0.7164634 44 Y 
AlF140311 53 F 2.51 93.8 3.07 0.8175896 80 y 
ViV130912 59 F 3.05 109.1 4.32 0.7060185 22.5 Y 
MaB170511 49 m 3.17 94.6 4.73 0.6701903 18 y 
VeB080311 60 F 1.61 76.6 2.32 0.6939655 22.5 Y 
DaH080311 62 M 3.28 105.4 3.96 0.8282828 20 Y 
CaHu050310 57 F 2.08 92.10 2.79 0.75 25.00 Y 
ChH070610 66 F 2.00 102.60 3.19 0.63 55.00 Y 
JaB140711 70 f       0.7 30.00 N 
JOSA200710 70 M 4.07 111.4 6.49 0.6271186   Y 
KaR190710 46 f 2.26 102.10 2.78 0.81   y 
RaK191109 62 M 3.15 102.80 4.56 0.69 30 y 
AnS220512 59 f 1.55 63.0 2.01 0.7711443 19 y 
 
Appendix II Table 2: Basic demographics of Smoker Participants Recruited for 
the Study. 
Basic lung function data of smoker volunteers recruited for the study. Patient 
identification is anonymised.  
Patients  AGE SEX FEV1 FEV1 % FVC  FEV1:FVC p/y C.SM EX.SM Experiment: 
AlMa040912 
(AIFA) 
82 M 0.71 29 1.48 0.48 23  
y 
Chapter 4: 
Fig 4.4A 
Fig 4.4B 
Fig 4.4C 
Fig 4.14A 
Fig 4.14B 
 
ChD021012 75 m 0.7 22.8 2.74 0.26 60  
Y 
Chapter 4: 
Fig 4.4A 
Fig 4.4B 
Fig 4.4C 
TELY 70 F 1.01 45.0 1.75 0.58 50 N 
y 
Chapter 4: 
Fig 4.8B 
 
 
JaF120612 80 f 0.59 32.0 1.55 0.38 50 n 
ex. 
Chapter 4 
Fig 4.14A 
Fig 4.14B 
Fig 7.10A 
Fig 7.10B 
Fig 7.10C 
Fig. 7.11A 
Fig7.11B 
Fig7.11C 
 
 
 
PaA180111 71 F 0.92 46.5 2.85 0.32 35 ex 
ex 30y 
Chapter 5: 
Fig. 5.2A 
Fig 5.2B 
Fig. 5.2C 
 Fig 5.3A 
Fig 5.3B 
Fig 5.3C 
Fig 5.4A 
Fig. 5.4B 
Fig 5.4C 
Fig. 5.5A, 
Fig.5.5B 
Fig5.5C 
Fig. 5.6A 
Fig5.6B 
Fig 5.6C 
Fig 5.7A 
 
Chapter 7: 
Fig. 7.4 A 
Fig. 7.4 B 
Fig 7.4C 
Fig. 7.6 A 
Fig 7.4B 
Fig 7.4C 
Fig 7.10A 
Fig 7.10B 
Fig 7.10C 
Fig. 7.11A 
Fig7.11B 
Fig7.11C 
 
 
BeT040810 83 M 0.83 36.0 1.97 0.42 38 n 
ex 
Chapter 5: 
Fig. 5.5A 
Fig. 5.5C 
 Fig. 5.6A 
 
Chapter 7: 
Fig. 7.4 A 
Fig. 7.6 A 
 
BrM240310 72 M 0.77 26.0 1.53 0.5 70 n 
y 
Chapter 5: 
Fig. 5.5A 
Fig. 5.5C 
Fig. 5.6A 
Fig 5.7A 
 
Chapter 7: 
Fig. 7.4 A 
 
JAP010911 65 F 0.7 31.82 1.6 0.44 120  
Ex.sm 
Chapter 5: 
Fig. 5.5B 
Fig. 5.5C 
Fig5.6B 
Fig 5.6C 
Fig. 5.7B 
Fig 5.7C 
 
Chapter 7: 
Fig. 7.4 A 
Fig. 7.4 B 
Fig 7.4C 
Fig. 7.6 A 
Fig 7.4B 
Fig 7.4C 
JuT200110 76 F 1.31 68.0 1.83 0.72 50 n 
 
Chapter 5: 
Fig. 5.5A 
Ex.sm 
7-years 
 
 Fig. 5.6A 
 
Chapter 7: 
Fig. 7.4 A 
Fig 5.7A 
MARR310712 69 f 0.74 36.0 2.18 0.3394495 25 n  
Chapter 6: 
Fig 6.10 
Fig 6.11 
GaH080512 58 m 0.52 15.0 1.67 0.31 25 n 
y 
Chapter 6: 
Figure 6.5 
JuY190412 66 F 0.45 22.0 1.28  35 n 
y 
Chapter 6: 
Fig. 6.6 
MaL250711 70 F 1.43 82.4 2.37 0.6   
Y 
Chapter 5: 
Fig5.6B 
Fig 5.6C 
 
Chapter 6: 
Fig. 6.6 
 
Chapter 7: 
Fig. 7.4 A 
Fig. 7.4 B 
Fig 7.4C 
Fig. 7.6 A 
Fig 7.4B 
Fig 7.4C 
Fig 7.10A 
Fig 7.10B 
Fig 7.10C 
Fig. 7.11A 
Fig7.11B 
Fig7.11C 
 WiC180612 61 m 1.55 49.5 2.21 0.7 15  
 
Chapter 6: 
Fig 6.7 
Fig 6.8 
Fig 6.10 
Fig 6.11 
 
Chapter 7: 
Fig 7.10A 
Fig 7.10B 
Fig 7.10C 
 
EdM080812 63 m 2.14 63.0 2.83 0.76 23 n 
y 
Chapter 6: 
Fig 6.10 
Fig 6.11 
GeWa020311 77 M 0.52  1.76 0.3 45 n 
y 
Chapter 7: 
Fig. 7.4 A 
Fig. 7.4 B 
Fig 7.4C 
Fig. 7.6 A 
Fig 7.4B 
Fig 7.4C 
 
 
 
KaR290910  F 0.37 23.0 1.10 0.34 10 n 
 
Chapter 7: 
Fig. 7.4 A 
Fig. 7.4 B 
Fig 7.4C 
Fig. 7.6 A 
Fig 7.4B 
Fig 7.4C 
 
Y 
Ex.sm 
Y 
Y 
 PeR140111 60 M 2.10 55 3.60 0.58   
 
Chapter 7: 
Fig. 7.4 A 
Fig. 7.4 B 
Fig 7.4C 
Fig. 7.6 A 
Fig 7.4B 
Fig 7.4C 
 
RaD300412 67 m 1.2 40.4 2.31 0.52  never 
 
Chapter 6: 
Fig 6.1 
 
Chapter 7: 
Fig 7.10A 
Fig 7.10B 
Fig 7.10C 
Fig. 7.11A 
Fig7.11B 
Fig7.11C 
JoWe030210 82 M 1.08  2.21 0.49 50 n 
 
Chapter 5: 
Fig. 5.6A 
 
Chapter 7: 
Fig. 7.4 A 
 
JuT200110 76 F 1.31 68.0 1.83 0.72 50 n 
 
Chapter 5: 
Fig. 5.5A 
Fig. 5.6A 
DaS170310 69 M 0.76 28.0 3.04 0.25 50 n 
 
Chapter 5: 
Fig. 5.5A 
Fig. 5.6A 
Fig 5.7A 
 
 Chapter 7: 
Fig. 7.4 A 
 
CyR290512 86 m 1.68 71.0 4.16 0.4 18 n 
 
Chapter 5: 
Fig. 5.5B 
Fig. 5.5C 
 
Chapter 7 
Fig. 7.4 B 
Fig 7.4C 
 
Appendix II Table 3: Basic demographics of Ex-Smoker COPD Patients Recruited for the Study. 
Basic lung function data of ex-smoker COPD patients recruited for the study. 
 Patient AGE SEX FEV1 FEV1 % FVC FEV1:FVC P/Y C.SM EX.SM Experiment: 
 
MaLe250912 50 f 0.87 31.6 3.59 0.24 60 y  Chapter 4: 
Fig 4.4A 
Fig 4.4B 
Fig 4.4C 
Fig 4.14A 
Fig 4.14B 
 
LeH141111 68 m 2.36 86.8 4.33 0.55  Y  Chapter 5: 
Fig. 5.2A 
Fig 5.2B 
Fig. 5.2C 
Fig 5.3A 
Fig 5.3B 
Fig 5.3C 
Fig 5.4A 
Fig. 5.4B 
Fig 5.4C 
Fig. 5.5B 
Fig. 5.5C 
Fig. 5.7B 
Fig 5.7C 
 
Chapter 7: 
Fig. 7.4A 
Fig. 7.4 B 
Fig 7.4C 
Fig. 7.6A 
Fig 7.4B 
Fig 7.4C 
Fig 7.10A 
 Fig 7.10B 
Fig 7.10C 
Fig. 7.11A 
Fig7.11B 
Fig7.11C 
CaH210410 72 F 1.28 77.80 2.41 0.53 10.00 Y  Chapter 4: 
Fig. 4.8A 
Fig 4.8B 
Fig 4.8C 
 
Chapter 6 
Fig. 6.6 
GoH 65 m 0.95 29.0 2.42 0.39 15 Y  Chapter 4: 
Fig. 4.8A 
Fig 4.8B 
Fig 4.8C 
DEM240610 77 M 0.87 54.0 1.92 0.45 >40 Y  Chapter 5: 
Fig. 5.5A 
Fig 5.7A 
Chapter 7: 
Fig. 7.4 A 
Fig. 7.6 A 
 
LaU151009 63 M 2.17 66% 3.11 0.7 10 y y(ex 7 
yrs) 
Chapter 5: 
Fig. 5.5A 
Fig. 5.6A 
Fig 5.7A 
 
Chapter 7: 
Fig. 7.4 A 
 
PF 005 62 F 1.11 57 1.62 0.69 24 y  Chapter 5: 
 JJ020310 Fig. 5.5A 
Fig. 5.6A 
Fig 5.7A 
 
Chapter 7: 
Fig. 7.4 A 
 
TEB090810 63 m 0.5  1.44 0.4 70 Y  Chapter 5: 
Fig. 5.5A 
Fig 5.7A 
 
Chapter 7: 
Fig. 7.4 A 
 
THWA 75 m 1.27 48 3.72 0.3 25 y  Chapter 5: 
Fig. 5.5A 
Fig 5.7A 
 
Chapter 7: 
Fig. 7.4 A 
 
AIA 57 F 1.4 59 2.45 0.57 25 Y  Chapter 5: 
Fig. 5.5B 
Fig. 5.5C 
Fig5.6B 
Fig 5.6C 
Fig. 5.7B 
Fig 5.7C 
 
Chapter 7: 
Fig. 7.4 A 
Fig. 7.4 B 
 Fig 7.4C 
Fig. 7.6 A 
Fig 7.4B 
Fig 7.4C 
 
AlT190911 63 F 1.03 36.9 2.23 0.46 36 Y y Chaoter 6: 
Fig. 6.6 
ClP300412 59 M 2.5 70.0 4.14 0.6 52.5 Y  Chapter 7 
Fig 7.10A 
Fig 7.10B 
Fig 7.10C 
Fig. 7.11A 
Fig7.11B 
Fig7.11C 
 
GaB080512 49 M 3.11 83.1551 4.93 0.63 12 Y  Chapter 7: 
Fig. 7.4 B 
Fig 7.4C 
Fig 7.4B 
Fig 7.4C 
Fig 7.10A 
Fig 7.10B 
Fig 7.10C 
Fig. 7.11A 
Fig7.11B 
Fig7.11C 
 
GeQ090211 57 M 0.92 32.00 2.50 0.37 65 y  Chapter 5: 
Fig. 5.5A 
Fig. 5.6A 
Fig 5.7A 
 
  
Chapter 7: 
Fig. 7.4 A 
 
JuM240610 79 F 1.26 75.6 1.65 0.76 10 Y  Chapter 5: 
Fig. 5.5A 
 
Chapter 7: 
Fig. 7.4 A 
Fig. 7.6 A 
 
 
Appendix II Table 4: Basic demographics of Current-Smoking COPD Patients Recruited for the Study. 
Basic lung function data of current-smoking COPD patients recruited for the study. 
 
 
 
 
 
 
 
 
 
 PATIENT  AGE SEX FEV1 FEV1 % FVC  FEV1:FVC p/y C.SM EX.SM 
Experiment: 
MaCO200912 69 M 1.81 52.2 3.15 0.57       
Chapter 4: 
Fig 4.4A 
Fig 4.4B 
Fig 4.4C 
VEH/HuI300412 59 m 1.89 61.6 4.12 0.46 70     
Chapter 7: 
Figure 7.4A 
Fig. 7.4 B 
Fig 7.4C 
 
MaG030512 67 f 1.1   1.81 0.61 30     
Chapter 6: 
Figure 6.5 
SuC050512 59 F 1.09 47.6 2.53 0.43 30     
Chapter 6: 
Fig 6.1 
Fig 6.5 
 
ALB190410 53 M 2.92 86.6 3.69 0.79   N   
Chapter 5: 
Fig 5.6A 
Fig 5.7A 
 
Chapter 7: 
Fig. 7.4 A 
 
ELP110110 58 F 1.75 73.4 2.67 0.66   n   
Chapter 5: 
Fig.5.5A 
Fig. 5.6A 
 
 
 
Chapter 7: 
Fig. 7.4 A 
 AnP260512 74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
m 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.63 
0.65   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n 
  
 
Chapter 5: 
Fig. 5.2A 
Fig 5.2B 
Fig. 5.2C 
Fig. 5.5B 
Fig. 5.5C 
 
Chapter 6: 
Fig 6.7 
Fig 6.8 
Fig 6.10 
Fig 6.11 
 
 
Chapter 7: 
Fig. 7.4 B 
Fig 7.4C 
Fig 7.10A 
Fig 7.10B 
Fig 7.10C 
Fig. 7.11A 
Fig7.11B 
Fig7.11C 
 
 
VeM030512 59 F 1.13 44.0 1.9 0.59   n   
Chapter 5: 
Fig. 5.2A 
Fig 5.2B 
Fig. 5.2C 
 
 
 Chapter 6: 
Fig 6.1 
Fig 6.8 
 
Chapter 7: 
Figure 7.4A 
Fig. 7.4 B 
Fig 7.4C 
Fig 7.10A 
Fig 7.10B 
Fig 7.10C 
Fig. 7.11A 
Fig7.11B 
Fig7.11C 
 
 
 
RoFr 66 m 1.81 56.4 3.53 0.51   n   
Chapter 4: 
Fig. 4.8A 
Fig 4.8B 
Fig 4.8C 
ShS300412 unknown unknown 
Chapter 6: 
Fig 6.1 
 
Appendix II Table 5: Basic demographics of COPD Patients Recruited for the Study. 
Basic lung function data of COPD patients recruited for the study. No or limited information is provided, in regards to current 
smoking or ex-smoking patients recruited (only pack years given). No lung function is provided for the patient highlighted in yellow. 
  
 
Appendix II Table 6: Basic demographics of Current-Smoking and Ex-Smoking 
COPD Patients Recruited for the Study. 
Basic demographics of current-smoking and ex-smoking COPD patients recruited for 
the study. Demographics of COPD patients with unknown or limited information 
regarding current or ex-smoking status are also provided.  
 
 
COPD 
 
(Never Smoked/ 
Limited Information 
Supplied) 
 
n=9 
COPD 
 
(Ex-Smoker) 
 
 
 
n=25 
COPD 
 
(Current 
Smokers) 
 
 
n=15 
Age (Years) 
 
63 ± 2 71 ± 2 64 ± 2 
FEV1 (L) 
 
2 ± 2 1 ± 0.1 1 ± 0.2 
FEV1 
(% Predicted) 
61 ± 5 44 ± 4 58 ± 5 
FVC 
 
3 ± 0.3 2 ± 0.1 3 ± 0.3 
FEV1:FVC 
 
0.6 ± 0.04 0.5 ± 0.03 0.5 ± 0.04 
Smoking 
History 
(Pack Years) 
43 ± 13 42 ± 5 32 ± 6 
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Appendix III: 
NIST Certificates 
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